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 Abstract  
Tumour growth and metastasis depend on the vascularization of tumours by 
angiogenesis. This is regulated by the combined action of several growth factors 
(e.g. vascular endothelial growth factor, VEGF) that are secreted by the growing 
tumour, and activate VEGF receptors (VEGFR) expressed on the surface of 
endothelial cells to stimulate new blood vessel formation. Therapies that target 
VEGF/VEGFR signalling have indicated that anti-angiogenic therapy may be a 
useful supplementary anti-cancer treatment in the clinic. In addition to VEGF, 
malignant cells secrete transforming growth factor (TGF)-β, which is thought to 
stimulate new blood vessel formation by interacting with endoglin, an endothelial 
co-receptor for TGF-β that regulates angiogenesis. However, it is not yet clear 
whether this property could also be utilised to inhibit angiogenesis and metastasis, 
consistent with endoglin acting as a therapeutic target in a clinical setting.  
 
Therefore, the aim of my project was to investigate the role of endoglin in tumour 
angiogenesis and metastasis and its potential as an anti-angiogenic therapeutic 
target. I used a conditional endoglin knockout mouse model, that was generated by 
combining a floxed endoglin allele with a tamoxifen inducible vascular specific Cre 
(Cdh5(PAC)Cre-ER
T2
). Angiogenesis was tested using the matrigel subdermal plug 
assay and was significantly less in endoglin-deficient adult mice compared with 
tamoxifen treated control mice. Subsequently, angiogenesis and metastasis were 
investigated using a subdermal lewis lung carcinoma (LLC) model. The growth of 
the primary tumours was initially reduced, suggesting that targeting endoglin may 
delay tumour progression at an early stage. However, there was no significant effect 
of endoglin loss on primary tumour growth at later stages of tumour progression. 
Furthermore, loss of endoglin was associated with a significant increase in 
metastases, in a similar way to recent findings for other anti-angiogenesis 
treatments. The reasons for this are not yet clear. 
 iii 
In terms of animal health, endothelial specific loss of endoglin alone did not appear 
to cause any major adverse effects. Endoglin inducible knockout (Eng-iKO
e
) mice 
did not lose weight and appeared healthy (over two months). However, Eng-iKO
e
 
mice did exhibit abnormal venous enlargement close to matrigel plugs 
supplemented with angiogenic growth factors compared to control mice. There was 
no evidence for a similar response in the peritumoral vasculature.  
 
In parallel to the in vivo studies, I took advantage of combining the conditional 
Eng- iKO line and the „immortomouse‟ line to create conditionally immortalised 
Eng-iKO mouse lung endothelial cell lines (MLECs) to investigate the role of 
endoglin in regulating endothelial cell viability, proliferation and migration. In 
standard media, MLECs showed normal cell viability, proliferation and migration 
in the absence of endoglin. However, titration of the growth factor supplements did 
result in significant reduction in viability in the absence of endoglin, suggesting 
endoglin is important for maintaining endothelial cell viability.  
 
Although the exact mechanisms regulating the role of endoglin in angiogenesis are 
still unclear, this study has increased our understanding of the endothelial cell 
phenotype in pathophysiological conditions in the absence of endoglin. In 
particular, the finding that endoglin depletion delays tumour progression in the 
early stage but is associated with increased metastatic risk is important when 
considering appropriate utilisation of anti-endoglin therapy, which is already being 
given to cancer patients in phase I/II clinical trials. 
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1.1 Vasculogenesis and angiogenesis  
Vessel growth can be classified in two distinct ways, vasculogenesis and 
angiogenesis (Figure 1.1). Vasculogenesis leads to the first primitive vascular 
plexus of the embryo and its yolk sac, via the in situ differentiation and growth of 
blood vessels from mesoderm-derived haemangioblasts. Subsequently, blood 
vessels are remodelled and expanded from pre-existing ones, which can occur by 
both sprouting and non-sprouting angiogenesis. The sprouting of vessels and 
intussusceptive microvascular growth (also known as splitting angiogenesis) are 
two distinct processes of angiogenesis. The sprouting angiogenesis includes 
endothelial cell (EC) migration, proliferation and tube formation (Carmeliet, 
2005). Intussusceptive angiogenesis involves the capillary wall extending into the 
lumen to split a single vessel in two. This type of angiogenesis is totally different 
from sprouting angiogenesis since it is a reorganization of existing cells and does 
not require intense local EC proliferation (Djonov et al., 2000).  
Figure 1.1 Formation of blood and lymph vessels.  
Endothelial progenitors generate primitive vascular capillaries during 
vasculogenesis. Afterwards, the primitive vascular network expands by 
angiogenesis, the nascent endothelial channels are covered by pericytes (PCs) and 
smooth muscle cells (SMCs), and then a stereotypically organized vascular network 
of arteries and veins emerges. Arteriogenesis refers to the remodelling of an 
existing artery to increase its luminal diameter in response to increased blood flow. 
In addition, lymphatic vessels are transdifferentiated from veins. Adapted from 
(Carmeliet, 2005). 
Angiogenesis 
Arteriogenesis 
        Vasculogenesis 
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1.2 Tumour angiogenesis, tumour growth and metastasis 
1.2.1 Carcinogenesis and cancer stem cells 
Carcinogenesis is a dynamic process where cancer cells are transformed from 
normal cells. Mutations in DNA of normal cells can disturb the balance between 
normal cell proliferation and cell death leading to carcinogenesis. Typically, a 
number of serial mutations in critical genes including tumour suppressor genes, 
proto-oncogenes and DNA repair genes are required before a normal cell 
transforms into a cancer cell. More recently, carcinogenesis has been considered 
in the context of developmental biology and stem cells. The hypothesis of the 
cancer stem cell (CSC) proposes that misregulation of this pluripotent cell type 
can result in a variety of heterogeneous tumour cells. Either transformation of 
adult stem cells or differentiated cells within a tissue might generate CSCs. These 
cells still maintain the key features of stem cells such as differentiating into 
different kinds of cells and self-renewal capability and also function as a 
subcomponent of the tumour. Moreover, these cells may also contribute to 
cancerous relapse and metastatic emergence (Dalerba et al., 2007; Bomken et al., 
2010).  
 
1.2.2 Tumour angiogenesis and cancer progression 
Tumour angiogenesis is basically the formation of new blood vessels from pre-
existing vasculature, which is extremely important for the survival and 
proliferation of cancer cells since tumour-associated neovasculature supplies 
oxygen and nutrients and removes waste products (Figure 1.2). Tumour 
angiogenesis is a complicated process that is divided into several processes: 
vasculogenesis, vascular remodelling (co-option), angiogenesis (vascular 
sprouting and intussusception), vasculogenic mimicry (formation of tumour 
neovasculature partially contributed by tumour cells) and vessels formed partially 
by ECs that differentiated from cancer stem-like cells and is regulated by a 
number of pro-angiogenic and anti-angiogenic molecules (Chang et al., 2000; 
Carmeliet and Jain, 2011a).  
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The initiation of angiogenesis is largely determined by the balance between pro-
angiogenic factors and anti-angiogenic factors. In most normal tissues the balance 
favours the anti-angiogenic factors and angiogenesis is inhibited. In contrast, many 
tumour cells switch toward an angiogenesis-stimulating phenotype associated with 
an increase in producing angiogenic factors. Cancer cells secrete pro-angiogenic 
growth factors that bind to receptors on the surface of endothelial cells (ECs) on 
neighbouring vessels. Then ECs that acquire an angiogenic phenotype as a result of 
this stimulation are capable of migration and proliferation to form new sprouts from 
the pre-existing vasculature. In fact, during tumour progression, genetic alterations 
of tumour oncogenes and suppressors and responses to oxygen reduction can lead 
to overexpression of pro-angiogenic growth factors. These include vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF), epidermal 
growth factor (EGF), platelet-derived growth factor (PDGF) and transforming 
growth factor (TGF)β (Chung et al., 2010). The initial stimulation of tumour 
vasculature formation is termed the „angiogenic switch‟ and can occur at any stage 
of tumour progression and also plays an important role in several steps of tumour 
progression including promoting a small avascular primary tumour to a large 
vascular tumour, activating a dormant lesion and in the conversion of 
micrometastases to macrometastases (Bergers and Benjamin, 2003). Hypoxia 
caused by insufficient oxygen supply in a rapidly growing tumour is one of the 
most important factors triggering the angiogenic switch. For example, stabilisation 
of hypoxia inducible factor (HIF)-1α in response to hypoxia leads to a major 
increase in the expression of vascular endothelial growth factor A (VEGFA) which 
promotes angiogenesis (Forsythe et al., 1996; Bergers and Benjamin, 2003; Manalo 
et al., 2005; Majmundar et al., 2010). Therefore, it will be useful to know whether 
the inhibition of the angiogenic switch can reduce the conversion of pre-angiogenic 
micrometastases to angiogenic macrometastases.   
 
In addition to tumour vessels originating from the neighbouring vasculature by 
angiogenesis, two recent independent studies showed that glioblastoma stem-like 
 5 
cells are capable of giving rise to their own blood vessels (Ricci-Vitiani et al., 
2010; Wang et al., 2010a). It appears that glioblastoma cells with stem cell like 
features can make ECs as well as cancer cells. The anti-angiogenic drug 
Bevacizumab (Avastin, described below) did not affect the differentiation of 
cancer stem cells into endothelial progenitor cells (EPCs), however it did inhibit 
their further differentiation to ECs. Targeting endothelial cells generated by 
glioblastoma derived stem cells resulted in significant reduction of tumour 
growth. Although these studies were performed using a glioblastoma model, 
similar mechanisms may be involved in other tumours and their metastases. The 
findings describe a novel link between glioblastoma stem-like cells, endothelial 
progenitors and tumour derived endothelium. It is thus a new mechanism for 
tumour neovascularisation, which remains to be confirmed in a wide range of  
other tumours.  
 
Figure 1.2 Schematic picture of tumour new blood vessel formation. 
Tumour angiogenesis is the formation of new blood vessels that penetrates into a 
solid cancer mass, supplying nutrients and oxygen and removing waste products. 
Cancer cells release pro-angiogenic molecules to stimulate ECs to form new 
vessels to vascularise the growing tumour. These tumour vessels also provide an 
opportunity of tumour dissemination. Adapted from National Cancer Institute, 
NIH, http://www.cancer.gov/. 
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1.2.3 Tumour angiogenesis and lymphangiogenesis in the tumour metastatic 
cascade 
The growth of secondary tumours that are seeded from and are distant to the 
primary tumour causes the majority of cancer patient mortality. The primary 
tumour may be removed surgically, but numerous secondary tumours may be 
present, for example in the liver, lung or bone tissues. A better understanding of the 
complex metastatic process that is responsible for the spread of the tumour is 
extremely important for exploring novel anti-cancer treatments. The formation of 
new blood vessels (angiogenesis) and new lymphatic vessels (lymphangiogenesis) 
are critical for cancer metastasis as these provide the „conduits‟ for spread of the 
cancer cells (Figure 1.3). As mentioned above, tumour angiogenesis can be 
stimulated by VEGF-A (as well as by VEGF-C and VEGF-D). In addition, VEGF-
C and VEGF-D can induce lymphangiogenesis of the primary tumour and 
subsequent metastatic spread of cancer cells to lymph nodes. Cancer cells may be 
disseminated using both the lymphatic and blood circulation systems. For instance, 
the spread of tumour cells could be via blood vessels from lymph nodes to distant 
organs (Achen and Stacker, 2008).  
 
Interestingly, both clinical observations and experimental studies have found that 
certain tumours metastasize to specific organs (Langley and Fidler, 2007). It seems 
that these findings can be explained by the cross-talk between the „seed and soil‟, 
which was proposed by Stephen Paget in 1889 (Fidler, 2003) and refined by Isaiah 
Fidler. Metastasis to specific organs is likely due to interactions between specific 
subpopulations of metastatic cancer cells (seed) and host homeostatic factors in 
specific organ microenvironments (soil) that include the vasculature. Though, the 
cellular and molecular mechanisms by which disseminating tumour cells 
metastasize to a pre-determined conducive location are largely unknown. There are 
a number of possibilities underpin the „seed and soil‟ hypothesis, for example, bone 
marrow derived VEGFR1 (+)-haematopoietic progenitor cells (HPCs) in 
combination with the expression patterns of fibronectin at pre-determined 
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metastatic niches to generate a conducive microenvironment for tumour cell 
adhesion and extravasation (Kaplan et al., 2005). Furthermore, some adhesion 
molecules such as metadherin (a tumour cell surface adhesion molecule) mediates 
specific adhesion of breast cancer cells to the lung vasculature (Brown and 
Ruoslahti, 2004). Therefore, a new understanding of these issues should result in 
new therapeutic development against metastases by targeting metastatic cells and/or 
the specific organ microenvironment, such as organ-specific vasculature. It seems 
that anti-angiogenic therapy against metastases is an important area for future 
research (Langley and Fidler, 2007; Psaila and Lyden, 2009; Hanahan and 
Weinberg, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Summary of a metastatic cascade via blood and lymphatic vessels 
Metastasis is a multistage process that consists of sequential, interlinked, and 
selective steps and requires cancer cells to escape from the primary tumour, survive 
in the circulation, seed at distant sites and grow. Primary tumour cells can spread to 
metastatic sites via blood vessels and/or lymphatic vessels. Adapted from (Achen 
and Stacker, 2008).  
 
1.2.4 Tumour associated endothelium and vasculature 
Tumour angiogenesis is associated with the formation of poorly muscularised and 
high permeable vasculature in a chaotic and disorganized pattern that enable 
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metastatic cancer cells to disseminate via the blood and/or lymphatic vessels. 
Tumour associated endothelium differs from the endothelium of normal 
vasculature- there are both morphological differences from normal ECs within the 
same organ, as well as changes at the molecular level (Charalambous et al., 2006; 
Bussolati et al., 2010). It was shown that cultured ECs derived from 
neuroblastomas, meningiomas and glioblastoma multiforme were morphologically 
characterized by a veil-like flat structure with large nuclei which was totally 
different from the typical cobblestone-like appearance of cultured normal ECs 
(Alessandri et al., 1999; Charalambous et al., 2005). It was also found that some 
endothelial cell-specific genes were expressed only in angiogenic blood vessels of 
tumours rather than in physiologically angiogenic blood vessels (Seaman et al., 
2007). For example, Tie-2 (Fathers et al., 2005), endoglin (di Tomaso et al., 2005) 
and PECAM-1 (di Tomaso et al., 2005) may be heterogeneously expressed in some 
tumour-associated ECs. Coevolution of tumour cells and the tumour stroma and 
tumour-specific angiogenic growth factors may cause intratumoural differences in 
the endothelium (Langenkamp and Molema, 2009; Bussolati et al., 2010). In 
addition, tumour vasculature might be temporally and spatially different depending 
on tumour stage and tumour microenvironment (Hellebrekers et al., 2007; 
Langenkamp and Molema, 2009). A mosaic phenotype of tumour blood vessels 
results from discontinuities in the expression of EC-specific markers and gaps 
between adjacent ECs. Thus, the heterogeneity and alterations of tumour-associated 
ECs appear to be associated with specific stage and tumour type and these 
differences may contribute to the evasiveness of some tumours to anti-angiogenic 
drugs (Aird, 2009; Bussolati et al., 2010). Therefore, deciphering the molecular 
mechanisms that regulate tumour-associated ECs within the specific tumour 
microenvironment might lead to novel ways of overcoming tumour resistance to 
current therapies. 
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1.2.5 Anti-angiogenic therapy 
It seems that targeting tumour-associated ECs has opened a new era in the field of 
cancer therapy. In the past four decades, a large number of anti-angiogenic 
therapeutic agents have been tested in the clinical settings, but currently only four 
anti-angiogenic drugs are approved by the Food and Drug Administration (FDA) 
for six tumour indications (Ebos and Kerbel, 2011). The humanized murine anti-
vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) 
bevacizumab (avastin; Genentech) was the first molecular-targeted anti-angiogenic 
therapy approved by the FDA. It was found to have a beneficial effect when used in 
combination with chemotherapy and has received FDA approval for the treatment 
of metastastic colorectal cancer (CRC) (Hurwitz et al., 2004; Ferrara and Kerbel, 
2005). Afterwards, the FDA granted approval for the treatment of non-small cell 
lung cancer (NSCLC), metastatic HER2-negative breast cancer (MBC), 
glioblastoma mulifore (GBM) and metastatic renal cell carcinoma (mRCC) (The 
information originated from http://www.cancer.gov/cancertopics/druginfo/fda-
bevacizumab). In patients with solid tumours, however, who are found to benefit 
from VEGF-targeted therapy, the improved overall survival is relatively short (Ellis 
and Hicklin, 2008). Moreover, it has been recently announced that FDA will take 
the first step to remove the usage of bevacizumab in metastatic breast cancer since 
the data from 4 clinical trials indicated there was almost no improvement in 
progression-free survival (PFS) or overall survival (OS) in patients with metastatic 
breast cancer with bevacizumab treatment. In addition, patients were at risk of 
serious side effects such as hypertension, stroke, organ damage and wound healing 
complications (The information was summarized on the Medscape Medical News 
website: http://www.medscape.com/viewarticle/734373).  
 
The mammalian VEGF family is a large family of potent angiogenic regulators 
including VEGFA, VEGFB, VEGFC, VEGFD and placental growth factor (PIGF, 
also known as PGF). The well characterized member of VEGF family is VEGFA 
(commonly termed as VEGF), which is expressed as various isoforms (mature 
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121-, 165-, 189- and 206-amino-acid proteins), depending on alternative splicing. 
VEGF-A165 is the major isoform and is overexpressed in a wide range of human 
solid tumours. Binding of VEGFA to the VEGF receptor, VEGFR2 (primarily 
restricted to the vasculature), promotes EC differentiation, proliferation and 
sprouting. Also, the vascular response to VEGF is increased within the tumour 
due to the upregulation of VEGFR2 in response to hypoxia (Brekken and Thorpe, 
2001). In addition, the pro-angiogenic and anti-angiogenic responses such as ECs 
proliferation, migration and tube formation are tightly regulated by different 
VEGF ligands. For instance, the pro-angiogenic isoform VEGF-A165 and the anti-
angiogenic isoform VEGF-A165b can be produced via alternative splicing of exon 
8 (Bates et al., 2002). In addition, another member of the VEGF xxxb family, 
VEGF121b, which is also a VEGF-A splice isoform, functions as an anti-
angiogenic agent to inhibit tumour-associated neovascularisation and tumour 
progression (Rennel et al., 2009). Therefore, regulating splicing of the different 
VEGFA isoforms from pro-angiogenic to anti-angiogenic forms could provide a 
novel therapeutic strategy to regulate blood vessel growth (Nowak et al., 2010). 
 
In addition to Bevacizumab, there are some other VEGF or VEGFR targeted 
agents that are being tested in current clinical trials. For instance, the multi-
tyrosine kinase inhibitor (TKI) Sunitinib (Sutent, Pfizer), which is a small-
molecule inhibitor with high affinity for VEGFR, PDGFR, receptor tyrosine 
kinase encoded by the ret proto-oncogene and c-Kit receptors. Another example is 
Sorafenib (Nexavar, Bayer/Onyx), which is a potent inhibitor of Raf-1 kinase and 
VEGFR-2. These kinase inhibitors are approved for use as single agents for 
patients with certain types of cancer such as renal cell carcinoma (RCC) and 
hepatocellular carcinoma (HHC). Recently, Pazopanib (Votrient, 
GlaxoSmithKline) has been approved to treat metastatic RCC by the FDA and 
supposed to inhibit VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-Kit 
(Escudier et al., 2007; Motzer et al., 2007; Josep M. Llovet, 2008; Llovet et al., 
2008; Ivy et al., 2009). However, these clinical successes have been accompanied 
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by some unexpected difficulties - the majority of patients are resistant to or do not 
respond at all to these anti-angiogenic therapies (Ebos and Kerbel, 2011).  
 
Therefore, three crucial things must be emphasized as priorities, one is to 
understand multiple mechanisms of the therapeutic benefits associated with 
VEGF-targeted therapies, these will refine current knowledge and guide towards 
more effective use of these agents in the clinic. The second priority has to be to 
investigate drug resistance mechanisms resulting from VEGF-targeted therapies in 
appropriate pre-clinical animal models of all tumour progression stages. Finally, 
in order to use anti-angiogenic agents precisely and efficiently, it will be 
important to identify predictive biomarkers that indicate which patients are likely 
to have a good and stable response (Murukesh et al., 2010) and also to discover 
new combination regimens that improve their efficacy. 
 
1.3 Prospective developments of anti-angiogenic therapy for cancer 
1.3.1 Targeting tumour angiogenesis  
Unexpectedly, it was recently reported that targeting VEGFA/VEGFR2 in mouse 
studies can lead to increased primary tumour invasion and metastasis (Ebos et al., 
2009; Paez-Ribes et al., 2009). These pre-clinical studies have demonstrated that 
VEGF-targeted therapies may make cancer cells more aggressive and invasive, 
ultimately leading to increased metastasis. In addition, it has been reported that a 
rapid re-growth of tumour and associated vasculature occurs following withdrawal 
of VEGF-targeted treatment in pre-clinical studies (Mancuso et al., 2006). These 
findings, although interesting, have caused concern to clinicians and patients in 
consideration of anti-VEGF therapies‟ detrimental effects. It is absolutely necessary 
to look into the relevant data from collective recent clinical trials to determine 
whether these pre-clinical observations are likely to occur in the clinic. The answer 
from leading clinical investigators appears to be “No”. The data from a number of 
phase III trials including 4205 patients with a variety of tumour types was reviewed 
and analysed using meta-analysis, which indicates there is no clinical evidence that 
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VEGF-targeted treatment lead to accelerated tumour aggressiveness and growth or 
increased death caused by enhanced metastasis. Also there was no evidence for 
earlier relapse occuring following cessation of bevacizumab treatment in patients 
(Ellis and Reardon, 2010). Further studies will help understand the mechanisms 
involved in generating increased tumour aggressiveness in the pre-clinical anti-
VEGF models and these factors may yet be important in bevacizumab treated 
patients with longer survival times. Continuous and responsive pre-clinical and 
clinical research cycle – from bench to bedside and back to bench- are required to 
facilitate the best outcomes for patients in the longer term. 
 
1.3.2 Effects of anti-angiogenic therapy in multistages of cancer progression 
“Stage-dependent anti-angiogenic therapy” means that the efficiency of different 
anti-angiogenic therapies is dependent on specific stages of tumour progression. 
Transgenic mice (RIP1-Tag2) that develop pancreatic islet carcinoma in a 
multistage process were treated with four angiogenesis inhibitors AGM-1470, 
angiostatin, BB-94, and endostatin at three distinct stages of disease progression. 
This resulted in preventing the angiogenic switch in premalignant lesions, 
intervening in the rapid expansion of small tumours, or inducing the regression of 
large end-stage cancers, indicating that anti-angiogenic drugs may prove most 
efficacious when they are targeted to specific stages of cancer progression (Bergers 
et al., 1999). Furthermore, it was shown in this RIP1-Tag2 mouse model that 
Semaxinib (SU5416), targeting VEGFRs, effectively inhibits the formation of 
early-stage angiogenic islets rather than late-stage, intensely vascularized and 
invasive tumours (Bergers et al., 2003). In contrast, a PDGFR inhibitor (SU6668) 
prohibits advanced-stage tumour growth due to targeting more mature tumour 
vasculature. Application of SU5416 in combination with SU6668 were shown to be 
more efficacious against all stages of islet carcinogenesis than either single agent. 
Hence, it seems to be promising to apply combinatorial targeting of receptor 
tyrosine kinases in multiple stages of tumorigenesis (Bergers and Benjamin, 2003). 
Clinically, it should be informative to profile overexpression of pro-angiogenic 
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growth factors in distinct stages of cancer progression and explore specific 
biomarkers that can predict potential efficacy of certain anti-angiogenic agents.  
 
1.3.3 Vascular ‘normalisation’ and combination therapies 
Jain (2001) has proposed that some anti-angiogenic therapies can transiently 
„normalize‟ tumour vasculature. This principle is based on the fact that tumour-
associated blood vessels are leaky and dysfunctional and can result in inadequate 
delivery of chemotherapeutics from the bloodstream to the tumour cells. For 
example anti-VEGF therapies can promote „Vascular Normalization‟ to reduce 
vascular leakiness and promote more uniform tumour vasculature that allows 
improved drug delivery (Jain, 2005b). This would synergise the effects of an anti-
angiogenic therapy in combination with chemotherapy or radiation therapy over a 
defined time window. Anti-angiogenic therapy is supposed to be used in this 
transient defined time window when tumour vasculature are properly 
„normalized‟. In principle, tumour vascular „normalization‟ improves the delivery 
of blood to the tumour which may underlie the synergistic benefit of both anti-
angiogenic and cytotoxic therapies (Jain, 2005a). However, it remains to be 
established whether such a mechanism accounts for the long-term beneficial 
effects of combination treatment observed in some trials and also those benefits 
must be tested in randomized clinical trials. 
 
„Metronomic Therapy‟ was proposed by Dr. Robert Kerbel and colleagues, which 
means chemotherapy delivered at close regular intervals using relatively low 
doses with no prolonged drug-free break periods and was thought to preferentially 
damage tumour associated ECs  (Kerbel and Kamen, 2004; Emmenegger et al., 
2010). Unlike conventional chemotherapy, which is designed to target 
proliferating cancer cells, the main targets of metronomic therapy are proliferating 
tumour associated ECs, so that this treatment strategy was also described as „anti-
angiogenic chemotherapy‟ (Browder et al., 2000). In addition, there is the 
possibility of combining metronomic therapy with anti-angiogenic agents, as well 
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as other types of targeted therapies. It was recently reported that metronomic 
delivery of irinotecan (CPT-11) combined with semaxinib (SU5416) to a human 
colon adenocarcinoma (HT-29) xenograft mouse tumour model significantly 
inhibits tumour growth which was coupled with reduced microvessels (Bocci et 
al., 2008). In addition, metronomic therapy may also inhibit circulating 
endothelial progenitor cells (cEPCs) that may support tumour regrowth (Daenen 
et al., 2009). Taken together, it will become increasingly critical to explore the 
more efficacious anti-angiogenic agents and design more effective ways of 
combining such drugs with metronomic chemotherapy (Hashimoto et al., 2010; 
Wong et al., 2010). 
 
Basically, anti-vascular therapies in tumours can take place using two main 
approaches. One approach is that of vascular targeting using vascular disruptive 
agents (VDAs). This type of therapy aims to target endothelium of pre-existing 
tumour blood vessels leading to selective and rapid destruction of the tumour 
vasculature. This may be accompanied by extensive hemorrhagic necrosis due to 
tumour cell ischemia death (Tozer et al., 2005). A second approach is anti-
angiogenic therapy that aims to prevent the formation of new vessels in the 
tumour. In principle, it will be more efficacious to combine these two types of 
agents targeting both existing and new intratumoural vasculature, particularly in 
advanced and late tumour diseases (Tozer et al., 2005; Siemann and Shi, 2008).  
 
In fact, some critical questions must be considered in both pre-clinical and clinical 
studies, such as 1) the timing of anti-angiogenic therapy; 2) the optimal 
scheduling of chemotherapy in combination with anti-angiogenic therapy; 3) 
understanding reasons for unfavourable effects; 4) whether a combination of anti-
angiogenic therapies has a synergistic anti-tumour effect; 5) tailored therapy 
depending on the different angiogenic phenotype and expression of endothelial 
growth factors at the distinct stages of tumour progression; 6) the optimal 
biological dose and minimal toxicity. Althought the question list is still extending, 
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we should continue to explore and identify novel anti-angiogenic agents and 
approaches. For example, Endoglin, a homodimeric transmembrane glycoprotein 
overexpressed on angiogenic tumour-associated endothelium (Burrows et al., 
1995; F.J. Burrows, 1995; Seon et al., 1997; Miller et al., 1999; Fonsatti et al., 
2001; Benetti et al., 2008; Clasper et al., 2008; Yoshitomi et al., 2008), seems to 
be a promising novel target for anti-angiogenic therapy.  
 
1.4 Endoglin and its role in TGF-β signalling pathway 
1.4.1 Endoglin structure and functional features 
Endoglin, also known as CD105, is a disulphide-linked homodimeric 
transmembrane glycoprotein of 180 kDa that consists of an extracellular domain 
(561 amino acid residues) and a cytoplasmic region (serine/threonine-rich 47 
amino acid residues) (Figure 1.4) (Gougos and Letarte, 1990; Bellon et al., 1993). 
The extracellular domain comprises a zona pellucida (ZP) domain, with an 
arginine-glycine-aspartic acid (RGD) binding motif (Gougos and Letarte, 1990; 
Jovine et al., 2005; Llorca et al., 2007), while several potential phosphorylation 
sites are located in the intracellular region (Lastres et al., 1994). The N terminus 
region of the ZP domain plays a role in protein-protein interactions (Jovine et al., 
2002) (Figure 1.4) and is involved in ligand dependent or independent 
heteromeric interactions with receptors of the TGF-β family. Therefore, it seems 
that the ZP domain of endoglin may be responsible for its heteromeric association 
with TGF-β type I receptor (TGFBR1) and TGF-β type II receptor (TGFBR2), to 
transduce the signalling of the TGF-β receptor complex (Guerrero-Esteo et al., 
2002). The RGD tripeptide is a critical recognition structure in cellular adhesion 
and has an interaction motif for integrins of cell surface (Gougos and Letarte, 
1990; St-Jacques et al., 1994). Although endoglin lacks a signalling kinase 
domain, it has been shown to promote TGF-β signalling through the type I 
receptor, ALK1 (Lebrin et al., 2004). 
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Figure 1.4  Schematic structure of the human TGF-β type III receptor 
endoglin.  
Human endoglin protein consists of 625 amino acids and is present on the cell 
surface as a homodimeric transmembrane glycoprotein. The extracellular domain 
contains two long extracellular cysteine domains (orphan domain and ZP domain). 
A conserved RGD binding motif is found at the ZP domain. However, unlike its 
human counterpart, mouse endoglin does not itself contain an RGD tripeptide. Also 
endoglin has a short transmembrane region and a short C-terminal intracytoplasmic 
region and there is approximately 95% amino acid sequence identity between the 
transmembrane and cytoplasmic domains of human and mouse endoglin. Adapted 
from (Garcia-Pozo et al., 2008). 
 
1.4.2 TGF- β superfamily 
Transforming growth factor-beta (TGF-β) is the prototypical member of a large 
family of cytokines, which include the TGF-β isoforms (TGF-β1, TGF-β2 and 
TGF-β3), activins, bone morphogenetic proteins (BMP) and growth 
Extracellular domain 
Cytoplasmic domain 
Signal peptide 
Orphan domain 
ZP domain 
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COOH COOH 
NH2 NH2 
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differentiation factors (GDFs) (Isaac Yi Kim et al., 2005; Schmierer and Hill, 
2007). The ligands of the TGF-β superfamily exert their signalling effects by 
binding to specific transmembrane Ser/Thr kinase receptors that are referred to as 
type I and type II receptor, some ligands can bind directly to their type II receptors 
while others can only interact with type II-type I receptor combinations (Lebrin et 
al., 2005). In addition, there are accessory TGF-β receptors, also known as type 
Ш receptors, endoglin and betaglycan (Gougos and Letarte, 1990; Lopez-Casillas 
et al., 1993). There is a possibility of crosstalk between different ligands and 
receptors in the different TGF-β signalling pathways, which modulate many 
aspects of cellular function, including cellular proliferation, differentiation, 
migration, apoptosis, adhesion, and immune surveillance. Consequently, TGF-β 
signalling can regulate a variety of important process such as embryonic 
development, wound healing, haematopoiesis, inflammation, fibrosis, 
carcinogenesis and angiogenesis (Gordon and Blobe, 2008).  
 
1.4.3 Endoglin regulates angiogenesis through TGF-β signalling in 
endothelium 
Endoglin, can be bound to TGF-β ligands in a complex with type I and type II 
TGF-β receptors. The type I receptors include activin-like receptor kinase (ALK)1 
to ALK6. It has been reported that the type II TGF-β (TGFBRII), activin (ActRII) 
and BMP (BMPRII) receptors can interact with various type I receptors (Feng and 
Derynck, 2005; ten Dijke and Arthur, 2007; Gordon and Blobe, 2008). Moreover, 
it has been shown that endoglin interacts with TGF-β1, TGF-β3, activin-A, BMP-
2 and BMP-7 ligands in combination with type I and type II receptors (Cheifetz et 
al., 1992; Yamashita et al., 1994; Letamendia et al., 1998; Barbara et al., 1999). 
More recently, Endoglin has been shown to bind BMP-9 to promote signalling 
through ALK1. This pathway inhibits bFGF-induced EC proliferation and VEGF-
stimulated angiogenesis (Scharpfenecker et al., 2007). Furthermore, BMP10 may 
also act in a similar way to BMP9 (David et al., 2007). Therefore, it seems that the 
binding of endoglin to type I/II receptor ligand-complexes potentially plays a role 
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in the dynamic interactions of type I/II receptor of the TGF- β superfamily and 
their downstream signalling pathways. 
  
How endoglin regulates TGF-β-dependent responses in vascular endothelial cells 
remains unclear. It has been proposed that endoglin influences TGF-β signals in 
ECs through two alternative pathways - the balance of which regulating the 
activation state of the endothelium and angiogenesis (Figure 1.5). Essentially 
TGF-beta binds the type II receptor (TGFBR2) which then recruits and activates 
the type I receptor (TGFBR1, also known as ALK5) by phosphorylation, 
subsequently ALK5 phosphorylates Smads 2 and 3 which then form a complex 
with Co-Smad 4 and translocate to the nucleus. Here, they regulate the 
transcription of target genes which, in ECs, lead to the inhibition of cell migration 
and proliferation-resolution phase of angiogenesis. In contrast, if the ALK1 type I 
receptor is activated, Smads 1, 5 and 8 bind Co-Smad 4 and are transported to the 
nucleus and regulate expression of specific downstream genes which conversely 
leads to promotion of cell proliferation and migration- processes associated with 
the activation phase of angiogenesis (Lebrin et al., 2004). ALK5 is the 
predominant mediator of TGF-β signalling in quiescent endothelial cells, but 
during angiogenesis, ALK1 is preferentially activated (Bertolino et al., 2005). In 
addition, the absence of ALK5 in cells results in a decrease in ALK1 signalling, 
demonstrating the presence of ALK5 is also required for signalling via ALK1 
(Goumans et al., 2002; Goumans et al., 2003; Lebrin et al., 2004). Therefore, 
endoglin may exert “positive” or “negative” effects on endothelial cell growth and 
differentiation by regulating the balance between ALK1 and ALK5 receptor 
signalling. It seems to be well-recognized that endoglin functionally associated 
with ALK1 is critical for endothelial cell responses to TGF-β (Lebrin et al., 2004).  
 
TGF-β1 exerts bifunctional effects on ECs in vitro, it can both stimulate and 
inhibit the proliferation of endothelial cells. Low concentrations (0.1-0.5 ng/ml) of 
extracellular TGF-β1 added in culture medium promotes the proliferation and 
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migration of ECs that leads to angiogenesis. In contrast, high levels (5-10 ng/ml) 
of TGFβ1 result in inhibition of cell proliferation, induction of apoptosis, cellular 
adhesion and synthesis of ECM proteins (Pepper et al., 1993; Lastres et al., 1996; 
Letamendia et al., 1998; Li et al., 2000; Li et al., 2003; Lebrin et al., 2004; Pardali 
and ten Dijke, 2009; Serrati et al., 2009). Endoglin can modulate these TGF-β-
dependent responses in ECs but there have been a number of contradictory 
reports. For example, suppression of endoglin expression was shown to enhance 
the inhibition of endothelial cell proliferation associated with TGF-β1. This 
indicates endoglin expression has a pro-proliferative effect (Li et al., 2000). 
Similarly, it was shown that endoglin promotes endothelial cell proliferation 
through a TGFβ-ALK1 pathway in studies using Eng−/− and Eng+/− mouse 
embryonic endothelial cells (MEECs) (Lebrin et al., 2004). However, it was also 
reported that an Eng
−/−
 mouse embryonic endothelial cell line can proliferate 
faster in response to TGF-β than control Eng+/+ ECs, suggesting that endoglin is 
not required for EC proliferation (Pece-Barbara et al., 2005). Therefore, in order 
to clarify these endoglin-dependent effects on endothelial cell responses, future 
studies are required using appropriate primary endothelial cells. 
 
Although important evidence of the TGF-β and BMP signalling pathways in 
vasculogenesis and angiogenesis were shown in several in vitro and in vivo 
studies, there are still some contradictions in the field. For instance, it was 
reported that BMP9 and ALK1 have pro- and anti-angiogenic effects on 
angiogenesis. ALK1 was reported to play an important role in either promoting 
the resolution phase of angiogenesis (Oh et al., 2000; Lamouille et al., 2002) or 
improving the activation phase of angiogenesis (Goumans et al., 2002; Goumans 
et al., 2003). This contradiction may be due to different cell types used in the 
studies or ALK1 could be alternatively implicated in both the resolution and 
activation phases of angiogenesis (Pardali et al., 2010). In addition, BMP9 
appears to be an anti-angiogenic agent. It was reported that BMP9 inhibits 
proliferation and migration of ECs via binding with ALK1 and ALK2 and 
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phosphorylating Smad1 (David et al., 2007; Scharpfenecker et al., 2007) and also 
BMP9 signalling was shown to inhibit expression of VEGF through ALK1 (Shao 
et al., 2009). In contrast, BMP9 induced proliferation of a variety of ECs in in-
vitro and in-vivo studies (Suzuki et al., 2010). Moreover, BMP9 in combination 
with TGF-β can promote VEGF induced EC proliferation and VEGF/bFGF 
induced angiogenesis in a matrigel in vivo assay (Cunha et al., 2010). The 
contradictions associated with the pro- and anti-angiogenic effects of TGF- β, 
ALK1 and BMP9 on EC function and angiogenesis remain to be elucidated.  
 
Figure 1.5 TGF-β family members and its signal transduction in endothelium   
TGF- signals transduce through specific serine/threonine heterodimeric TGFBR1 
and TGFBR2 receptor complexes. Binding of TGF- to the extracellular domains 
of TGFBR2 leads to phosphorylation of TGFBR1, which can then specifically 
activate Receptor associated – Smads (R-Smads; either SMAD2/3 or SMAD1/5/8). 
Activated R-Smads form complexes with the Co-Smad, Smad4, and subsequently 
translocate and accumulate in the nucleus. Nuclear Smad complexes can bind to the 
DNA either directly or indirectly, in complex with other DNA-binding proteins, and 
regulate the transcription of specific target genes. The TGF- signals can be 
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modulated by the accessory receptors betaglycan and endoglin. Endoglin may 
function to promote binding of members of TGF-β family to their receptors. 
Moreover, in most cells, TGF-β signals via TGFBR2 and ALK5, and bone 
morphogenetic proteins (BMPs) signal via the BMP type II receptor (BMPR2) and 
ALK1, -2, -3 and -6. Adapted from (ten Dijke and Arthur, 2007). 
 
1.5 Endoglin and tumour angiogenesis 
1.5.1 Endoglin overexpression as a marker of tumour angiogenesis 
Endoglin is considered to be strongly overexpressed on tumour-associated 
vascular ECs, whereas variable levels of endoglin expression were shown in ECs 
of different normal tissues (Wang et al., 1993; Burrows et al., 1995; Seon et al., 
1997; Miller et al., 1999; Fonsatti et al., 2000). Although it is considered that 
endoglin is a specific marker of proliferating ECs, it has also been shown to be 
expressed on several other cell types such as activated monocytes/macrophages, 
myofibroblasts (Lastres et al., 1992; O'Connell et al., 1992), vascular smooth 
muscle cells in atherosclerosis (Conley et al., 2000), neural crest stem cells during 
development (Mancini et al., 2007), adult bone marrow hematopoietic stem cells 
(HSCs) (Chen et al., 2002) and tumour associated lymphatic endothelium (Clasper 
et al., 2008; Yoshitomi et al., 2008). 
 
In solid tumours, the expression of endoglin is almost exclusively restricted to 
ECs of tumour blood vessels (Fonsatti et al., 2001), while it is weakly expressed 
or absent on malignant cells (Gerhardt et al., 2003). In several solid malignancies 
of different histotypes, anti-endoglin mAb reacted almost exclusively with venous 
and arterial endothelium of both peritumoural and intratumoural vessels (Wang et 
al., 1993; Burrows et al., 1995; Seon et al., 1997; Bodey et al., 1998c; Bodey et 
al., 1998a; Bodey et al., 1998b; Seon et al., 2011). Occasionally, the antibody 
weakly stained the cytoplasm of neoplastic cells in sarcomas of different 
histotype, ovary carcinomas (Henriksen et al., 1995) and breast carcinomas 
(Fonsatti et al., 2000), or the tumour stromal components in ovarian endometrioid 
carcinomas (Fonsatti et al., 2001). 
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Endoglin is a marker of activated endothelium, and is associated with tumour 
associated proliferating ECs (Miller et al., 1999). Patterns of endoglin expression 
in primary colon adenocarcinomas and normal colon tissue have been compared 
with expression of the pan-endothelial marker, CD31. Whilst anti-CD31 
antibodies stained blood vessels in both normal and malignant colon equally, 
endoglin expression was observed primarily in malignant lesions, with little to no 
expression in the vessels of normal colon tissue (Hawinkels et al., 2010). 
Furthermore, there were a number of studies that identified upregulation of 
endoglin expression in many other tumour associated ECs, including those of 
mammary gland (Li et al., 2001), prostate (Kassouf et al., 2004), cervix (Brewer 
et al., 2000), colon and rectum (Takahashi et al., 2001b; Akagi et al., 2002), lung 
(Tanaka et al., 2001), head and neck (Kyzas et al., 2006), kidney (Sandlund et al., 
2006), esophagus (Saad et al., 2005) and uterus (Saad et al., 2003). In addition, a 
number of studies have reported endoglin expression in prostate cancer (Kassouf 
et al., 2004), squamous cell carcinomas (Wong et al., 2008), Ewing sarcoma and 
melanoma (Pardali et al.) and hematopoietic tumours including hairy cell 
leukemia (Pruneri et al., 2003) and multiple myeloma (Pruneri et al., 2002). In 
addition, it has been reported that endoglin may regulate proliferation, migration 
and invasion of cancer cells in carcinogenesis of human and experimental animal 
models (Perez-Gomez et al., 2010). This suggests anti-endoglin therapy may have 
effect on cancer cells but it is not yet clear that whether endoglin functions as a 
suppressor or promoter of tumour progression and metastasis (Perez-Gomez et al., 
2010). 
 
1.5.2 Endoglin as a diagnostic and prognostic marker 
As discussed above, endoglin is predominantly expressed in the active and 
angiogenic tumour-associated vascular endothelium and this indicated that 
endoglin antibodies might be useful for tumour diagnosis. Therefore, the presence 
of increased endoglin expression in tumour angiogenic tissue might potentially be 
used to distinguish malignant neoplasm from benign tissue and help to select 
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patients who would be suitable for anti-angiogenic therapy. There were a number 
of promising early studies using radiolabelled antibodies against endoglin that 
indicated useful applications for immunoscintigraphy of tumours. For example, 
99
Tc
m
-labeled anti-endoglin mAb E9 applied in renal carcinoma patients (Costello 
et al., 2004), 
125
I-labeled anti-endoglin mAb MAEND3 used for a canine 
mammary carcinoma model (Fonsatti et al., 2000) and 
111
In-labeled rat anti-mouse 
endoglin mAb MJ7/18 for imaging a mouse Bl6 melanoma xenograft model 
(Bredow et al., 2000) were all used to detect and monitor primary tumour growth 
and metastasis. These studies indicate tumour imaging might gain from taking 
advantage of endoglin labelled targets and may also benefit diagnosis of other 
angiogenic diseases. Furthermore, a similar approach using alternative reagents to 
label antibodies against endoglin could be used for other in vivo imaging systems 
such as MRI and PET scanning. In addition, these types of imaging methods may 
be valuable to monitor the response to anti-angiogenic therapies. 
 
Microvessel density (MVD), a measure of tumour angiogenesis, has been 
examined as a potential and independent prognostic indicator of several human 
tumours, since increased MVD was significantly correlated with faster tumour 
progression, metastasis and shorter overall survival (Weidner et al., 1991; Horak 
et al., 1992; Weidner et al., 1992; Tanigawa et al., 1997; Choi et al., 2005). 
However, these findings were not replicated in other similar studies (Page and 
Jensen, 1995; Lindmark et al., 1996). Thus, it has been suggested that different 
methods used to define MVD and the use of different pan-endothelial antibodies 
may result in such discrepancies. The principal measuring approach is direct 
microscopic immuno-histochemisty/cytochemistry and vessel number counting. 
This approach has some limitations such as quantification, limited numbers of 
fields of view, selection of region of interest and subjective bias. Indeed, a number 
of vascular endothelium markers have been considered for routine use including 
CD31/PECAM-1, CD34 and von Willebrand factor (vWF). The measurement of 
MVD using these endothelial markers has been compared with MVD as 
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determined using anti-endoglin antibodies. In breast carcinoma, the MVD 
measured with antibodies directed against endoglin rather than anti-CD34 
correlated with disease-free and overall survival and the MVD determined using 
anti-endoglin antibodies was also considered as an independent prognostic factor 
in a multivariate analysis (Wang et al., 1994). Also a high MVD measured by 
endoglin staining in a group of patients with head and neck squamous cell 
carcinomas (HNSCCs) showed endoglin, but not CD34, was an independent 
indicator of tumour recurrence or death in a multivariate analysis (Martone et al., 
2005). Additionally, it was shown that the MVD score of endoglin expression is 
positively correlated with Gleason score of prostate cancer (Wikstrom et al., 
2002) and with the tumour stages in oral squamous cell carcinomas (Schimming 
and Marme, 2002). These studies not only indicated that MVD determined using 
endoglin staining appears to be a more reliable prognostic indicator compared 
with other pan-endothelial markers, but also showed that levels of endoglin 
expression may be a useful marker of disease progression, recurrence and 
metastases. 
 
1.5.3 Targeting endoglin as an anti-angiogenic therapy  
A number of in vitro and in vivo studies have recently demonstrated that a variety 
of anti-endoglin monoclonal antibodies (naked, radiolabelled and immunotoxin 
conjugated) localized to the vicinity of major tumour neovascularization in vivo and 
inhibited proliferation of micro- and macro-vascular ECs in vitro. For example, 
anti-endoglin mAb significantly inhibits growth of human ECs in vitro, mainly in 
the presence of TGF-β1, indicating this anti-endoglin mAb synergistically interacts 
with TGF-β to inhibit EC proliferation (She et al., 2004). Moreover, a variety of 
engineered antibodies such as a bispecific antibody (Korn et al., 2004), single-chain 
Fv fragments (Volkel et al., 2004) and nanobodies (Ahmadvand et al., 2008) that 
target endoglin have also been developed and applied to ECs in vitro. These studies 
indicate that these engineered anti-endoglin mAb present additional promising tools 
for therapeutic applications. Furthermore, the immunotoxin conjugated (Seon et al., 
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1997; Matsuno et al., 1999), radiolabelled (Tabata et al., 1999), or naked anti-
endoglin mAb including SN6f, SN6j, and SN6k (Takahashi et al., 2001a; Shiozaki 
et al., 2006; Tsujie et al., 2006; Tsujie et al., 2008; Uneda et al., 2009; Seon et al., 
2011) have been tested in pre-clinical studies using severe combined 
immunodeficiency (SCID) mice bearing human tumours, human skin/SCID mouse 
chimera. These studies demonstrated that tumour growth and metastasis can be 
suppressed with relatively long-lasting efficacy. For example, anti-endoglin mAbs 
were injected in mice with human breast or colon cancer xenografts and these anti-
endoglin therapies significantly inhibited tumour growth and improved survival 
rates (Matsuno et al., 1999; Tsujie et al., 2006). Furthermore, to examine the effect 
of anti-endoglin therapy on metastatic activity, the metastasis models were 
generated by mammary fat pad injection of 4T1 murine mammary carcinoma cells  
and splenic injection of murine colorectal carcinoma cells. The anti-metastatic 
activity of endoglin specific antibodies was observed for both lung and liver 
metastases in this study (Uneda et al., 2009). All these positive responses are likely 
to be mediated by the inhibition of tumour-associated angiogenesis and/or by the 
destruction of tumour-associated vasculature. 
 
Much of our understanding about the growth of new blood vessels has come from 
studies of angiogenesis and vasculogenesis during embryonic development. Many 
of the processes regulating vessel growth are recapitulated in disease. It was 
reported that endoglin is essential for angiogenesis in the mouse embryonic 
development and its expression is up-regulated on proliferating ECs during 
developmental angiogenesis (Arthur et al., 2000; Lebrin et al., 2004). It was thought 
that endoglin may also play an important role in tumour angiogenesis. Bernabeu 
and colleagues have investigated the role of endoglin in tumour
 
angiogenesis and 
growth using endoglin heterozygous (Eng
+/–
)
 
and control mice (Eng
+/+ 
littermates) 
that were subcutaneously
 
inoculated with 10
6 
Lewis Lung carcinoma (LLC) cells 
and tumours harvested after 9 days. The results of these
 
studies indicated that 
endoglin deficiency decreased tumour
 
vascularization and growth (reduction of 
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tumour weight) in the short time frame used in this study (Duwel et al., 2007). 
However, this study did not investigate outcomes after longer time points nor the 
effect of reduced endoglin levels on metastasis.  
 
Anti-endoglin therapy has now reached the clinic. A phase I study, aiming to 
assess tolerability and safety of the therapeutic anti-endoglin mAb, its 
pharmacokinetics and immunogenicity, as well as signs of clinical activity is in 
progress. Patients with advanced and/or metastatic cancer were given naked 
human/murine chimeric anti-endoglin mAb (TRC105) as a tumour vascular 
targeting agent (clinicaltrials-NCT00582985/ last update on 8
th
 Sept 2010). 
Preliminary data from 50 patients with advanced refractory cancer in this clinical 
trial suggest clinical activity and good tolerability of the TRC105 antibody at 
doses up to 1 mg/kg every 2 weeks. In addition, a phase І/II study of TRC-105 in 
metastatic castrate resistant prostate cancer (CRPC) is now active. This study aims 
to define the maximum tolerable dose (MTD) and safety of TRC105 in treating 
CRPC, but also to determine the effects of TRC105  as a treatment for CRPC, in 
particular to determine whether single-agent TRC105 is associated with a 6-month 
progression-free survival probability of 30%, when administrated at the MTD to 
patients with CRPC (clinicaltrials-NCT01090765/ last update on 28
th
 Jan 2011). 
 
Altogether, in light of its tissue distribution pattern (e.g., predominantly restricted 
to tumour-associated vacular ECs), molecular nature (e.g., a transmembrane 
glycoprotein) and functional properties (e.g., actions in TGF- signalling pathway), 
it seems that endoglin can be used as a tumour-associated vascular target for 
cancer diagnosis and therapeutic anti-angiogenic strategies (Dallas et al., 2008; 
ten Dijke et al., 2008; Bernabeu et al., 2009; Fonsatti et al., 2010; Seon et al., 
2011). However, the potential adverse effects of pre-clinical and clinical 
applications and the most appropriate therapeutic applications in the clinical 
setting still need to be investigated.  
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1.6 Adverse effects of anti-angiogenic therapy 
It is generally considered that anti-angiogenic therapies are safer and more 
tolerable than conventional chemotherapy agents, mainly because anti-angiogenic 
agents are more likely to be exclusively selective in their cellular effects. 
Nonetheless, a variety of distinct side effects caused by the validated agents such 
as Bevacizumab (Avastin), Sorafenib (Nexavar), Sunitinib (Sutent) and Pazopanib 
(Votrient) are strictly required to be monitored and managed in clinic. 
Bevacizumab is the first approved anti-angiogenic drug and most of its side 
effects are associated with hypertension, proteinuria, thrombosis and bleeding 
events. Less frequent side effects from Bevacizumab therapy include wound 
healing complications, gastrointestinal perforation and renal damage (Gressett and 
Shah, 2009). In addition, the TKI inhibitors, sorafenib (Nexavar) and sunitinib 
(Sutent) generated a wider range of adverse effects than anti-VEGF antibody 
therapy. The toxicities most often reported include diarrhea, hypertension, fatigue, 
and nausea in clinical trials of sunitinib, while for sorafenib they were diarrhea, 
skin toxicities, and alopecia (Porta et al., 2007).  
In principle, anti-endoglin therapy may potentially develop some similar adverse 
effects to those caused by other anti-angiogenic agents. Anti-endoglin therapy 
related side effects are currently being tested in the two ongoing phase І clinical 
trials (NCT00582985/NCT01090765). Unexpectedly, there has been a Grade 3 
severe allergy and a Grade 4 hemorrhage (gastric ulcer bleeding in one out of 50 
patients) observed to date. Although only one case has been reported so far it 
seems that anti-endoglin treatment may result in haemorrhage similar to anti-
VEGF mAb therapy (Rosen et al., 2008; Rosen et al., 2009; Goldman et al., 
2011). This side effect could also be in line with concerns that anti-endoglin 
therapy may lead to vascular defects similar to those present in Hereditary 
Haemorrhagic Telangiectasia (HHT) patients. HHT type I is caused by a 
heterozygous mutation of endoglin (McAllister et al., 1994) and this vascular 
disorder is characterized by bleeding from small vascular malformations 
 28 
(telangiectases) in the nose and gastrointestinal tract, and by larger arteriovenous 
malformations (AVMs) that have most frequently been reported in the lung, brain 
or liver, but may also occur in the retina (Guttmacher et al., 1995). In addition, 
endoglin heterogyzous mutation mice in Ola/129 gene background spontaneously 
developed phenotypes such as telangiectases on the ears, bleeding from 
nose/mouth and gastrointestinal surface and some AVMs occurred in the lung 
brain and liver, which are similar to clinical symptoms of HHT type I patients 
(Bourdeau et al., 2001). This possibility of side effects caused by anti-endoglin 
therapy therefore remains to be more fully determined in patients and will also be 
addressed in part using mouse models in C57BL/6 gene blackground in this 
thesis. 
1.7 Justification for the project and a list of the aims 
As mentioned above, endoglin is predominantly overexpressed in the tumour-
associated vascular endothelium, where it modulates tumour angiogenesis. 
Although some investigations showed an effect of endoglin reduction or anti-
endoglin therapy on primary tumour growth, when this project commenced no 
studies had been performed on the effect of endoglin depletion on metastasis. 
Therefore, I used a floxed endoglin mouse that had been generated in my host 
laboratory (Allinson et al., 2007) to determine the effect of endoglin depletion on 
angiogenesis, tumour growth and metastases. The LLC-RFP subcutaneous 
primary tumour model was used taking advantage of RFP expressing LLC cells 
for the detection of lung metastases.  
 
The main hypothesis to be addressed in this thesis is that loss of endoglin in ECs 
can delay or reduce angiogenesis and primary tumour growth, and also reduce the 
frequency and severity of metastases.  
 
To address this hypothesis the aims of the work described in this thesis are as 
follows: 
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1. Optimize endoglin depletion in ECs using adult mice with a conditional 
knockout allele (Eng-iKO
e
); 
2. Test the effect of endoglin loss in ECs on in vivo angiogenesis; 
3. Optimize and characterize the LLC subcutaneous primary and 
„spontaneous‟ secondary tumour model; 
4. Investigate the effect of endoglin depletion on LLC primary tumour 
growth and lung metastases; 
5. Examine potential side effects of targeting endoglin using the Eng-iKOe 
mouse model; 
6. Investigate the effect of endoglin loss on mouse lung endothelial cells 
(MLECs) in vitro. 
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Chapter 2. Materials & Methods 
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      2.1 Materials 
2.1.1 Suppliers 
In general, most chemicals and reagents were provided by Sigma Aldrich, 
Invitrogen, BD Biosciences, PeproTech, eBioScience Technology.  
 
All plasticware for cell culture and general laboratory consumption was obtained 
from Greiner, Iwaki, or Corning. The medium for primary endothelial cells and 
cancer cells was purchased from PromoCell and Invitrogen respectively. 
 
Magnetic separator was obtained from Invitrogen. 
 
2.1.2 General Solutions 
PBS, Tris, citrate buffer and 0.1% gelatin solutions were sterilised by 
auotoclaving at 121°C for 30 mins. The constituents of the solutions are listed 
below: 
PBS 
80g of NaCl 
2g of KCl  
14.4g of Na2HPO4 
2.4g of KH2PO4  
in 800ml of distilled H2O. Adjust the pH to 7.4 with HCl. Add H2O to make 1 
litre. 
4% Paraformaldehyde Solution (PFA) 
Add 4g Para-Formaldehyde (PFA) powder to 100ml  PBS and dissolve at 60
°
C. 
Store in 10 ml aliquots at -20
°
C until required. 
1M Tris-HCL 
TRIZMA base dissolved in Milli-Q H2O and adjusted to the appropriate pH 
using HCl. 
TE Buffer 
Add 10mM Tris.Cl at pH 7.4 to 1mM EDTA at pH 8.0 then make up to a final 
pH of 7.4 
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Citrate Buffer (pH 6.0) 
Add 0.1M citric acid, 0.1M Trisodium citrate in deionised water and adjust the 
pH to 6.0 with 0.1M NaOH. 
PBST 
0.1% Tween 20, 1x PBS 
β-galactosidase (β-gal) Staining 
Components  Volume Stock concentration 
0.2% Gluteraldehyde 160µl 25% (stored at -20°C) 
0.02% NP40 40µl 10% 
0.005M EGTA 200µl 0.5M 
0.002M MgCl2 40µl 1.0M 
0.1M Phosphate buffer at pH 7.6 4ml 0.5M 
DDH2O Make up to 20ml 
Table 2.1  Glutaraldehyde Fixative Solution  
Notes: just before use add Glutaraldehyde to a final concentration of 0.2%. 
0.5M Sodium Phosphate Buffer (pH 7.4) 
Add 34.2ml  1M Na2HPO4 , 15.8ml 1M NaH2PO4 and DH2O to make up to 
100ml buffer. 
Components Volume Stock concentration 
0.005M K3 Ferricyanide 1ml 0.5M 
0.005M K4 Ferrocyanide 1ml 0.5M 
0.1M Sodium-Phosphate buffer (pH 7.4) 20ml 0.5M 
2mM MgCl2 200µl 1M 
0.01% Sodium Deoxycholate 1ml 1% 
0.02% NP40 200µl 10% 
DDH2O  Make up to 100ml 
Tabel 2.2 X-gal Staining Solution 
Notes: Staining solution stored in dark without X-Gal at 4°C. 
X-gal 
X-gal powder dissolved in 99% dimethylformamide to a concentration of 25 
mg/ml in glass container stored at -20°C and was added to staining solution at a 
final concentration of 1mg/ml just before use. 
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Wash Buffer 
0.02% NP40 in PBS 
DNA Preparation 
Tris-Acetate (TAE) Buffer 
0.04M Tris-acetate, 0.001M EDTA 
Gel Loading Buffer 
0.25% bromophenol blue, 0.25% xylene cyanol FF and 40% sucrose in water. 
Lysis Buffer A 
0.5M NaOH, 0.5M EDTA, Milli-Q H20, adjust to pH 12 
Lysis Buffer B 
0.5M Tris-HCL, Milli-Q H20, adjust to pH 5. 
Counterstains 
Triple Eosin Counterstain 
9g of Eosin (water soluble) powder, 1g of erythrosin B, and 0.5g of Phloxine. 
Dissolve in 160ml of 20% ethanol then add 640ml of tap water. A 1/30 dilution 
was used to counterstain  x-gal stained sections (see below). 
Carazzi‟s Haematoxylin 
Add 2g of Haematoxylin to 200ml glycerol, leave overnight to dissolve. 
Dissolve 50g Potassium Alum (Potassium aluminium sulphate) in 600ml ddH2O 
then add 0.2g potassium iodate. Mix and add to the haematoxylin and glycerol 
mixture. Make up to a final volume of 1 litre with ddH2O. 
1% Acid Alcohol 
1% HCl in 70% Ethanol. 
Ammonia Water 
2.5 ml Ammonium Hydroxide in 1000ml Tap Water. 
 
2.1.3 Mice 
All of the mouse models were bred in ventilated rooms, in a germ-free facility, 
under controlled conditions of light, temperature and humidity (FGU, IGM, the 
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Centre for Life, Newcastle University, UK) and fed a standard chow for 
laboratory mice with water ad libitum. 
 
All experiments using experimental animal models should incorporate the 3Rs: 
replacement (avoids the use of animals or use alternative approaches to animals), 
reduction (minimises the number of animals used) and refinement (improves 
experimental design and techniques to minimise animal suffering). The 3Rs must 
be considered as an integral part of designing experiments using animals and also 
the 3Rs need to be followed throughout studies. However, in all cases, 
experimental designs and procedures should be tailored to the requirements and 
purposes of the specific studies. 
 
Studies were performed in accordance with international and national institution 
guidelines for the care and use of laboratory animals under home office licence 
PPL60/3622. 
 
Inducible Cdh5(PAC)Cre-ER
T2
 Endoglin
fl/fl
 mice 
Cdh5(PAC)Cre-ER
T2  
mice were obtained from Dr Ralf Adams (CRUK, London). 
This mouse expresses the tamoxifen activated Cre-ER
T2
 sequence that was 
inserted into a PAC (P1 artificial chromosome) containing the vascular 
endothelial Cadherin -VE-Cadherin (Cdh5)- promoter gene to generate the 
transgene construct (Source: http://www.informatics.jax.org/searches/accession 
_report.cgi?id=MGI:3848980). To activate Cre-ER
T2
, mice were injected 
intraperitoneally with 2mg tamoxifen (specific binding to estrogen receptor (ER)) 
for 5 consecutive days and two additional injections on subsequent alternative 
days. Eng 
fl/fl
 Cdh5(PAC)Cre-ER
T2 
mice  were backcrossed for 5 generations with 
C57BL/6 to generate an approximately syngeneic line. 
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Inducible Rosa-Cre Endoglin
fl/fl
 mice 
Inducible Rosa-Cre-ER
T2 
mice were generated in Dr. Alex Joyner‟s Lab, New 
York and obtained from Dr Li, Connecticut, USA. This mouse expresses 
tamoxifen-activated Cre recombinase (Cre-ER
T2
) under the regulation of the 
ubiquitously expressed Rosa26 promoter. Adult Eng
fl/fl
 Rosa26-Cre-ER
T2
 mice 
were injected intraperitoneally with 2mg tamoxifen (10mg/ml) for 5 consecutive 
to activate Cre-ER
T2
. 
 
Rosa26R mice 
A stock colony of Rosa26R mice were obtained from Prof D. Henderson 
(Newcastle University). This gene trap strain contains a loxP flanked neo 
expression cassette (“floxed stop cassette‟‟) upstream of a lacZ gene. LacZ 
expression driven by the ubiquitous Rosa26 promoter is conditional on the 
removal of this intervening floxed stop cassette by Cre recombinase (Soriano, 
1999). These mice were crossed with Cdh5(PAC)Cre-ER
T2 
and Rosa26-Cre-ER
T2
 
mice to map the expression of these respective Cre recombinases by X-gal 
staining in adult tissue or primary ECs.  
 
Immortomouse 
H-2K
b
-tsA58 transgenic mice (Immortomice) were obtained from Dr. Peter 
Hohenstein (Edinburgh University), and express a thermolabile form of the SV40 
T antigen (Jat et al., 1991). The mouse major histocompatibility complex H-2K
b
 
promoter directs expression of tsA58 to a broad range of tissues including ECs 
(Lidington et al., 2002). Immorto- Eng
fl/fl
 RosaCre-ER
T2
 mice, were used for 
isolation of conditionally immortalized EC lines. 
 
2.1.4 Cell lines 
Endothelial cell lines 
The sEND-1 cell line was originally derived from mouse skin microvasculature 
from a transgenic mouse line expressing expressing polyoma middle T antigen 
 36 
(Williams et al., 1988). sEND-1 cells were obtained from Prof. Roy Bicknell 
(University of Oxford) and were grown in Dulbecco's modified Eagle medium 
(DMEM, Invitrogen) supplemented with 10% fetal calf serum (FCS, Invitrogen). 
 
The conditionally immortalized EC line was initially isolated and purified from 
mouse lung microvasculature of Immorto-Eng
fl/fl
 RosaCre-ER
T2
 mice and 
Immorto-Eng
fl/fl
 mice. To passage this cell line, microvascular ECs growth 
medium (PromoCell) was used, and „pure‟ primary ECs were seeded into 0.1% 
gelatin pre-coated 12-well plates under permissive temperature conditions (33°C, 
5% CO2) and presence of interferon (IFN)-γ (20U/ml). Normally, medium was 
refreshed every other day and cells were maintained at high confluence (passaging 
using a twofold dilution on reaching 85–90% confluence). The protocol to prepare 
conditionally immortalised ECs from mouse lungs is described below (2.2.13) 
 
Cancer cell lines 
A lewis lung carcinoma cell line  that constitutively expresses m-cherry red 
fluorescent protein (LLC-RFP) was provided courtesy of Dr. Vivek Mittal (Cold 
Spring Harbor Lab, USA) (Gao et al., 2008).  LLC cells were originally derived 
from the lung of a C57BL/6 mouse implanted with a primary lewis lung 
carcinoma (Bertram and Janik, 1980). LLC-RFP was grown in DMEM + 2mM 
Glutamine + 10% Fetal Bovine Serum (FBS). Confluent cultures were passaged at 
a 1:10 to 1:20 dilution and were grown in standard conditions (5% CO2 and 
37°C). Once every 50-60 passages Puromycin (2µg/ml) was added to enrich for 
cells carrying the RFP construct. 
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          2.2 Methods 
2.2.1 Genotyping of mouse models 
To genotype the offspring from each mouse line, normally, an earclip from each 
mouse was used for DNA extraction. 100μl of 25mM NaOH/0.2mM EDTA 
(pH~12) was added to each clip and samples incubated at 95°C with constant 
shaking (350rpm) for ~1 hour. After vortexing, the addition of 100μl of 40mM 
Tris-HCl ~pH5 to neutralise pH, and centrifugation at 13000g for 5 mins to 
remove the cell debris, 2μl of the supernatant was used in a 25μl polymerase chain 
reaction (PCR) reaction using RedHot DNA Polymerase (Thermoscientific) or 
stored at -20°C until required. 
 
Genotyping was performed using PCR technique. In one reaction, two primer 
pairs were used to amplify regions of the target genes. The standard PCR protocol 
was used (see section 2.2.2) with an annealing temperature of 58C and 35 cycles.  
 
Primers are listed in Table 2.3 Positive (DNA of known genotype) and negative 
(no DNA) control samples were also used. PCR products were separated by 
electrophoresis on a 2% agarose gel, and visualised under UV light followed 
ethidium bromide staining. 
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Table 2.3 Primers used in genotyping PCR and cell PCR reaction.  
To distinguish between wild type, heterozygous, and knockout genotypes, primer 
pairs for the endoglin gene and the other genes were used in the PCR reaction. 
The size of the PCR product is shown in the right column.  
Note: The size of the PCR product is shown in the right column, bp = base pairs 
and wt = wild type. Figure7.9 shows the position of endoglin primers relative to 
the floxed endoglin allele.  
 
2.2.2 Standard PCR amplification 
PCR was carried out in 200μl thin walled PCR tubes using 2μl of DNA, 0.5µl of 
10mM of dNTPs consisting of dATP, dTTP, dGTP and dCTP (Invitrogen), 0.2µl 
1x Taq polymerase, 2.5µl, 25mM MgCl2, 2.5µl 10x Buffer IV (all from Thermo 
Primers Sequences (5‟ to 3‟) Size of Products 
LacZ Forward AGATGATCACACTCGGGTG 
250bp 
LacZ Reverse AATCTCTATCGTGCGGTGG 
m-Eng-NewF4 GGTCAGCCAGTCTAGCCAAG 
602bp (for Eng ∆ 
allele in PCR with m-
Eng-R7) 
m-Eng-R7 CCACGCCTTTGTCCTTGC 420bp (for WT allele)  
500bp (for Eng
fl
 allele) m-Eng-F6 GACGCCATTCTCATCCTGC 
m-Eng-F9b TCAGTTTTCCCGTCAGGCTC 
600bp 
m-Eng-R10 GTTCGATGGTGGTGGATGC 
m-Eng-F12 ATGCGCCTGAACATCGTC 
900bp 
m-Eng-R13 AATCAGGAAGGCACCAAAGG 
CreF GATCGCTGCCAGGATATACG 
574bp 
CreR AATCGCCATCTTCCAGCAG 
WT-R26 GCGAAGAGTTTGTCCTCAACC 
600bp (for WT allele) 
310bp (for Rosa allele) 
R26 GGAGCGGGAGAAATGGATATG 
R26Gtrgeo AAAGTCGCTCTGAGTTGTTAT 
Immorto-F AGCGCTTGTGTCGCCATTGTATTC 
1000bp 
Immorto-R GTCACACCACAGAAGTAAGGTTCC 
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Scientific), 0.25 µl of 20μM forward primer, 0.25µl of 20μM reverse primer and 
17.8µl of sterile filtered distilled water. A negative control containing sterile 
filtered water was included to make sure the reaction mixture was not 
contaminated with another source of DNA. In addition to this, a positive control 
was used to make sure all the reagents were still working appropriately. A Perkin 
Elkin thermal cycler was used and the cycling parameters are shown in the 
following table (Table 2.4). 
 
Reaction Step Reaction Conditions 
1 95
o
C (1 minute) 
2 95
o
C (15 seconds) 
3 58
o
C (30 seconds) 
4 74
o
C (1 minute) 
5 74
o
C (7 minutes) 
6 4
o
C (infinite) 
Cycles (Steps 2-4) 35 
Table 2.4 The conditions required for PCR reactions to genotype Eng
fl/fl
, 
Eng
fl/∆
, Cdh5(PAC)Cre-ER
T2
, Rosa26R and Immorto-mice. 
 
2.2.3 Agarose gel electrophoresis 
The standard concentration of agarose was 2% in 100ml 1x TAE buffer. The 
agarose was boiled in a microwave for 3 minutes to make sure the agarose was 
fully dissolved. The solution was cooled with cold running tap water for around 
two minutes to allow the temperature to cool to about 55-65°C. When cooled the 
solution was slowly poured into a gel tank containing a 14 well comb (which 
allowed 13 samples including the 1Kb ladder to be run) and this was left to set for 
approximately 40 minutes. When solidified the comb was carefully removed and 
the gel was fully immersed in 1x TAE buffer.  The samples were prepared by 
adding 4μl of DNA sample to 1 μl of 5 x DNA loading buffer and loading 4 μl 
into the wells of the gel. A 1kb DNA ladder (Invitrogen) was also loaded onto the 
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gel to permit size analysis of PCR products. Electrophoresis was performed at 65-
75 v for approximately 45 minutes allowing the fragments to completely separate. 
On completion, the agarose gel was immersed in Ethidium Bromide (1μg/ml) 
diluted in H2O for 20 minutes. The DNA bands were visualised by placing the gel 
into a UV transluminator and the image was captured with using Genesnap 
software (Syngene Bio Imaging). 
 
2.2.4Tamoxifen administration 
To activate Cre-ER
T2
, tamoxifen was prepared at 10mg/ml, by dissolving 1mg 
tamoxifen powder in 10 µl 100% ethanol and then mixing with 90µl peanut oil. 
This method was used to prepare tamoxifen for activating Cre enzyme in adult 
mice, such as topical tamoxifen application and tamoxifen intraperitoneal (i.p.) 
injection. Following tamoxifen application, the health of the mouse models were 
carefully monitored.  
 
Topical application of Tamoxifen on ears 
100 µl tamoxifen (10mg/ml) was applied to the right ear using a gilson pipette 
whilst the left ear was used as an internal control and 100µl peanut oil was 
applied. The treatments were repeated 3 times per week (Monday, Wednesday 
and Friday) for 6 weeks. 
 
Subcutaneous implantation of 21-day slowly resealing tamoxifen pellet 
Slow-release pellet containing 25mg Tamoxifen citrate (Innovative Research of 
America) was implanted subcutanously into the scruff by making a 1cm incision 
in the dorsal skin and inserting the pellet away from the wound towards the tail of 
the mouse. The wound was closed using stitches of absorbable thread. The mouse 
was anaesthetised by isoflurane (oxygen flow rate: 500ml/min, isoflurane 
induction rate: 5% and isoflurane sustained rate: 2-3%) throughout the procedure. 
 
Intraperitoneal injection of tamoxifen 
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Mice were injected intraperitoneally once daily with 2 mg tamoxifen (10mg/ml) 
per mouse for 5 consecutive days followed by a further injection at day 7 and one 
more at day 9 (total dose of tamoxifen for per mouse is 14mg over 9 days). Care 
was taken during the injection to avoid any damage to internal organs.  
 
2.2.5 Histological procedures 
Tissue dissection 
Mouse skin, matrigel plugs, LLC primary tumour and heart & lungs were 
dissected for tissue analysis. Fixatives (0.2% PFA, 4% PFA or Formalin) and 
dissecting instruments (a fine/round tipped pair of scissors, old scissors for cutting 
bone, and forceps) were assembled prior to culling mice. Mice for isolation of 
mouse lung primary endothelial cells were killed by cervical dislocation and all 
other mice were sacrificed using CO2. 
 
To harvest matrigel skin or primary tumour, mice cadavers were pinned to a 
dissecting board with dorsum/back of mouse facing up under a light source. The 
hair surrounding matrigel plugs or primary tumour was shaved off, and the skin  
was moistened using 70% ethanol. Skin close to matrigel plug or primary tumour 
was tightly held up using a fine tipped forceps and an incision made with fine 
tipped scissors underneath the deep muscle layer. The integrated tissue block 
including skin, matrigel plugs or primary tumour and deeper muscle layer was 
dissected. 
 
To remove lungs for preparing ECs, mice cadavers were pinned out on the 
dissecting board with the peritoneal wall facing up under a light source. The 
mouse body was moistened using 70% ethanol and a longitudinal incision through 
the skin was made from the abdomen to the top of the thorax. The abdominal wall 
was opened below the ribcage, the sternum raised with tweezers and the 
diaphragm cut. Then the main part of the ribcage was cut away to partially expose 
the heart and lungs. A small incision in the left atrium was made under a 
 42 
dissecting microscope for drainage. A 10 ml syringe with 10ml cold PBS was 
inserted into the apex of the right ventricle and used to flush the blood from the 
mouse. Fat and connective tissue was trimmed away around the heart and lungs 
which were then removed from the thoracic cavity and processed as described in 
2.2.13 below. 
 
Processing tissue to paraffin wax blocks 
To prepare paraffin sections for histological analysis, tissue was briefly washed in 
PBS and then fixed in 4% formaldehyde/PBS for at least 3 hours at room 
temperature. Tissues were washed well in 3 changes of PBS for 3 hours (= 3 x 1 
hour) at room temperature. Tissue was dehydrated by transferring to 50% 
Ethanol/H2O for a minimum of 2 hours at room temperature on the shaker, and 
then overnight in 70% Ethanol/H2O. Dehydration was completed in 100% Ethanol 
in 3 changes for 6 hours (=3 x 2hours) at room temperature. Tissue was cleared in 
a glass container in Histoclear (National Diagnostics)  overnight in fume 
cupboard, and then equilibrated in 3 changes of paraffin over 6 hours (= 3 x 2 
hours) at 60°C with occasional swirling of the glass tubes to ensure adequate 
penetration of the wax. Finally, tissue was orientated in plastic moulds (Lamb) 
such that the cut surface accurately represents the tissue and left to set at room 
temperature for at least 1 hour and cooled on ice or in fridge before removing 
paraffin block from mould.  
 
Processing tissue to frozen blocks 
Tissues were removed from mice quickly and carefully, rinsed in cold PBS and 
then washed in 2 changes of PBS. Tissues were subsequently fixed in 0.2 % or 4 
% PFA/PBS (fixative concentration depends on tissue and antibody requirements) 
overnight on the shaker at 4°C. Next morning tissues were rinsed with cold PBS 
and left overnight at 4°C in 30% sucrose/PBS. Tissues were briefly washed with 
cold PBS, covered in OCT (Lamb), orientated in the plastic moulds, rapidly 
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transferred to the dry ice box and left for at least 15 minutes. When tissues were 
frozen, blocks were put in the -80°C freezer for storage until required.   
 
Microtome sectioning 
Paraffin blocks of skin and matrigel plugs were sectioned at a thickness of 5μm - 
10 μm using a Leica RM2135 rotary microtome with disposable microtome blades 
(Lamb).  Transverse or sagittal serial sections were cut into small ribbons. 
Sections were floated into a water bath at 37°C for the sections to expand and 
creases removed. The sections were carefully floated onto Histobond slides 
(Marienfeld, Germany) and drained. To remove the remaining water, the slides 
were dried for a couple of hours at 39°C on a heating plate, this also promoted 
adhesion of the sections to the glass slides. The slides were stored in the plastic 
slides box at room temperature until required. At least one hour before staining, 
slides were left in the 60
 o
C oven, and then paraffin sections were dewaxed in two 
changes of histoclear for 10 minutes (2 x 5 minutes) and hydrated in graded 
concentrations of ethanol from 100% ethanol (2 minutes) through 70% ethanol (2 
minutes), 50% ethanol (2 minutes),  to water. 
 
2.2.6 Cryostat sectioning 
The tissue blocks taken from -80°C freezer were left to equilibrate at -20
o
C for at 
least 30min in the chamber of cryostat (Microm HM 560 cryostat, Germany). 
Serial horizontal cryostat sections (thickness: 10m - 20m) were cut at -20oC to 
-22
o
C and mounted on polylysine glass slides (VWR). Sections were left to air dry 
for 60 minutes at room temperature before being stored in labeled slide mailers in 
the -80°C freezer. Before use, slide mailers were taken out of -80°C freezer and 
left at room temperature for 30 minutes. Subsequently, slides taken out from 
mailer were left at room temperature for another 30minutes. Sections were fixed 
in cold acetone on ice for 10 minutes and taken out of acetone to air dry for 
15minutes, before washing in PBS for 5 minutes.  
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2.2.7 H&E staining 
Paraffin sections were stained in Carazzis Haematoxylin (H) for 5 minutes 
followed by a 2 minutes rinse in H2O. The sections were then differentiated in 1% 
acid alcohol for 5-10 seconds. After a quick water rinse the sections were then 
immersed in ammonia water for 10 seconds or until the sections turned blue. 
Sections were then washed in running tap H2O for 10 minutes then stained with 
eosin (E) for 45 seconds. For even staining results, slides were dipped several 
times before leaving them in the solutions for the desired time. The sections were 
dehydrated through a separate series of increasing ethanol solutions. Finally 
stained sections were mounted on slides using Histomount mounting medium 
(National Diagnostics). In H&E stained sections the nuclei are stained blue, 
cytoplasm pink and muscle fibres, fibrin and connective tissues are shades of red 
to pink. 
 
To stain nuclei, cryosections were stained for 2 minutes in Mayers Haematoxylin 
(Lamb), quickly rinsed in tap water, before dipping into eosin counterstain for 1-2 
seconds. Sections were dehydrated rapidly through graded ethanol solutions by 
dipping slides 3 times in each of 50 %, 70 %, 100 % and a second 100 % ethanol. 
Sections were left in histoclear solutions (2 x 10 minutes) to clear. Finally, slides 
were mounted with coverslips using histomount. 
 
2.2.8 X-gal staining 
The bacterial beta-galactosidase gene lacZ is frequently used as a reporter gene 
and was monitored by histochemistry with the chromogenic substrate X-gal.  
 
Whole Mount X-gal Staining 
Tissue was dissected into cold PBS (4°C) on ice, and then washed in enough cold 
PBS (4°C) to remove excess serum completely. Next, tissue was fixed by 
immersion in pre-cooled glutaraldehyde fixative solution (Table 2.1) at 4°C for 30 
minutes, using the shaker in cold room to ensure even fixation. Subsequently, 
tissue was rinsed with PBS to remove excess fixative, then thoroughly washed 3 
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times (for 30 minutes each wash) at room temperature in plenty of washing 
solution (PBS/0.02% NP40) using a rocker. Finally, the tissue was stained in the 
dark in X-gal staining solution (Table 2.2) at 33°C overnight in a water bath with 
gentle agitation. (Note: background beta galactosidase activity, which may be a 
problem in adult tissues, was minimized by using 33°C incubation temperature). 
 
X-gal staining on frozen sections 
Tissue cryosections from freezer (-80ºC) were brought to room temperature inside 
slide mailers to minimize condensation (30 minutes) then air dried for an 
additional 30 minutes. Sections were encircled with a hydrophobic barrier pen 
(ImmEdge,Vector), whilst drying. Frozen sections were postfixed in 0.2% PFA on 
ice for 10 min and then washed twice in PBS containing 2mM MgCl2 on ice (= 2 
x 10 minutes wash ),  (Placing slides in detergent rinse – 0.02% NP40 in 1x PBS 
is an option to improve penetration of stain into tissues in the next step). The X-
gal staining solution (X gal was used at a final concentration of 1.25mg/ml) was 
gently placed on the sections and incubated at 32°C overnight in the dark. Slides 
were washed twice in PBS with 2mM MgCl2 and rinsed in distilled water, before 
counterstaining with light eosin (1/30) for 8 minutes. Slides were then washed 
three times in distilled water for 5 min each and dehydrated through the graded 
ethanol series (50%, 70% and 100%). Finally, sections were cleared by placing in 
Histoclear (= 2 x 5 minutes) and mounted in histomount.  
 
X-gal staining on cells 
Cells were seeded onto 8-well glass slides (Lab-Tek, USA), and it was not 
necessary to pre-coat wells with gelatin for adherence of endothelial cells. To 
promote endoglin deletion in Eng
fl/fl
 Cre-ER
T2
 lines, cells were allowed to grow 
for 24 – 48 hours before adding 1µM 4-Hydroxy Tamoxifen (4-OHT) (Sigma 
Aldrich) for 48 hours. The media was replaced and cells left for another 24 to 48 
hours to allow time for lacZ expression. Cells were washed twice with 200µl PBS 
and then fixed for 10 minutes at room temperature in 2ml of 0.5% glutaraldehyde 
 46 
diluted in PBS. The fixative was removed by washing cells 3 times with 2 ml PBS 
containing 1 mM MgCl2 and then X-gal staining solution (Table 2.2) was added to 
wells before incubating at 37°C until the desired staining was achieved (overnight 
incubation gives the most intense staining). The cells were then washed with PBS 
and counterstained with a light eosin counterstain (achieved by staining slides for 
1min in 1/30 eosin, followed by brief wash in tap water). Finally, slides were 
rapidly dehydrated through 50% and 100% ethanol and cleared in histoclear 
before being mounted with Histomount (National Diagnostic) and coverslipped 
prior to examination under the microscope. 
 
2.2.9 Immunohistochemistry (IHC) 
Anti-CD31(Clone MEC13.3, provided as 15.625 µg/ml stock solution, BD 
Biosciences, Pharmingen) and anti-endoglin (Clone MJ7/18, provided as 0.5 
mg/ml stock solution, eBioscience) are both monoclonal rat anti-mouse antibodies  
and used on mouse tissue cryosections. Preliminary experiments were carried out 
to determine the optimum dilutions of each primary antibody that resulted in clear 
staining with low background. This was determined to be a 1:25 dilution and 
1:100-200 dilution in 5% rabbit serum (Vector Laboratories) for CD31 and 
endoglin antibody respectively.  
 
Prior to commencement of staining, the tissue cryosections were removed from 
the freezer and allowed to reach room temperature. All subsequent staining steps 
were done at room temperature and all incubations were done in a humidified 
chamber. For immunostaining with anti-CD31 or anti-endoglin, the sections were 
blocked by 5% rabbit serum (Vector Laboratories) in PBS for 20 minutes, washed 
in PBS for 5 minutes, then incubated with the primary antibody in cold room 
(4ºC) overnight. Sections were washed in 3 changes of PBS (5 minutes each) 
before application of the biotinylated secondary rabbit anti-rat antibody (Vector 
Laboratories) at 1:200 dilution in 5% rabbit serum in PBS for 30 minutes. 
Following the secondary antibody incubation, sections were washed in 3 changes 
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of PBS (5 minutes each) then incubated with the Vectastain  Elite ABC Reagent 
(Vector Laboratories) for 30 minutes. After further washing in PBS (3 changes, 5 
minutes each), antibody binding was visualized using the liquid DAB substrate kit 
(BioGenex). Sections were counterstained with Mayer‟s haematoxylin (Sigma-
Aldrich®), washed in PBS, and then dehydrated in a graded alcohol series of 
70%, 90% and 100% ethanol. Following dehydration of the sections, the slides 
were cleared in Histoclear (National Diagnostics) and coverslipped with a 
mountant (HistoMount). Negative controls for the immunostaining were carried 
out as above, except that the primary antibodies were replaced with PBS. 
 
2.2.10 Isolection B4 staining 
Cryosections were removed from freezer (-80ºC), and allowed to air dry as before. 
The tissue area was marked using a hydrophobic barrier pen (ImmEdge,Vector). 
Sections were gently washed once in PBS and incubated with 1% bovine serum 
albumin (BSA, ≥ 98%, Sigma-Aldrich) blocking solution for 1 hour. Then, 
sections were washed twice in PBS (5 minutes each wash), and incubated with 
Isolectin B4 conjugated Alexas 488 IgG (Invitrogen, stock concentration: 
500µg/ml, diluted in PBS + 0.1mM CaCl2 to a working concentration of 20µg/ml) 
at RT in a dark humidified chamber for 1 hour. Surplus isolectin was removed by 
washing slides 3 times with PBS (2 minutes for each wash). Slides were mounted 
using Vectashield Mounting Medium Hard set with DAPI (Vector) and stored in 
the dark at 4 ºC until inspection under the microscope. (Note: Staining of 
Isolection B4 and DAPI was stable for at least 10 -15 days and 4-5 days, 
respectively, when slides were stored in this way). 
 
2.2.11 Immunofluorescent staining 
There were two types of immunofluorescence staining methods used in this thesis. 
One was to do direct immunofluorescence staining in which the primary antibody 
labeled with fluorescence dye (e.g. αSMA- fluorescein isothiocyanate (FITC) 
(1:200)), and the other one was to do indirect immunofluorescence staining in 
 48 
which a secondary antibody labeled with fluorochrome (e.g. Alexas488 (1:200), 
Alexas594 (1:200) and Alexas647 (1:10); incubation for 1hour at RT) was used to 
recognize primary antibodies (working concentrations and conditions of a number 
of primary antibody used in my experiments as follow, CD31 (PECAM-1, 1:25-
50), endoglin (CD105, 1:100-200), Collagen IV (1:200), lymphatic vessel 
endothelial HA (hyaluronic acid) receptor (LYVE-1) (1:200), HIF-1α (1:100), 
fibroblast specific protein (FSP)1 (1:100); incubation at 4
o
C, O/N). The same 
approach was performed prior to commencement of staining as described in the 
section 2.2.9. In addition, the blocking solution (5% blocking serum and 1% BSA 
incubation for 1hour at RT) were used before adding primary antibodies. 
Immunofluorescence stained samples are examined under a fluorescence 
microscope. 
 
2.2.12 In vivo matrigel angiogenesis assay 
Matrigel implantation 
High concentration Matrigel (BD Biosciences) was thawed at 4ºC and kept on ice 
to maintain a liquid consistency. Growth factors: 600ng/ml bFGF and 300ng/ml 
VEGF (Peprotech) were added on ice and the mixture left on the rotator overnight 
at 4
o
C to ensure good mixing prior to injection. 
 
A small volume of Matrigel and growth factor mixture (400µl) was injected 
subcutaneously into the right flank region of mice under anesthesia with 
Isoflurane. Staring the same day, 200μl (10mg/ml) liquid tamoxifen was injected 
intraperitoneally, and i.p. injections continued over 7 days as described above 
(Section 2.1.3.1). Animals were humanely culled on day 15 after matrigel 
injection. Each matrigel plug was harvested and processed by fixing overnight in 
4% PFA and processed to paraffin for H&E staining, or by directly freezing in 
liquid nitrogen-cooled isopentane for immunohistochemistry.  
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Immunohistochemistry of matrigel plugs 
Frozen matrigel plugs were sectioned and immunostained for CD31 and endoglin 
as before (Section 2.2.9) except that sections were briefly fixed for 10 minutes 
with cold 100% acetone before immunostaining.  
Vessel quantification in matrigel plugs 
For vessel quantification, cryosections of the whole matrigel tissue block taken 
from each mouse were prepared and every fifth slide was chosen for CD31 
immunostaining and vessels were counted for the images taken. The section with 
maximum number of blood vessels in each matrigel plug was selected for 
statistical analysis.  
 
2.2.13 Isolation of primary mouse lung endothelial cells (MLECs) 
Prepare mouse lung 
cell suspension
Add Dynabeads
pre-coated with 
CD31 Ab
Incubate for 40mins 
at 4°C
Separate on magnet
Positively isolated 
Endothelial cells
 
Figure 2.1 summary of optimized MLECs isolation using antibody-Dynabeads 
conjugates by magnetic separator.  
Finely minced mouse lungs from 3-4 mice (8-10 weeks) were digested by collagenase 
(2mg/ml) for 1 hour at 37
o
C. All the following procedures were carried out under 
sterile conditions in a tissue culture hood. The cell suspension was incubated with 
CD31-Dynabeads conjugates in endothelial cell growth medium for 40 minutes at 4
o
C. 
The tube containing MLECs bound with CD31-magnetic Dynabeads conjugates and 
non-MLECs were placed on the magnetic separator for 1 minute before pipetting off 
the non-MLECs. This step was repeated three times in the exactly same way, to obtain 
the „pure‟ MLECs which were then cultured in complete endothelial cell growth 
medium MV2 (Table 2.5). As any contaminating fibroblasts tended to grow more 
rapidly than ECs, then after about 1-2 weeks in culture, a second sorting step used 
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CD102 (ICAM-2) antibody pre-coated Dynabeads (see below). After these two rounds 
of cell sorting and subsequent cell passaging, there was a relatively good yield of 
almost pure endothelial cells for the subsequent functional assays. 
Prior to Cell Isolation 
Mouse lung endothelial cell media were prepared as follows:  
Isolation Medium was MV2 endothelial cell growth medium (Promocell) without 
supplement mix + 20% FCS + 1% Penicillin/Streptomycin  
Growth Medium was MV2 Endothelial cell growth medium (Promocell) with 
supplement mix + 1% Penicillin /streptomycin 
   
Components Concentration 
Fetal calf serum 5% 
Epidermal Growth Factor (EGF) 5.0ng/ml 
Vascular Endothelial Growth. Factor  (VEGF) 0.2μg/ml 
Hydrocortisone 0.5ng/ml 
basic Fibroblast Growth Factor  (bFGF) 10ng/ml 
R3  IGF-1 20ng/ml 
Ascorbic Acid 1μg/ml 
  Table 2.5 Components of complete MV2 endothelial cell growth medium   
Preparation of Anti-mouse CD31 (PECAM-1, BD) Dynabeads: 
Prior to use, 75µl sheep anti-rat Dynabeads (Invitrogen) were resuspended in 5 ml 
of 0.1% BSA/PBS in a 15ml falcon tube and then placed on a magnetic separator 
(DynaMag-15, Invitrogen ) for 1 minute. The supernatant was removed and the 
washing step repeated 3 times. Beads were resuspended in original volume (75µl) 
of 0.1% BSA/PBS. Afterwards, 15µl of CD31-Ab (MEC13.3, BD Pharmingen, 
Cat.553369) was added to 75µl of beads and the volume made up to 0.5 ml with 
0.1% BSA/PBS.  The beads and CD31-Ab mixture was mixed overnight on 
rotator at 4°C (or for 2 hour at RT). Excess antibody was removed by washing 
beads with 0.1% BSA/PBS 4 times as before. Finally, beads were resuspended in 
original volume (75µl) with 0.1% BSA/PBS to maintain beads at 4 x 10
8
 
beads/ml. (Beads were stored at 4°C and used within 1-2 weeks). 
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On The Day of The Isolation 
Collagenase Preparation: 
Type I Collagenase (Sigma-Aldrich) was dissolved at 2mg/ml (150-170 U/mg) in 
15 ml of DPBS + Ca
2+
/Mg
2+
 (Invitrogen) by gentle shaking (50 – 60 times per 
minute) at 37°C for 1 hour then filter sterilized using a 0.22 μm filter (Life 
Science).  
 
Dissection: 
A young adult mouse (age 8-10 weeks) was sacrificed by cervical dislocation and 
was thoroughly wetted with 70% ethanol. The skin was nicked above the pubis 
with scissors and removed to above the chest. The mouse cadaver was pinned out 
supine on a Styrofoam board on bench top and any loose fur from gloves was 
carefully removed. The anterior abdomen was cut open, and the anterior 
diaphragm was taken down with sterile scissors. Using a fresh sterile set of 
scissors and tweezers for within the thorax, the lung lobes and heart were 
dissected out from the mediastinum. Lung lobes and heart were placed in 50 ml 
falcon tube containing 20ml cold Isolation Medium and kept on ice until 
beginning the cell isolation procedure. (Note: it is possible to store the lungs for 
up to 6 hours on ice before beginning the cell isolation procedure, but longer 
storage may result in a lower yield and reduced viability of cells). These steps 
were repeated for a second mouse and lobes from different mice were pooled. At 
least 3 mice were found to be required for a good yield of ECs. 
 
Tissue Dissociation: 
The Falcon tube with lung lobes was transferred to a sterile laminar flow hood for 
subsequent work. To clean and dissect the lungs, three 5-cm diametre Petri dishes, 
each containing 10 ml growth medium were prepared. Using new sterile scissors, 
the heart was cut off (taking care to avoid as much of the aorta as possible) and 
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any visible bronchi and mediastinal connective tissue was carefully removed from 
the lung lobes. The lungs were placed in a dry 5cm dish and minced finely with 
scissors for 5 -10 minutes (This step is important because the smaller the tissue 
pieces are the better will be the final cell yield).  
 
To separate the cells, all lung pieces (including all bits off the plate) were placed 
in 15 - 20 ml (this volume depending on how many lung lobes were used, usually 
15ml for lung lobes of 3 mice) of pre-warmed (37°C) collagenase (2 mg/ml, 
dissolved in DPBS with Ca
2+
 and Mg
2+
) and incubated in a shaking water bath 
(shaking speed at 80 – 90 times per minute) for 1 hour at 37°C. The timing is 
critical  because longer or shorter incubations will compromise the final cell yield. 
The cell suspension was removed from the waterbath and 10 ml of growth 
medium was added. Then a 20 ml syringe attached firmly to the cannula, was used 
to triturate (bring up and down through the syringe) the suspension 4 times, taking 
care to avoid frothing (bubbles in the tube can dislodge beads that are attached to 
the magnet in the next step; also oversyringing can cause whitish strands of DNA 
to precipitate out of the cells which may compromise the culture). 
 
 
The cell suspension was filtered through a 70µm cell strainer (Falcon) into a 50 
ml tube (optional: containing 20 ml of growth medium) and centrifuged for 5 min 
at 1000g (1029rcf =2300rpm). Most of the supernatant was carefully removed 
leaving approximately 0.5 ml of liquid and the cell pellet in the bottom of the 50 
ml tube. (It was important to avoid creating bubbles in the tube, as before.) The 
cell pellet was carefully resuspended in an additional 1ml growth medium by 
gentle pipetting. This cell suspension was incubated with anti-CD31 pre-coated 
Dynabeads for cell sorting. 
 
Cell Sorting: 
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Approximately 1.5ml cell suspension was transferred to a cryotube containing 
7.5µl anti-mouse CD31- Dynabeads. The cryotube was incubated on a rotator at 
4°C for 40 minutes (Note: when incubating Dynabeads and cells, the incubation 
temperature must be 2-8°C to reduce phagocytic activity and other metabolic 
processes). Bead and cell suspension mixture was transferred to a 15ml falcon 
tube in a magnetic separator and left for 1 minute. The supernatant was removed. 
(Note: the beads & cells should look somewhat foamy if there is good yield of 
positive selection.) The falcon tube was removed from magnetic separator and 
beads & cells resuspended in 5 ml growth medium by vigorous trituration. (Note: 
This step needs to be vigorous to avoid overgrowth of contaminating non-
endothelial mesenchymal cells.) The beads & cells were transferred to the 
magnetic separator for 1min and this washing step was repeated until the 
supernatant was clear (usually 4-5 washes). The cells were resuspended in Growth 
Medium and plated in one 0.1% gelatin-coated T25 flask or 6 wells of 0.1% 
gelatin-coated 12-well plate. The next day, the cells were washed three times with 
growth medium to remove any loosely adherent cells and surplus beads. 
 
Second Sort (optional): 
Cells were fed with Growth Medium every other day until  approaching 
confluence (approx. 80%) at 5-9 days after plating (Note: Nests of „cobblestone‟ 
endothelial cells should be seen and other mesenchymal cells are notable for the 
way they pile up and don‟t form monolayers). Cells were rinsed once with Ca2+ 
/Mg
2+
 -free PBS and then Trypsin-EDTA (0.05%:0.5M, Invitrogen) was added for 
the minimum time necessary to detach the cells. Approximately 2-10ml of 
isolation media was then added to inactivate Trypsin. The cell suspension was 
transferred to a 15 ml falcon tube and centrifuged at 1000g for 5 minutes. The 
supernatant was carefully removed and cells resuspended in 2 ml of DPBS. 
CD102 (ICAM-2, BD) coated sheep anti-rat Dynabeads were prepared in a similar 
way to the CD31 beads and added to the cell suspension (15 µl/ml) for 40 minutes 
at 4°C. The dynabead- bound cells were washed gently three times in 5 ml growth 
 54 
media using the magnetic seperator as before. After the final wash the cell pellet 
was resuspended in 10 ml growth media and plated onto gelatin-coated flasks or 
multiwell plates.  
NOTES: 
Anti-CD31 antibody-coated Dynabeads are used in the first cell sorting, but their 
use in later sorts is hindered by CD31 sensitivity to trypsin digestion. The washes 
of the initial plating of cells can also be done as early as two hours after plating, 
but yield may suffer. Additionally, the first rinse (containing non-adherent cells) 
can be plated on a second flask to increase yield, while still maintaining a fairly 
high purity of ECs. 
 
2.2.14 Cryopreservation and cells recovery culture 
Recovery Cell Culture Freezing Medium (Invitrogen) was prepared on ice and 
cryotubes fully labelled with details about cells to be frozen. Subconfluent cells 
were detached with Trypsin-EDTA as before and cells were washed with cold 
medium in cold centrifuge and a pellet of cells was obtained. The cells were 
resuspended in 1 ml ice-cold freezing medium (1ml for per T75 flask of cells) on 
ice and 0.5 ml was dispensed into one cryovial on ice. Cells were slowly cooled 
down to -80C using a cell freezing container containing Isopropanol, ensuring a 
steady freezing process. After 1 – 3 days, the tubes were then transferred into 
liquid nitrogen for prolonged storage. 
 
To recover frozen cells, the cryovial was removed from liquid Nitrogen into an ice 
bucket for transfer to cell culture room. The cells were then thawed rapidly in 
37
o
C waterbath or rolled between hands. When just liquid, a pipette was used to 
gently drip cells into 10ml pre-chilled complete medium on ice. After 
centrifugation, the supernatant was removed and cells were resuspended in pre-
warmed medium and were pipetted gently up and down. Cells from each cryovial 
were seeded into one T25 flask. When seeding density was critical, a dilution 
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series (1:2, 1:4; 1:8 etc) can be prepared using a 12 well plate as one of these is 
likely to generate the correct cell density.  
 
 
2.2.15 Immunocytochemistry 
Table 2.6 The details of optimization for immunocytochemistry on MLECs. 
 
Cells were grown for 24 to 48 hours on multiwell slides (Lab Tek II, Nunc) in the 
presence or absence of cytokine at 37C in humidified chambers and 5% CO2 
atmosphere. All subsequent incubations were carried out at room temperature. 
Cells were washed in PBS, and fixed with 2.5% paraformaldehyde in PBS for 20 
Major optimized 
steps 
Original two-
step method 
Test of three-
step method 
Optimized two-
step method 
Fixation 2.5% PFA @ RT 
10 minutes 
Cold acetone @ 
4oC 
10 minutes 
Acetone @ RT 
5 minutes 
Washing post-
fixation 
1x PBS wash 
0.3% Triton X-
100/ PBS 
1x PBS wash 
 
1x PBS wash 
 
Blocking solution 10% FCS, 0.3% 
Triton X-100, 2% 
BSA, 5% Marvel 
milk powder 
30 minutes 
10% rabbit 
serum, 30 
minutes; 
Strepavidin/biotin 
blocking kit 
5% Goat serum 
1% BSA 
@RT, 20 minutes 
1
o
Ab titration 1/25, 1/15, 1/10 1/25, 1/15, 1/10 1/25 
1
o
Ab incubation Diluted in 
blocking solution, 
@ RT, 2 hours 
Diluted in 1.5% 
rabbit serum, @ 
4
o
C, O/N 
Diluted in 
blocking solution, 
@ 4
o
C, O/N 
Washing post-1
o
Ab 
incubation 
0.1% Triton X-
100/PBS, 3 times 
0.1% Triton X-
100/PBS, 3 times 
1x PBS wash, 3 
times 
 
2
o
Ab incubation Diluted in 
blocking solution, 
@ RT, 1 hour 
Diluted in 1.5% 
rabbit 
serum+0.1% 
Triton X-
100/PBS, @ RT, 
45 minutes 
Diluted in 
blocking solution, 
@ RT, 1 hour 
Washing post-2
o
Ab 
incubation 
0.1% Triton X-
100/PBS, 3 times; 
dH2O, twice 
0.1% Triton X-
100/PBS, 3 times 
1x PBS wash, 3 
times 
 
Mounting medium Vectorshield 
Mounting 
Medium with 
DAPI 
Vectorshield 
Hardset 
Mounting 
Medium with 
DAPI 
Vectorshield 
Hardset Mounting 
Medium with 
DAPI 
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minutes. Alternatively, when staining for CD31 protein, cells were fixed in 100% 
methanol for 2 minutes. Fixative was removed and followed by 2 washes in PBS. 
To diminish background fluorescent signal, the cells were incubated with 
blocking solution (5% goat serum, 1% BSA) for 20 minutes. The blocking 
solution was removed and the primary antibody, diluted in blocking solution, was 
applied. After the time indicated for the particular antibody in Table 2.7, the slides 
were rinsed three times in PBS. The appropriate fluorescein conjugated secondary 
antibody (1.5 mg/ml, Vector Laboratories) was applied for 1 hour at 1/200 
dilution in blocking solution. Cells were washed three times in PBS, and slides 
were mounted with anti-fade water-based mountant hard set with DAPI (Vector 
Laboratories) and coverslips.  
Table 2.7  Antibodies used for immunofluorescence.  
 
2.2.16 PCR to genotype cultured cells  
PCR was performed following the protocol for genotyping in section 2.2.1. The 
minimal cell number required for genotyping by PCR was optimized using the 
sEND-1 cell line.  
 
 
 
 
 
 
 
 
Primary antibody Source Dilution Incubation  
PECAM1(CD31) BD Pharmingen 
(cloneMEC13.3) 
1/25 o/n, 4°C 
Endoglin (CD105) eBioscience 1/100 o/n, 4°C 
Secondary antibody Source Dilution Incubation  
Fluorescein goat anti-rat 
Alexa488 IgG 
Invitrogen 1/200 1 hr, RT 
Fluorescein goat anti-rat 
Alexa594 IgG 
Invitrogen 1/200 1 hr, RT 
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2.2.17 MTT assay 
To measure cell viability, the MTT assay was performed following the approaches 
shown in Figure 2.2.   
 
Figure 2.2 MLECs Viability –MTT Assay 
For the viability assay, MLECs were incubated in 100µl microvascular endothelial 
cell medium (MV2) with 5 % FBS at an initial density of 5x10
3
 per well in 96-well 
microplates (coated with 0.1% gelatine). After 24 hours, the media were replaced 
by MV2 medium with 1µM 4-OHT, and the control wells with MV2 medium only. 
After 48 hours of incubation, the medium in all the wells were changed to MV2 
medium, after another 48 hours, 10 µl MTT (5 mg/ml in PBS) was added to each 
well. After 4 hours of MTT incubation, the media were discarded, and 100µl 
dimethylsulfoxide (DMSO) was added to each well. The plate was shaken for 30 
seconds and the absorbance was measured at 570 nm using a Multiskan microplate 
reader (MultiScan Ascent, Thermo Labsystems).   
 
2.2.18 Scratch assay 
Prior to the assay, a line was drawn with a marker on the bottom of the well and 
5x10
4
 cells/ml (sEND-1) were seeded per well of a 12-well plate. Cells were 
cultured for 24 – 48 hours until confluent (90% confluence is best). On the day of 
the assay, a sterile trimmed cell scraper (approx. 1.5-2 mm) was used to scratch 
one „wound‟ through the cells moving perpendicular to the line drawn on the base 
of the well. (Note: it was important to keep the same angle of the pipet tip at 90
o
 
to well surface and to maintain constant pressure of the tip). A picture of the 
„wound‟ was taken using phase contrast and 5 x objective (Note: If this is done 
MLECs Viability – MTT Assay 
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just above and/or just below each line, this will help orientate the measurements). 
The distance between the two migrating fronts of the cells was measured using 
„measure‟ tool in Axiovision software. Further images were taken at 6, 12 and 24 
hours and so on until confluence was reached (the final selection of different 
timepoints depends on the rate of cell growth and cell type). Based on the sEND-1 
cell line wound healing study, MLECs scratch healing assay was optimized and 
performed following the approaches shown in Figure 2.3. 
 
 
Figure 2.3 In Vitro MLECs Monolayer Scratch „Wound‟ Healing Model 
For the in vitro monolayer scratch-healing model, MLECs were incubated in 1ml 
microvascular endothelial cell medium(MV2) with 5 % FBS at an initial density of 
20 x 10
4
 cells/well in 12-well plates coated with 0.1% gelatin. After 24 hours, the 
media was replaced by MV2 medium with 1µM 4-OH tamoxifen, and the control 
wells with MV2 medium only. After 48 hours of incubation, an approx. 2-mm-wide 
incision in the cell monolayer was created using a sterilized trimmed cell scraper (it 
was optimized in this experiment since it was easier to make uniform scratch 
compared with using a pipet tip). Subsequent to wounding, the media were 
removed, and the plates were washed with PBS and were added endothelial cells 
growth medium MV2. The absence of cellular materials in the „wounded‟ area was 
monitored under a microscope using the Nikon Biostation. Subsequently, 
endothelial cells migrated from both leading edges to close the „wound‟ and digital 
images were taken using a x4 objective every 2 hours over a 28-hour period 
(starting 90 minutes after the wounding to minimize condensation) for subsequent 
measurements of „wound‟ areas. Throughout this period, the cells were incubated at 
   Migration – Scratch Assay 
 59 
37
o
C in a humidified atmosphere of 5% CO2 and 95% air. This experiment was 
performed three times. 
 
2.2.19 MLECs proliferation study – cell counting 
MLECs proliferation study was simply performed by cell counting following the 
procedures shown in Figure 2.4. 
 
 
Figure 2.4 Cell number counting – MLECs proliferation assay. 
For the cell counting proliferation assay, MLECs were incubated in 1ml 
microvascular endothelial cell medium (MV2) with 5 % FBS at an initial density of 
5x10
4
 cells/well in 12-well plates (coated with 0.1% gelatine). After 24 hours, the 
media were replaced by MV2 medium with 1µM 4-OH tamoxifen, and the control 
wells with MV2 medium only. After 48 hours of incubation, the medium in all the 
wells were changed to MV2 medium, afterwards, endothelial cells proliferating 
measurement areas were set up for every 4 hrs images taken within 80 hours using 
Nikon BioStation. During the observation and images taken, the cells were 
incubated at 37
o
C in a humidified atmosphere of 5% CO2 and 95% air. Digital 
images were taken every 4 hours using a x10 objective, starting 90 minutes after the 
wounding (to minimize condensation). This experiment was performed three times 
(truly include pilot study). 
 
2.2.20 Microscopy and image analysis 
Apart from work using the Nikon Biostation, cells grown in tissue culture dishes 
or flasks were viewed and photographed with a Zeiss Axiovert 200 inverted 
microscope. Slides with fixed tissue sections or cells were viewed using a Zeiss 
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Axioplan 2 microscope, a Zeiss Axio Imager II or a Zeiss Axiovert 200 inverted 
scanning confocal microscope. Whole mount stained or lungs with metastatic 
lesions were visualized using a Zeiss Axioplan stemimicroscope. 
 
Images of primary tumour were obtained with Axiovision software and 
vascularity of primary tumour was quantitatively analysed using ImageJ software 
(NIH, USA). The other images were obtained and analysed with Axiovision 
software. 
 
2.2.21 Statistical analysis 
Statistical analysis was performed using Minitab 15 statistical software (Minitab 
Ltd. USA). In order to promote valid data collection, I designed a database on the 
platform of Microsoft Access 2000. This has the advantage of promoting 
validation and security of data and was also equally important to input data to 
statistical software rapidly and automatically for analysis. The basic statistical 
description includes whether the data set is normally distributed. Generally, 
normally distributed data sets were analysed using parametric statistics whilst 
non-normally distributed data sets were analysed using non-parametric statistics.  
 
Parametric statistical tests used were Fisher‟s exact test, student‟s t-test and the 
Chi-square test. The nonparametric data were analyzed by using the Mann 
Whitney test. A linear regression analysis and power analysis were also used. 
Multiple testing was corrected using slopes analysis. Differences at the P < 0.05 
level were defined as being statistically significant.  
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Chapter 3. Establishing the Endoglin Conditional Knockout 
Adult Mouse Model 
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3.1 Introduction 
To investigate the role of endoglin, three different laboratories have generated 
endoglin homozygous null mice. All mice with null endoglin alleles showed early 
embryonic lethality at E10.5–11.5 and were characterized by defective 
angiogenesis of the yolk sac and aberrant cardiac development (Bourdeau et al., 
1999; Li et al., 1999; Arthur et al., 2000). This early embryonic lethality does not 
give any opportunity to look into the function of endoglin at later developmental 
stages in adult life. In order to investigate whether endoglin is required for the 
formation and stabilization of neovasculature in neonatal development and adult 
life and whether it plays a major role in tumour angiogenesis, growth and 
metastasis, an endoglin floxed mouse (Eng
fl/fl
), having two loxP sites flanking 
exons 5 and 6 of the endoglin alleles (Figure 3.1) was generated in my host 
laboratory for conditional knockout studies (Allinson et al., 2007). 
 
To allow time-specific activation of Cre-recombinase function and tissue-specific 
depletion of target gene, a tamoxifen inducible Cdh5(PAC)Cre-ER
T2 
transgenic 
mouse (Mahmoud et al., 2010; Wang et al., 2010b) was crossed with the Eng
fl/fl
 
mouse to generate Eng
fl/fl
 Cdh5(PAC)Cre-ER
T2 
mice (Figure3.1). Homozygous 
endoglin floxed mice (Eng 
fl/fl
) are viable and fertile, with no obvious phenotype. 
However, in the presence of active Cre recombinase a recombination event occurs 
between the two loxP sites to generate specific deletion of endoglin exons 5 and 6. 
This also leads to a frameshift mutation in exon 7 and generates a null allele. The 
tamoxifen-inducible Cre-recombinase (Cre-ER
T2
) under the regulation of the 
vascular endothelial cadherin promoter (Cdh5) was used to achieve temporal 
control of endoglin expression in the endothelium (Figure 3.1). In the 
Cdh5(PAC)Cre-ER
T2 
line, Cre recombinase is expressed as a fusion protein with 
part of the estrogen receptor which can in turn bind to tamoxifen, leading to the 
activation of Cre enzyme. Therefore, Eng
fl/fl
 Cdh5(PAC)Cre-ER
T2 
mice were used 
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to conditionally knockout endoglin expression specifically in vascular ECs at 
specific time-points during adult life. 
 
In order to monitor Cre activity, the Rosa26R reporter line was used. Here, the 
lacZ gene is inserted into the ubiquitously expressed Rosa locus in front of which 
a transcriptional stop cassette flanked by loxP sites is located (Mao et al., 1999; 
Soriano, 1999). In the presence of Cre recombinase the stop cassette is removed 
by recombination between the loxP sites (Figure 3.2) and lacZ is expressed and 
can be monitored using X-gal staining of whole mount and tissue cryosections. As 
the Cdh5(PAC)Cre-ER
T2
 line was not fully characterised at the start of my 
project, an early goal was to optimise Cre activation prior to using this line to 
deplete endoglin. 
 
To investigate how endoglin depletion in Eng
fl/fl
 Cdh5(PAC)Cre-ER
T2 
mice 
affected new blood vessel formation, in vivo matrigel implantation angiogenesis 
assays were performed. Tissues were analyzed using immunostaining with 
antibodies to CD31 (also known as PECAM-1, a pan-endothelial cell marker) and 
CD105 (endoglin). Importantly, i.p. injection of tamoxifen in adult control 
animals was tested for any impact on general health or on new blood vessel 
formation in the matrigel plugs. The work described in this section aims to 
establish whether the Eng
fl/fl
 Cdh5(PAC)Cre-ER
T2 
mouse is a valuable tool to 
study the function of endoglin in tumour angiogenesis, growth and metastases. 
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Figure 3.1 The temporal & spatial inactivation of endoglin bifloxed allele by 
Cre-loxP technology.   
The activation of the Cdh5(PAC)Cre-ER
T2 
recombinase following tamoxifen 
administration, leads to EC specific recombination between loxP sites and  
excision of exons 5 and 6 of the endoglin gene. This also leads to a frameshift 
mutation in exon 7, giving rise to a null endoglin allele encoding a truncated 
protein. 
 
 
Figure 3.2 Cre mediated recombination of the Rosa26R allele 
The Rosa26R gene trap strain contains a loxP flanked neo expression cassette 
(„floxed stop cassette‟) upstream of a lacZ gene. LacZ expression driven by the 
ubiquitous Rosa26 promoter is conditional on the removal of this intervening 
floxed stop cassette by Cre recombinase. 
 
Exon5 Exon6 Exon7 
loxP loxP 
Engfl/fl 
Exon4 
      Functional allele 
Exon7 Exon4 
loxP 
Eng Δ Exon5&6 
Inactive allele 
Cdh5(PAC)
Cre-ER
T2
 tamoxifen 
+ 
Rosa26R Allele 
 
   Activated Rosa26R Allele 
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3.2   Results 
3.2.1 Cdh5(PAC)Cre-ER
T2
 expression   
In order to assess activation and cell specifity of the Cdh5(PAC)Cre-ER
T2
 line, I 
first crossed with the Rosa26R Cre reporter line and used X-gal staining to detect 
Cre activity following intraperitoneal (i.p.) injection of tamoxifen. Wholemount 
stained skin tissues clearly showed Cre activity in the blood vessels of the ear and 
dorsal skin (Figure 3.3). For a more detailed examination of vessels where Cre 
recombinase had been activated, light eosin counterstained paraffin sections of X-
gal stained wholemount ear and dorsal skin tissues were prepared (Figure 3.4). 
The blue staining was mainly localized within the ECs of blood vessels, 
confirming that Cdh5(PAC)Cre-ER
T2
 is located in vascular ECs (Figure 3.4). In 
contrast, no detectable lacZ enzyme was detected in control sections from 
ROSA26R animals that had been treated with tamoxifen. Although the X-gal 
staining of sections from the skin stained in whole mount preparations clearly 
showed endothelial X-gal staining the intensity was weak and incomplete (Figure 
3.4 A). This may be because of inefficient perfusion of the X-gal staining 
solution. To address this possibility, I therefore performed X-gal staining directly 
on dermal cryosections. It can be seen in Figure 3.5 A that almost all the dermal 
vasculature was stained with X-gal indicating efficient Cre activation in adult 
dermal blood vessels following i.p. tamoxifen treatment of Cdh5(PAC)Cre-ER
T2
 
Rosa26R mice. Due to technical reasons I was unable to stain using the vascular 
endothelial marker CD31 on cryosections stained with X-gal, to confirm 100% 
activation in all blood vessels. However, the X-gal staining specificity and 
efficiency appeared to be at a high enough level to confirm suitability of the 
Cdh5(PAC)Cre-ER
T2
 line for further experiments. 
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Figure 3.3 Characterizing expression patterns of activated Cdh5(PAC)Cre-
ER
T2
 recombinase by wholemount X-gal staining. 
A&C, The expression of Cre enzyme on the ear (A) and dorsal skin (C) of              
           Cdh5(PAC)Cre-ER
T2
; Rosa26R
T/+
 adult mice; a network of blue stained  
           blood vessels was detected by X-gal whole mount staining.  
B&D, Ear (B) and dorsal skin (D) of Rosa26R
T/+
 adult mice revealed no blue  
           blood vessels following X-gal whole mount staining. Note small amount of  
           background staining likely due to endogenous galactosidase activity (see  
           section 3.3 for discussion of this problem). 
Note mice used in this experiment were treated with tamoxifen i.p. injection. 
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Figure 3.4 Skin sections following whole-mount staining in X-gal.    
A, Light eosin counterstained paraffin skin sections show that X-gal positive  
     staining is associated with the capillary network in Cdh5(PAC)Cre-ER
T2
;  
     Rosa26R
T/+ 
mice. Red arrows show the unstained region of an arteriole and a  
     venule (The possible reasons for incomplete activity are discussed in section  
     3.3.1); 
B, No lacZ expression was detected in the control (Rosa26R
T/+ 
) skin, but there are  
     some small blue crystals likely due to non specific background staining  
     (blue arrow; discussed in section 3.3.1), black arrows indicate unstained  
     blood vessels. 
Scale bar = 100µm. Abbreviations: a, arteriole; v, venule; c, capillaries. 
 
 
Figure 3.5  Direct X-gal staining of dermal cryosections   
A, X-gal staining shows efficient Cre activation in adult dermal blood vessels   
     following tamoxifen treatment of Cdh5(PAC)Cre-ER
T2 
Rosa26R mice. Blue  
     colour represents endothelial expression of lacZ resulting from Cre activation  
     of the Rosa26R Cre reporter allele. Sections were lightly counterstained with  
     eosin to show tissue morphology. 
B, No blue staining detected in the skin of control Rosa26R mice without Cre.  
     Black arrows indicate non-stained blood vessels.  
Scale bar = 100 µm. Abbreviations: a, arteriole; v, venule; c, capillaries. 
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3.2.2 Endoglin expression is reduced following topical tamoxifen application to 
ears 
Although the work described above showed activation of Cre-ER
T2
 by i.p. 
injection of tamoxifen in the Cdh5(PAC)Cre-ER
T2 
line, I also wished to explore 
the efficiency of other protocols for tamoxifen delivery to determine which was 
the most efficient and the most convenient for regular use in the remainder of the 
project. I therefore tried three means of tamoxifen application: 28-day 
continuously released tomoxifen pellets, topical application and compared these 
with i.p. injection (following similar published protocols (Alva et al., 2006; 
Monvoisin et al., 2006) and also personal communication with Dr. Ralf Adams). I 
also focussed on the outcomes in terms of efficient knockdown of endoglin 
protein expression (rather than induction of LacZ expression) as this was the 
primary objective for the remainder of the study. To do this I used 
immunostaining with CD31 and endoglin antibodies on ears and skin of 
Eng
fl/Δ
Cdh5(PAC)Cre-ER
T2 
mice and control mice following tamoxifen topical 
application, tamoxifen pellets and i.p. injection of tamoxifen. Eng
fl/Δ
 indicates 
heterozygosity for the floxed endoglin allele and an endoglin deficient (Δ) allele, 
generated in a previous cross of the endoglin floxed line with the PGK-Cre line. 
The aim was to reduce the starting level of endoglin protein to maximise 
knockdown efficiency.  
 
Firstly, I investigated whether endoglin expression is reduced following topical 
application of tamoxifen. In this case it is important to consider that tamoxifen is 
converted to the active hydroxytamoxifen after being absorbed through the skin 
and passing through the liver. Left ears of mutant and control mice were treated 
with peanut oil and right ears were treated with tamoxifen three times per week 
for 6 weeks. Tissues were then examined by immunostaining with CD31 and 
endoglin antibodies. The results showed similar CD31 expression in ears of 
Eng
fl/Δ 
Cdh5(PAC)Cre-ER
T2
 mice and control mice (Figure 3.6). However, there 
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was some loss of endoglin expression in the right ear of Eng
fl/Δ 
Cdh5(PAC)Cre-
ER
T2 
mice compared with that of control mice (Figure 3.7). This demonstrates that 
Cre-ER
T2
 recombinase can be activated by topically applied tamoxifen and also 
that there was partial deletion of the endoglin. Some reduction of endoglin 
expression in the left ear of Eng
fl/Δ
 Cdh5(PAC)Cre-ER
T2 
mice compared with that 
of control mice, indicated systemic reduction of endoglin expression. However, 
there was significant background staining, which may have been due to 
endogenous pseudoperoxidase activity within tissues (Figure 3.8). Tissue 
elements most commonly responsible for pseudoperoxidase activity are 
hemoproteins such as hemoglobin in red blood cells, myoglobin in muscle cell, 
cytochrome in granulocytes, and monocytes. Further optimisation of the endoglin 
immunostaining protocol was required to reduce the background staining. Despite 
the problem of background staining caused by possible endogenous 
pseudoperoxidase this data suggested that endoglin expression was partially 
reduced in both ears following topical tamoxifen application. 
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Figure 3.6  Vasculature of the ears from Eng
fl/Δ 
Cdh5(PAC)Cre-ER
T2 
and Eng
 
fl/+
 mice show similar CD31 expression.     
A, CD31 immunostaining of left ear of Eng
 fl/Δ 
Cdh5(PAC)Cre-ER
T2 
transgenic  
     mouse model (topical peanut oil treatment only); haematoxylin used as nuclear  
     counterstain. 
B, CD31 immunostaining of left ear of Eng
 fl/+ 
mouse model (topical peanut oil  
     treatment only); 
C, CD31 immunostaining of right ear of Eng
 fl/Δ 
Cdh5(PAC)Cre-ER
T2 
transgenic  
     mouse following topical tamoxifen treatment;               
D, CD31 immunostaining of right ear of Eng
 fl/+
 mouse following topical  
     tamoxifen treatment.  
Note that some sections appear thicker than others because they had been cut at 
slightly different angles. Scale bar = 100µm. 
 
Figure 3.7 Endoglin expression appears to be reduced in ears from Eng
 fl/Δ 
Cdh5(PAC)Cre-ER
T2 
mouse following topical tamoxifen application 
A, Endoglin immunostaining of left ear of Eng
 fl/Δ 
Cdh5(PAC)Cre-ER
T2 
transgenic  
     mouse model (topical peanut oil treatment only);  
B, Endoglin immunostaining of left ear of Eng
 fl/+
 mouse model (topical peanut oil  
     treatment only);  
C, Endoglin immunostaining of right ear of Eng
 fl/Δ 
Cdh5(PAC)Cre-ER
T2  
     transgenic mouse following topical tamoxifen treatment;               
D, Endoglin immunostaining of right ear of Eng
 fl/+
 mouse following topical  
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     tamoxifen treatment.  
Note: To allow direct comparison, these tissue sections were stained in parallel 
and images were taken using the same exposure time. Scale bar = 100µm. 
 
 
Figure 3.8 No primary antibody controls using ears from control and mutant 
mice to show level of background staining 
A, Left ear of Eng
 fl/Δ 
Cdh5(PAC)Cre-ER
T2 
transgenic mouse model (topical  
     Peanut oil treatment only);  
B, Left ear of Eng
 fl/+
 mouse model (topical peanut oil treatment only);  
C, Right ear of Eng
 fl/Δ 
Cdh5(PAC)Cre-ER
T2 
transgenic mouse following topical  
     tamoxifen treatment;               
D, Right ear of Eng
 fl/+
 mouse following topical tamoxifen treatment.  
Note: red arrows indicate background staining, black arrows indicate non-specific 
staining of hair follicles. Scale bar = 100µm. 
 
3.2.3 Endoglin expression is reduced following tamoxifen pellet implantation 
Slow release (over 21days) tamoxifen pellets were implanted subcutaneously. In 
principle, this is a very convenient method for tamoxifen treatment as the pellets 
once in place, can be left to release tamoxifen over a 3-week period. Tissue was 
harvested at 3 and 5 weeks and cryosections were immunostained with CD31 and 
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endoglin antibodies (Figure 3.9). The results showed partial loss of endoglin 
expression in the skin of Eng
fl/Δ 
Cdh5(PAC)Cre-ER
T2 
mice compared with that of 
control mice, demonstrating that the slow release pellets did lead to some 
recombination of the target loxP sites in the floxed endoglin allele. However, due 
to persistent problems with background staining (Figure 3.10 shows no primary 
control images), it was difficult to know how efficiently endoglin was deleted. In 
addition, conspicuous side effects of this method of tamoxifen delivery were 
observed. For example, local ulceration of the skin lying over the pellet occured in 
4/6 animals. And more seriously, stomach haemorrhage was observed in 1/4 
Eng
fl/Δ 
Cdh5(PAC)Cre-ER
T2 
mice when animals were observed post mortem. For 
this reason the pellets were not used in further experiments. 
 
Figure 3.9 CD31 and endoglin expression in the skin following 21 day slow-
release tamoxifen pellet application 
A, There is less endoglin expression in the skin of Eng
fl/Δ 
Cdh5(PAC)Cre-ER
T2
  
     mice compared with B, which shows many endoglin-positive microvessels in  
     the skin of Eng
fl/+
 mice. Scale bar = 100µm. 
C & D, CD31 expression in the skin of Eng
fl/Δ 
Cdh5(PAC)Cre-ER
T2
 (C) and  
A            Engfl/Δ Cdh5(PAC)Cre-ERT2 B                       Engfl/+   
 
C            Engfl/Δ Cdh5(PAC)Cre-ERT2 
 
D                      Engfl/+   
 
Endoglin 
CD31 CD31 
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     Eng
fl/+
 mice (D). Black arrows indicate hair follicles, red arrows indicate  
     microvessels.  
  
Figure 3.10 No primary antibody control using ears from an Eng
 fl/Δ 
Cdh5(PAC)Cre-ER
T2 
mouse to show level of background staining 
Black arrows indicate hair follicles and red arrows indicate background staining in 
muscle fibres. Scale bar = 100µm. 
 
3.2.4 Endoglin expression is absent following tamoxifen intraperitoneal 
injection  
Adult mice received tamoxifen i.p. injections 2 mg once a day for 5 consecutive 
days. On day 10 after the first injection, the skin and ears were removed and 
cryosections were immunostained with CD31 and endoglin antibodies (Figure 
3.11&12). Significant differences in endoglin expression between the skin of 
mutant mice and that of control mice can be seen. Endoglin protein expression 
appears to be completely lost from the skin of Eng
fl/fl
 Cdh5(PAC)Cre-ER
T2
 mice 
and also from the heart and lung (personal communication, Dr. Marwa Mahmoud 
and Rachael Redgrave). In addition, the immunostaining protocol was  optimized 
by using avidin/biotin blocking solution and prolonging washing times to remove 
background staining. Therefore from this immunostaining evidence, I was able to 
conclude endoglin was efficiently reduced in Eng
fl/fl
 Cdh5(PAC)Cre-ER
T2 
mice 
following i.p. injection of tamoxifen.  
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Figure 3.11 Endoglin is efficiently reduced in skin of Eng
fl/fl
 Cdh5(PAC)Cre-
ER
T2 
(Eng-iKO) mice compared with that of control mice  
A&C, Left panel shows cryosections of skin taken from control mice (Eng 
fl/fl
   
           Cdh5(PAC)Cre-ER
T2
 mice in the absence of tamoxifen treatment).  
           Immunohistochemistry on adult skin sections shows normal expression of  
           CD31 (A) and endoglin (C) on dermal blood vessels.  
B&D, Right panel shows CD31 is expressed in skin in the endoglin inducible   
           knockout (iKO) mouse (B) but endoglin expression is efficiently lost in the  
           Eng
fl/fl
Cdh5(PAC)Cre-ER
T2 
mouse (D) following tamoxifen treatment  
           (i.p.). Scale bar = 100µm. 
Endoglin 
CD31 CD31 
Endoglin 
Eng-iKO Control 
Eng-iKO Control 
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Figure 3.12 Endoglin is efficiently reduced in ears of Eng
fl/fl
 Cdh5(PAC)Cre-
ER
T2 
(Eng-iKO) mice compared with that of control mice 
A&C, Left panel shows cryosections of ear taken from control mice (Eng 
fl/fl
  
           Cdh5(PAC)Cre-ER
T2
 mice in the absence of tamoxifen treatment).  
           Immunohistochemistry on adult ear sections shows normal expression of  
           CD31 (A) and endoglin (C) on ear blood vessels.  
B&D, Right panel shows CD31 is expressed in ear in the endoglin iKO mouse (B)  
           but endoglin expression is efficiently lost in the Eng 
fl/fl
 Cdh5(PAC)Cre- 
           ER
T2 
mouse (D) following tamoxifen treatment (i.p.). 
Scale bar = 100µm. 
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3.2.5 Tamoxifen i.p. injection is the most appropriate method to activate Cre-
ER
T2
 recombinase in vivo 
Compared with the other two methods of tamoxifen administration, topical 
application on ears and pellet implantation, it seems that tamoxifen i.p.injection is 
the most appropriate and efficient method to activate Cre-ER
T2
 recombinase in 
vivo in adult mice. Endoglin expression was approximately 100% lost in skin and 
ears following tamoxifen i.p. injections (Figure 3.11&12). This appeared to be 
more efficient than endoglin knockdown using topical tamoxifen even when the 
previous background staining problems were taken into account. In addition, lacZ 
expression was activated efficiently by Cre-ER
T2
 recombinase following 
tamoxifen i.p. injections (Figure 3.5). Furthermore, during the course of these 
studies, we did not observe any deleterious effects of tamoxifen treatment 
delivered by i.p. injection in either control or Eng
fl/fl
Cdh5(PAC)Cre-ER
T2 
mice. 
Therefore, the i.p. injection method appears to be the most appropriate method of 
delivering tamoxifen to activate Cre-ER
T2
 recombinase to generate a satisfactory 
adult EC-specific endoglin inducible knockout (Eng-iKO
e
) mouse model for 
subsequent experiments.  
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3.2.6 In vivo angiogenesis is significantly reduced in Eng-iKO
e
 mice compared 
with control mice 
To identify the effect of endoglin loss on angiogenesis in vivo, the matrigel 
implantation assay was performed. Endoglin was depleted in the Eng-iKO
e
 mice 
using i.p. tamoxifen, and two control groups of mice were tamoxifen treated and 
untreated, respectively. The efficiency of endoglin gene deletion in the Eng-iKO
e
 
mouse and the formation of new vessels in the matrigel implant were monitored 
using immunohistochemistry (Figure 3.13).  
 
 
 
 
 
 
Figure 3.13 Summarized schematic picture of in vivo angiogenesis study 
using matrigel plugs   
Eng
fl/fl
Cdh5(PAC)Cre-ER
T2 
mice were intraperitoneally injected with tamoxifen 
to deplete endoglin. At the same time, 0.4 ml matrigel mixed with VEGF and 
bFGF was subcutaneously implanted into the right flank of mutant and control 
mice. After 15 days, mice were humanely killed and matrigel plugs together with 
surrounding skin tissues as well as skin from the contra-lateral (left) flank were 
removed from mice and tissue was processed for immunohistology and vessel 
counts.  
 
Cryosections from the matrigel plugs were evaluated for neovascular formation by 
immunostaining with CD31 and endoglin antibodies (Figure 3.14) and by counting 
the number of vessels as described in the vessel quantification in matrigel plugs in 
Chapter 2. Vessel quantitation was performed blind to the genotype of mice. In the 
control mice, new microvessels formed in the plugs, not only in the area close to the 
surface, but also in the central region of the matrigel plugs. In contrast, there was 
Eng-iKOe 
mice 
s.c. injection of 0.4ml 
matrigel +VEGF +bFGF 
15 days, killed mice, 
remove matrigel 
Immunohistology and 
vessels number count 
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either no neovasculature or few neovessels in the matrigel plugs from the Eng-iKO
e
 
mice. For statistical analysis, the number of neovessels in matrigel plugs from 
control mice with tamoxifen treatment was not normally distributed and therefore, 
the non-parametric Mann-Whitney test was used to compare results from Eng-iKO
e
 
mice with this control group (n = 6 in each group). There was a significant 
reduction in the number of microvessels in the plugs of the Eng-iKO
e
 mice 
compared with that of the control mice (P = 0.02, Figure 3.15). This result supports 
the idea that endoglin contributes to ECs migration as well as to neovessel 
formation. In some cases enlarged vessels occurred in the veins close to the 
matrigel plugs of the Eng-iKO
e
 mice. This was noted but the experiment was not 
designed to investigate whether this was a matrigel specific response. Further 
investigations of this phenotype are discussed in chapter 6.   
Matrigel
Matrigel Matrigel
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C D
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CD31 CD31
Endoglin Endoglin
 
Figure 3.14 New blood vessel formation is reduced in Eng- iKO
e
 mice 
compared with control mice 
Left panels show cryosections of matrigel implants taken from control mice.  CD31 
(A) and endoglin (C) positive neo-vessels, in which brown staining can be seen 
Control 
Control 
Eng-iKO
e
 
Eng-iKO
e
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invading matrigel in the control mouse. In contrast, right panels show few new 
CD31 positive vessels in the matrigel in Eng-iKO
e
 mice (B). Also endoglin 
expression is not detected in the Eng-iKO
e
 skin and was therefore efficiently 
knocked down by tamoxifen treatment (D). Dotted lines separated matrigel and 
skin, arrows indicated the matrigel area close to skin. Scale bar = 100µm. 
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Figure 3.15 The statistical analysis of vessel number whithin matrigel plugs 
in Eng-iKO
e
 mice and control mice. 
The figure shows reduced neovessel formation in Eng-iKO
e
 mice (Median = 62.5, n 
= 6) compared with tamoxifen treated control mice (Median = 12, n = 6). (W = 
24.0, P = 0.02, non-parametric Mann-Whitney test used). The interval bar (green 
bar) indicates the confidence interval for the median (the blue circle with inside 
cross). Each individual red dot represents the vessel number from a matrigel plug in 
each individual mouse model.  
 
3.2.7 Tamoxifen treatment alone does not significantly affect angiogenesis in 
vivo  
It was important to use an additional control in this study because the tamoxifen 
used to activate Cre-ER
T2
 also has the ability to induce TGF-β in vascular tissues 
(Grainger et al., 1993), and may therefore affect angiogenesis in the matrigel 
experiment. To test this, angiogenesis in matrigel plugs was compared in control 
mice with and without tamoxifen treatment and neovessel counting was 
performed and analysed as described above. There were no significant differences 
 e 
e 
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in the number of new blood vessels formed between the mice with and without 
tamoxifen treatment (Figure 3.16, P = 0.3613). According to this evidence, it was 
therefore concluded that tamoxifen does not significantly affect endothelial cell 
migration or new blood vessel formation in our matrigel angiogenesis in vivo 
study. Therefore, the tamoxifen treatment of mice for the induction of the Cre 
enzyme did not confound our results. 
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Figure 3.16 No significant difference in neovessel formation in tamoxifen 
treated control mice compared with no tamoxifen treated control mice. 
The figure shows there is no significant difference in neovessel formation between 
tamoxifen treated control mice (Median = 62.5, n = 6) and no tamoxifen control 
mice (Median = 46, n = 5). (W = 41.5, P = 0.3613, non-parametric Mann-Whitney 
test used). The interval bar (green bar) indicates the confidence interval for the 
median. The power of this statistical analysis was automatically set up at default 
value of 0.80 in Minitab 15 statistical analysis software.  
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3.3 Discussion 
            3.3.1 Cdh5(PAC)Cre-ER
T2 
expression 
The endothelial junction protein vascular endothelial (VE)-cadherin, originally 
termed cadherin-5 (Suzuki et al., 1991), also known as CD-144 and Cdh5, is 
located on the transmembrane part of the endothelial adherence junction and 
contributes to endothelium integrity and regulate vascular permeability as well 
(Breviario et al., 1995). At the start of the work described in this chapter, this 
endothelial specific and tamoxifen inducible Cre line was novel and unpublished 
and it was therefore extremely important to establish the Cre-ER
T2
 expression 
pattern and activation efficiency.  
In this chapter I have shown that the expression of Cdh5(PAC)Cre-ER
T2
 was in 
the vasculature of adult skin/ears and was efficiently activated by i.p. tamoxifen 
injections. LacZ is a widely applied reporter gene, encoding the bacterial 
escherichia coli enzyme β-gal. β-gal activity is visualized by the standard 
substrate X-gal in an intense blue colour. There was no significant background X-
gal staining found in either Rosa26R positive tissue or control tissue. LacZ 
expression is efficiently and specifically induced in vascular endothelial cells of 
arteries, veins and capillaries in adult skin (Figure 3.5), as well as in all other 
tissues tested to date including adult heart and lung (investigated in other projects 
in my host laboratory). Both X-gal whole mount staining and X-gal staining on 
cryosections were used. There are a number of ECs where LacZ is not expressed 
as the limitation of whole mount staining is mainly due to substrate penetration 
into the tissue, which can be a problem particularly in skin and very thick tissue, 
(even though tissue was left in staining solution in the shaking water bath 
overnight). The prolonged incubation time required for maximal tissue penetration 
might be responsible for the small amount of background staining. Where it was 
necessary to bypass the minor background X-gal staining difficulties and substrate 
penetration problems caused by whole mount staining, X-gal staining on 
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cryosections was performed. This showed that LacZ is expressed on almost all the 
ECs in skin tissue. 
Therefore Cdh5(PAC)Cre-ER
T2
 was efficiently induced following i.p. tamoxifen 
treatment, and specifically expressed in the vasculature. The dermal vasculature 
was the focus of the work in this chapter. In parallel, the Eng-floxed allele was 
converted to a null allele in the presence of activated Cre-ER
T2
, leading to loss of 
endoglin protein in the dermal blood vessels in Eng-iKO
e
 mice (Section 3.2.4). 
            3.3.2 Efficacy of endoglin depletion in the skin and lung of adult mice 
To investigate the efficency of endoglin depletion, immunostaining with CD31 
and endoglin antibodies was performed. The data show that deletion of endoglin 
in the skin of Eng-iKO
e
 adult mice was very efficient. This indicates that the Eng-
iKO
e
 mouse is likely to be suitable to study the function of endoglin gene in 
tumour growth and metastases as will be described in chapter 5. 
 
Some variabilities in the efficiency of depletion of endoglin protein did occur in 
lung tissue (Rachael Redgrave, personal communication). The range of endoglin 
deletion efficiency in the lung was approximately 70-80% even in mice where 
there appeared to be 100% loss of endoglin protein in the skin. The specific 
mechanism for this finding is unclear, however, several possibilities could explain 
these results: (1) the Cdh5(PAC)Cre-ER
T2 
used to drive the specific gene deletion 
may not be efficiently expressed in certain ECs of lungs; (2) activity of Cre or the 
Cre-ER
T2
 fusion is suppressed in some ECs in lungs; (3) Cre recombination was 
induced in a dose-dependent manner (Monvoisin et al., 2006), sufficient dose for 
gene deletion in skin might be insufficient for Cre recombination in lungs, or (4) 
the patterns of blood flow through the lungs might be variable in different lobes. 
Cre-ER
T2
 can not be activated if the hydroxytamoxifen in the blood does not reach 
the tissue. Since the efficacy of endoglin gene depletion in lung might be 
important for the growth potential of lung metastases, additional experiments 
would be needed to discriminate between these possibilities. Nonetheless, these 
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analyses highlighted the relatively high efficacy of endoglin depletion in the skin 
and lung of Eng-iKO
e
 mice. 
 
3.3.3 Effect of tamoxifen on angiogenesis in vivo 
Tamoxifen is an important oestrogen partial antagonist and most of its clinical 
effects are mediated via oestrogen receptors. It also has a number of oestrogen-
independent effects (Grainger and Metcalfe, 1996), including possible anti-
angiogenic effects (Gagliardi et al., 1996). Tamoxifen influences the expression 
level of  a number of cytokines involved in the regulation of angiogenesis, 
including insulin-like growth factor (IGF) (Huynh et al., 1993), basic fibroblast 
growth factor (bFGF) (Fujimoto et al., 1997) and VEGF (McNamara et al., 2001). 
 
Previous studies have also demonstrated that tamoxifen has additional effects on 
the potent pro-angiogenic cytokine TGF-β. Tamoxifen has the ability to induce 
vascular smooth muscle cells to induce TGF-β in vitro (Grainger et al., 1993). 
Also, tamoxifen elevates TGF-β expression in breast tumours in vivo (Butta et al., 
1992). The data in vivo show that a major effect of tamoxifen in the C57BL/6 
mice is to elevate TGF-β in the aortic wall and in the circulation. Active TGF-β 
reached a maximum at 7 days after a tamoxifen diet (equivalent to a dose of 
approximately 1mg tamoxifen per kg body weight per day) of 28 days (approx. 
1mg tamoxifen in total delivered by a diet over 28 days as an average body weight 
of adult C57BL/6 mice was assumed to be about 30g) and reduced after 28 days, 
active TGF-β was only elevated by 1.5-fold in serum and 2.2-fold in the aortic 
wall (Grainger et al., 1995). All this evidence seems to indicate tamoxifen affects 
TGF-β levels and may therefore indirectly affect angiogenesis. Although more 
tamoxifen was used in my project (14 mg tamoxifen in total delivered by i.p. over 
9 days), to evaluate any confounding effects of tamoxifen on in vivo matrigel 
angiogenesis study, I included two control groups, one with and one without 
tamoxifen treatment.  However, there was no significant difference in the degree 
of matrigel vascularisation between these two control groups. This indicates that 
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tamoxifen i.p. injection protocol used in this project did not affect in vivo 
angiogenesis in matrigel plugs. It appears that our results are not in line with the 
previous data published, possibly because the dose of tamoxifen used in this 
project is just sufficient to activate Cre recombinase, but is not enough to lead to 
other detectable effects. On the other hand, the previous publications mostly 
focused on the effect of tamoxifen on growth factor levels rather than 
angiogenesis.  
 
Tamoxifen also has a role in modulation of another important angiogenic 
molecule, VEGF. Tamoxifen inhibits EC proliferation and attenuates VEGF-
mediated angiogenesis and migration in vivo (McNamara et al., 2001). Tamoxifen 
treatment alone has been shown to have anti-angiogenetic effects in cancer animal 
models  which appear to be, at least in part, independent of tamoxifen's estrogen 
receptor antagonist properties (Blackwell et al., 2000). Therefore in each 
experiment in this thesis, any effects of tamoxifen were carefully tested.  
 
3.3.4 Limitations of methods used to quantify angiogenesis in vivo 
Analysis of the subdermal matrigel plug method used for evaluation of 
vascularization in this chapter requires antibodies that differentiate ECs from 
other cells within the matrigel. For this purpose, the pan endothelial marker CD31 
was used for immunohistochemical staining. However, the much more difficult 
step is the evaluation and appropriate interpretation of stained matrigel sections. 
One of the most common parameters for evaluating angiogeneis is calculation of 
microvessel density (MVD), which was considered to be the „gold standard‟. 
Various methods and guidelines for determining MVD in angiogenic 
area/tumours have been described, based on the initial method reported by 
Weidner et al. (Weidner et al., 1991; Takahashi et al., 1996). For example, vessels 
may be counted by choosing the five most vascularized areas in a tumour/matrigel 
plug and counting the vessels in these areas under higher magnification. Vessels 
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can also be quantified using image analysis software or vessel density can be 
graded on a scale 0+ to 3+, with being 3+ the most vascular. In addition, the 
degree of angiogenesis can be assessed by counting numbers of branch-points or 
by measuring inter-capillary distance. 
Visualization and quantification of the in vivo angiogenic response is problematic. 
The fractal nature of the vasculature may lead, under some circumstances, to false 
identification of nonangiogenic supporting macrovessels of the pre-existing 
venous bed as angiogenic capillaries (Rendell et al., 1998). It is also technically 
difficult to simultaneously follow the changes of the functional vasculature of the 
whole matrigel plug (or tumour) and in its capillary compartment over time (e.g. 
vessel proliferation). The direct observation or quantification of vessel remodeling 
is impeded by the fact that visibility of vascular system is dependent on the 
presence of markers such as CD31 staining, infused fluorescent dextran or 
IsolectinB4 and in situ erythrocytes and so on. However, vessel localization based 
on erythrocyte content can lead to misidentification, as they may not always be 
present in the lumen of small capillaries or may appear in haemorrhagic areas of 
tumour masses. Vascular perfusion analysis is necessary for identification of 
functional neovasculature (e.g. using fluorescent stains such as FITC-isolectin). 
Counting vessels on histological sections is prone to high variation as the 
vasculature of solid tumours is unevenly distributed and routine histological 
analysis can not distinguish between active and non-functional circulation. 
Although there is no ideal quantitative routine technique, I believe the analysis of 
matrigel vascularity used in the work described in this chapter was careful, 
thorough and objective. The whole matrigel region was sectioned generating 300 
sections per block per mouse; every 5th slide was stained with CD31 and vessel 
counting was blinded to the study groups for each sample. The maximum number 
of CD31 positive capillaries in an entire section were counted was selected for 
statistical analysis and was not limited to a few fields of view as normally used in 
these types of studies.  
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Taken together, the work described in this chapter shows the establishment of the 
Eng-iKO
e
 mouse in which endoglin is specifically deleted from ECs, and also that 
endoglin is important for new blood vessel formation in an in vivo matrigel plug 
angiogenesis assay. This work is now published as part of a study on the role of 
endoglin in angiogenesis (Mahmoud et al., 2010).  The next major task required, 
in order to investigate the role of endoglin in tumour angiogenesis and metastasis, 
was to establish and characterize an appropriate tumour model.  
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Chapter4. Primary and Secondary Lewis Lung Carcinoma  
Mouse Model 
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          4.1 Introduction 
For the work described in this thesis, the choice of tumour model is based on a 
clinically relevant tumour type (Lewis lung carcinoma), previous successful use in 
an endoglin heterozygote mouse study (Duwel et al., 2007) and labelled with an 
integral fluorescent protein label to track metastases. Using this model, I aimed to 
test whether loss of endoglin has an anti-angiogenic effect. To do this red 
fluorescent protein (RFP) labelled lewis lung carcinoma (LLC) cells were injected 
subcutaneously, primary tumour growth was measured over time and lung 
metastases were evaluated at the end of the study. Therefore, this chapter 
characterises the subcutaneous LLC-RFP primary tumour and „spontaneous‟ lung 
metastases to set an accurate framework for using this model in the work described 
in chapter 5. A further aim was to establish reliable methods for monitoring 
metastasis frequency and primary tumour vascularity. This part of the project was 
important as my host laboratory had no previous experience in using tumour 
models. 
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4.2 Results 
            4.2.1 Characterization of LLC-RFP cells 
Red fluorescent protein (RFP) expressing LLC cells were a kind gift from Dr. 
Vivek Mittal‟s lab (Cold Spring Harbor Laboratory) (Gao et al., 2008). The RFP 
is mcherry-RFP, which is an excellent general-purpose red monomer owing to its 
superior photostability and easy tractability using m-cherry red fluorescence 
detection (Shaner et al., 2005). The maximum excitation is at 584nm and the 
maximum emission is at 607nm (personal communication with Dr. Dingcheng 
Gao from Dr. Mittal‟s lab), and was confirmed using the confocal microscope in 
house (Carl Zeiss LSM 510). The recommended filter sets for mcherry are similar 
to TexasRed (Table 4.1). To visualize the red cancer cells, LLC-RFP cells were 
placed on a slide and observed via the TexasRed channel (Zeiss filter set 00) using 
the inverted fluorescent microscope (Carl Zeiss). Expression of RFP in these 
cancer cells was strong and stable over 50 passages (Figure 4.1). As a precaution, 
a selection step for the RFP expressing cassette was performed every 60 passages 
using puromycin (2µg/ml) for 24 hours.  
 
Fluorescent proteins mcherry TexasRed 
Maximum excitation(nm) 584 596 
Maximum emission (nm) 607 613 
Excitation*  585/20 575/50 585/20 
Emission*   675/130 640/50 620/20 
Filter sets from Carl Zeiss Filter set 00 M-Cherry Cube Filter set 00 
  Table 4.1 Recommended filter sets for visualizing LLC-RFP.  
      * Values are given as center/bandpass (nm). Bandpass filters with the steepest    
     possible cutoff are strongly preferred. 
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Figure 4.1 The visualization of red fluorescent protein (m-cherry) in LLC-
RFP  cancer cells.  
A, Red fluorescent protein was visualized via TexasRed channel of a Zeiss  
     Axiovert fluorescent microscope after 11 passages.  
B, After over 50 passages, the expression of red fluorescent protein was visualized  
     via Alexa594 channel of a Zeiss Axioplan fluorescent microscope, showing  
     that RFP was expressed in a strong and stable manner in the vast majority of  
     cells.  
Scale bars = 100µm. 
 
4.2.2 Effects of inoculum cell number on tumour growth and tumour takes 
Tumour implantation was performed by subdermally injecting LLC-RFP cells 
into C57BL/6 female mice (female mice were used because LLC-RFP cells were 
derived from C57BL/6 female mice). Subsequent development of the implant 
depends on the age and nutrition of the host animal, the site of inoculation and the 
character and quantity of the inoculum. In order to optimize the appropriate initial 
injection dose, different numbers of cells were used in the inoculum. The aim was 
to generate a tumour which had a reproducible and rapid growth rate. An 
inoculum less than 10
6
 cells led to unsuccessful tumour „take‟ (Table 4.2). Cell 
doses greater than 10
6
 cells indicated the probability of successful „tumour take' is 
high (100%) (Table 4.2). Therefore, the quantity of the cell inoculum is a very 
important factor which affects growth of the tumour. Finally, the dose of cells for 
injection was optimized at 2.5 x10
6 
in a volume of 50µl. The protocol for the main 
experiment is summarised below in figure 4.2. 
 
B A 
LLC-RFP LLC-RFP DAPI 
A 
A 
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Table 4.2 Summary of pilot experiments to compare tumour „take‟ and 
frequency of metastases following subdermal injection of different LLC-RFP 
cell doses. Note: The 11 mice given the optimised tumour cell dose (50ul of 2.5 X 
10
6
 LLC-RFP cells were added to the main study below for the final analysis. 
  
 
 
Figure 4.2 Sumary of LLC-RFP tumour model.  
C57BL/6 female mice (age ~8 weeks) were implanted subcutaneously into the 
right flank with 2.5 x 10
6
 (50µl) LLC cancer cells and monitored over 
approximately 3 weeks. Mice were then sacrificed and primary tumour masses 
and lung lobes were removed for analysis. Tissue sections of the primary tumour 
were stained with IsolectinB4 to examine vascularity which was quantified using 
ImageJ software. Lungs were visualized using a stereomicroscope in white light 
phase and fluorescent phase and the number of metastases was counted. In a small 
group of mice, MRI was also used for lung metastasis detection in vivo. 
 
 
 
 
No. of 
mice 
Volume of cells Cell 
number 
Primary 
tumour  
Lung 
metastasis 
1 50 µl 1 x 10
4
 absent none 
1 50 µl 5 x 10
4
 absent none 
1 50 µl 5 x 10
4
 absent none 
1 100 µl 5 x 10
4
 absent none 
1 100 µl 1 x 10
5
 present 
(1/1) 
present 
(1/1) 
1 100µl 2 x10
5
 present 
(1/1) 
none 
7 50 µl 5 x 10
6
 present 
(7/7) 
present 
(4/7) 
11 50 µl 2.5 x 10
6
 present 
(11/11) 
present 
(8/11) 
Immunohistology and  
quantify vascularity 
C57Bl/6  
Female  mice 
Implant RFP-LLC  
s.c. into mice 
20 days, kill mouse 
removed primary 
tumour& Lung 
 
 
 
   
 
Counting mets numbers  
and measuring mets size 
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4.2.3 Features of primary tumours 
To investigate the properties of tumour growth, vascularity and metastases using 
this model, 22 female C57BL/6 mice were injected subcutaneously with the 
optimal dose of LLC-RFP cells. To investigate the growth rate of the primary 
tumour, a digital calliper was applied every other day to measure tumour width 
and length (Figure 4.3).  Tumour diameter data were converted to tumour volume 
by the following formula (size = width x length
2
 x π /6) (Gao et al., 2008). In this 
way, the growth rate of the implanted tumour and its metastases (seen post 
mortem) were observed in the same mouse. 
 
The primary tumour growth appeared to have 3 phases mathematically determined 
within the observing duration period of 20 days, up to day8, day8-day14 and 
day14-day20 (Figure 4.4). The average change of 3 phases in tumour size is 113 
mm
3
 (16.10mm
3
/day), 363 mm
3
 (72.60mm
3
/day) and 902 mm
3
 (150.30mm
3
/day) 
respectively. This indicates the tumour size increased dramatically over these 3 
periods. This indicates that LLC primary tumour has differential progression stage 
based on the tumour size. 
 
Figure 4.3 The width and length of primary tumour was measured using a 
calliper with digital indication screen.  
A, shows the width of tumour is 9.92mm; 
B, shows the length of tumour is 8.36mm, therefore the tumour size is     
    362.83mm
3
. 
 
362.83mm
3 
A B 
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Figure 4.4  The LLC-RFP primary tumour size dramatically increases in 
C57BL/6 control mice over 20 days following an initial subdermal injection of 
2.5 x 10
6
 cells/50µl.  
Each data point corresponds to the mean and 95% confidence intervals of the mean, 
n = 22. Mean of final primary tumour size = 1352.83 mm
3
; standard deviation of 
final primary tumour size = 339.61 mm
3
. 
 
One of the most significant properties and capabilities of tumour is invasiveness, 
which is a key step for cancer cell spread and metastasis. The figure 4.5 shows the 
histological anatomy of mouse skin and the position of cancer cell injection. In 
fact, the LLC-RFP tumour is aggressively invasive and can invade into the 
surrounding tissue sub-dermis or deeper muscle. Severe invasiveness can even 
destroy the original histological structure of the skin (Figure 4.6). Using H&E 
stained sections to monitor the extent of invasiveness, I established a classification 
for this property of the primary tumour as 0, 1, 2, etc. that corresponded to the 
different level of invasiveness (Table 4.3) and was used to characterise all the 
dermal tumours. 
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Figure 4.5 Anatomy of mouse skin and position of cancer cell injection. 
Mouse skin generally comprises only three layers including epidermis, dermis and 
subcutaneous tissue. Cancer cells were injected underneath the panniculus carnosus 
(a subcutaneous muscle layer present in mouse skin) but above the deeper 
subdermal muscle layer. Adapted from (Gudjonsson et al., 2007). 
 
Invasion Scores  
0 NO 
1 Partial invasion of either dermis or subdermal muscle layer 
2 Partial invasion of dermis and subdermal muscle layer 
3 Complete invasion of either dermis or subdermal muscle layer  
4 Complete invasion of dermis and subdermal muscle layer 
5 
Complete invasion of dermis or subdermal muscle layer and loss of  the 
original structure 
Table 4.3 LLC primary tumour invasion scores 
 
 
 
 
 
Epidermis 
Dermis 
Site of cancer  
cell injection 
Panniculus carnosus 
Subcutaneous 
tissue 
Hair follicle 
Deeper subdermal 
muscle layer 
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Figure 4.6 Figure to show the different degrees of invasiveness of implanted 
LLC-RFP cancer cells into surrounding tissue.  
A, H&E stained section showing normal appearance of dermal and epidermal 
layers of mouse skin. Black arrows indicate hair follicles.  
B, Many LLC-RFP cancer cells invade into the dermal and epidermal layers of 
skin (white arrows) although the fundamental architecture of the skin was 
maintained.  
C, LLC-RFP cancer cells invade into the whole skin and destroy its normal  
     structure. 
D, The deeper muscle layer (which stains strongly with eosin) was invaded with  
     LLC-RFP cancer cells; 
E, Major cancer cell invasion into deeper muscle layer destroyed the normal  
     structure of muscle. The cancer cells grow around the muscle fibres to form a   
     lattice. 
White arrows indicate invasive cancer cells (likely also to be associated with an 
inflammatory infiltrate) and black arrows show hair follicles. Scale bar = 100µm. 
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Two features of primary tumour - tumour size and invasiveness- are used in the 
TNM staging system used clinically. Therefore, for this study I created a similar 
classification for the LLC stage based on the size and invasiveness of primary 
tumour and classified into 5 levels as described in table 4.4. In this way, the final 
tumour size, vascularity, invasion, primary tumour stage and number of lung 
metastases were summarized in table 4.5. In addition, I also found all primary 
tumours (at day20) had some haemorrhagic areas (Figure 4.7). 
Stage Criteria 
T1 final tumour size 700mm
3
 or less with/without invasion 
T2 
final tumour size larger than 700mm
3
 but smaller than 1000mm
3
, with 
invasion 
T3 
final tumour size larger than 1000mm
3
 but smaller than 1400mm
3
, with 
invasion 
T4 final tumour size larger than 1400mm
3
, with invasion 
T5 
final tumour size larger than 1400mm
3
 with deep invasion causing a 
change in normal structure  
Table 4.4  LLC primary tumour stage 
 
 
Figure 4.7 An example of haemorrhage in LLC-RFP primary tumours.  
A, Left panel shows the obvious haemorrhage (indicated by black arrows) in the  
     central part of a tumour;  
B, Right panel shows haemorrhage (indicated by black arrows) in a different  
     tumour at higher magnification and some cancer cells (indicated by red  
     arrows and although likely also to be associated with an inflammatory  
     infiltrate, a vast majority of cancer cells were identified based on  
     histopathologic characteristics of cancer cells that differ from normal cells  
     including nuclear size (large), shape (nonuniform), and haematoxylin staining  
     intensity (high)).       
Scale bar = 100µm.  
 
A  B  
 97 
 
Final tumour 
size 
Vascularity Invasion 
Tumour 
stage 
Number of lung 
metastasis 
635.491 11.680 4 1 0 
786.533 12.670 5 2 0 
842.971 11.503 5 2 3 
1071.866 4.321 3 3 0 
1110.984 6.665 3 3 2 
1128.368 9.465 3 3 0 
1138.101 17.422 5 3 2 
1180.418 3.852 2 3 0 
1229.743 11.128 3 3 0 
1315.795 8.985 5 3 4 
1369.326 12.752 3 3 5 
1390.030 11.882 5 3 3 
1484.417 19.752 5 5 12 
1531.273 13.733 3 4 6 
1549.320 6.458 4 4 0 
1622.823 14.980 4 4 2 
1636.377 14.062 5 5 3 
1655.417 8.431 3 4 2 
1691.748 20.079 4 4 2 
1767.146 12.300 2 4 0 
1767.146 15.868 4 4 3 
1856.924 10.981 4 4 1 
Table 4.5  Data summary: final tumour size, vascularity index, invasion 
score, primary tumour stage  and number of metastases (n = 22).  
Note the data were ordered based on the ascending final tumour size. 
 
To identify the vascularity of primary tumour, adjacent cryosections were taken 
from the central part of each tumour block and subjected to Isolectin B4 staining. 
To determine the vascularity index of the primary tumour, the percentage isolectin 
positive stained area on tissue sections was determined using ImageJ software 
(NIH) and averaged from 3 random fields of view (n = 22)  (Figure 4.8), in a 
similar way to a previously published method (Tammela et al., 2008). As Isolectin 
B4 staining can pick up some inflammatory cells and it seems to be difficult to 
indentify Isolectin B4 positive inflammatory cells from ECs, I therefore decided to 
use CD31 staining for vascularity quantification instead of Isolectin B4 in the 
subsequent experiments. 
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Figure 4.8  Vascularity of  LLC-RFP primary tumours; an example of images 
used to determine the vascularity index.  
A, RFP-LLC primary tumour cells (red);  
B, Blood vessels identified by isolectin B4-Alexa488 staining (green) on a  
     cryosection of a LLC-RFP primary tumour; the percentage isolectin positive  
     area of this field of view was  17.42%. 
C & D, Overlay with and without DAPI nuclear staining (blue).  
Scale bar = 100µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
D C 
Isolectin B4-Alexa488 
Isolectin B4-Alexa488 
LLC-RFP 
DAPI 
 
LLC-RFP 
Isolectin B4-Alexa488 
LLC-RFP 
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4.2.4 Frequency and Size of Lung Metastases 
The number of lung metastases was counted directly after the lungs were dissected 
(Table 4.5). Metastases (≥1 mm in diameter) were visualised under the 
stereomicroscope using white light and confirmed as originating from the LLC-RFP 
primary tumour using fluorescence to detect m-cherry (Figure 4.9).  
Figure 4.9  LLC-RFP metastatic lesions in lung lobes visualised using white 
light (left) and fluorescent light (right). Metastases are clearly seen in both views. 
  
4.2.5 Variability of Model 
The variability of the LLC tumour model was minimised as far as possible by 
controlling age and weight of mouse and size and position of inoculum. However, 
variability of primary tumour size, vascularity and frequency of lung metastases 
was present and evaluated by calculating range, interquartile range (IQR), variance 
and standard deviation (SD) and coefficient of variation (CV) (Table 4.6). 
 
To choose appropriate measure of variability, the shape of data‟s distribution is the 
most critical element to consider. If data are symmetric, with no serious outliers, 
range and standard deviation are used to evaluate variability. The primary tumour 
size and vascularity index of primary tumour showed a normal distribution of the 
data (analysed using Kolmogorov Smirnov test) and there were no serious outliers, 
therefore, the range and standard deviation reflect their variability (Table 4.6). 
However, the frequency of metastases data was not normally distributed and had 
serious outliers, therefore, the variability of frequency of metastases was presented 
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by interquartile range (IQR) (Table 4.6). Also variation across two data sets, for 
example, amongst primary tumour size, vascularity index of primary tumour and 
frequency of metastases, was compared using coefficient of variation (Table 4.6). 
Therefore, if we just consider coefficient of variation of primary tumour size, 
vascularity index of primary tumour and frequency of metastases to compare the 
variability, the variability of frequency of metastases was the maximal one. 
 
                      Items  
 
Measures  
Primary 
tumour size 
(mm
3
) 
Vascularity index 
of primary tumour 
Number of 
metastases 
Median 1379.68 11.781 2 
Range 1221.4 16.227 12.000 
Interquartile range 517.1 5.445 3.000 
Variance and 
standard deviation 
115331.5 
339.6 
19.084 
4.369 
7.827 
2.798 
Coefficient of 
variation 
25.10 37.11 123.10 
   Table 4.6 Variability of primary and secondary tumour model 
 
4.2.6 Vascularity of primary tumour correlates with frequency of lung metastases 
Tumour vascularity is clinically associated with probability of metastases (Davies 
et al., 2002) . One of most reasonable explanations is that increased primary tumour 
vascularity enhances haematogenous dissemination by offering greater opportunity 
for tumour cell invasion into the circulation (intravasation).  
The vascularity index of the primary tumours ranged from 3.852 to 20.0792 and 
frequency of lung metastasis ranged from 0 to 12, (Figure 4.10). A correlation 
analysis was performed using linear regression and correlation using Minitab15 
software, which indicates that there is a statistically significant correlation of 
metastases frequency with primary tumour vascularity index (Figure 4.11, Pearson 
correlation coefficient = 0.532; p = 0.011). These data strongly support our 
hypothesis that reducing primary tumour vascularity by targeting endoglin will 
reduce the frequency of metastases. 
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Figure 4.10  Metastases occur at higher frequencies in mice with  more 
vascular primary tumours.  
When primary tumour vascularity index increases from less than 7.5 to between 13 
and 20, the percentage of mice with one or more metastatic lesions goes up from 
25% to 100%. 
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Figure 4.11  Frequency of metastases correlates with vascularity index of 
primary tumour.  
This analysis not only indicates that there is a linear regression (shown by blue line) 
between probability of metastases and vascularity index of primary tumour, but also 
shows that frequency of metastases will increase accordingly with vascularity of 
primary tumour (Pearson correlation coefficient = 0.532; p = 0.011). 
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4.2.7 Stage of primary tumour correlates with frequency of lung metastases 
Clinical evidence had demonstrated that there was an interrelationship between 
primary tumour size and invasion and the frequency of metastases in certain types 
of solid tumour (Valdevenito et al., 2007). This may be simply because the bigger 
and more invasive tumour has the greater opportunity to allow cancer cells to 
intravasate into the nearest blood and/or lymphatic vessels and subsequently 
migrate to a distant tissue or organ. 
 
The primary tumour stage was classified into 5 levels (T1 - T5, see Table 4.4) in 
terms of primary tumour size and invasion and then converted to numerical values 
(1- 5), for statistical analysis. The number of lung metastases per mouse ranged 
from 0 to 12. A correlation analysis was performed using linear regression and 
correlation using Minitab15 software. This showed that there is a statistically 
significant correlation of metastases frequency with primary tumour stage (Figure 
4.12), Pearson correlation coefficient = 0.443; p = 0.039), which indicated that 
higher the primary tumour stage is, the higher the frequency of metastases is. 
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Figure 4.12 Frequency of lung metastasis correlates with primary tumour 
stage 
The linear regression line (blue line) represents interrelationship between primary 
tumour stage and frequency of metastases, and indicates there is a positive 
correlation. Red dots represent the number of metastases matched to corresponding 
primary tumour stage and show the vertical distance from each individual red dot to 
the linear regression line.  
Note: The red dot indicated by blue arrow represents 4 mice, the red dot indicated 
by red arrow represents 3 mice and the red dot indicated by black and green arrow 
demonstrates 2 mice respectively. Each of remaining red dots indicates one mouse. 
4.2.8 Detection of lung metastases in vivo with magnetic resonance imaging 
(MRI) 
The aim of this part of the study was to develop an MRI protocol to detect lung 
metastases of implanted LLC C57BL/6 mouse on a 7 Tesla horizontal bore 
magnetic resonance research system (Varian Inc., Palo Alto, CA). Both 
conventional T1- and T2-weighted imaging and dynamic, contrast-enhanced T2-
weighted imaging with the MR contrast agent Gadodiamide (a gadolinium-based 
contrast agent) were performed on an additional group of 10 C57BL/6 female mice 
at late stage of primary tumour progression (day19). Lung metastases were detected 
in different lung lobes (Figure 4.13 & 4.14). However, when lungs were checked 
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after dissection it was clear that MRI was not able to detect all metastases (Table 
4.7). In particular, the smaller lung metastases (less than 0.5-1mm in diameter) 
were not detected by MRI but can be visualized using fluorescent 
stereomicroscope. Therefore, in order to overcome the resolution limitation of MRI, 
we determined to take advantage of endogenous RFP in combination with 
fluorescent stereomicroscope for the detection of RFP-LLC lung metastasis for the 
remainder of the study. 
 
 
Figure 4.13 A schematic picture of mouse lung 
This picture shows the name and position of mouse lung lobes. 
Note that postcaval lobe, superior lobe and inferior lobe are also known as 
accessory lobe, cranial lobe and caudal lobe, respectively. Adapted from (Regal, 
2004) 
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Figure 4.14 Transverse views of thoracic cavity showing detection of lung 
metastases using MRI 
The arrows indicate large and relatively small lung metastases were detected in 
either left or right lung lobes of C57BL/6 mice that had been innoculated with 
LLC-RFP subdermally, 19 days earlier. Tumour sizes were measured in dorsal-
ventral direction and left-right dimension using MRI software and are listed below: 
A, 1.3 x 1.3 mm and 1.3 x 1.1 mm 
B, 1.6 x 1.5 mm 
C, 0.8 x 0.7 mm 
D, 0.7 x 0.6 mm 
Note: All MRI image data was obtained with fast-spin echo (multi-slice) imaging 
sequence, including respiratory gating; Notional TR = 1500ms (reality depends on 
respiration rate and how the gating works). Effective echo time (TE) = 48ms. 
Therefore best images are T2-weighted. Spatial resolution = 0.12mm in-plane and 
1mm slice thickness from 4 averages. 
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B 
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Mouse 
Lung metastases 
visible post mortem 
using stemi-
microscope 
Lung metastases visible or suspected 
using MRI 
No. Position No. Position&sizes 
YF1 0 None 1 
One suspect 
micrometastasis(slice 9) 
right lobe 0.8mm 
YF2 0 None 0 None 
YF3 1 accessory lobe 0 None 
YG1 1 left lobe 0 None 
YG2 0 None 0 None 
YG3 0 None 0 None 
YG4 1 accessory lobe 0 None 
YI1 11 
4 on left lobe 
& 4 on 
superior lobe, 
2 on middle 
lobe, 1 on 
inferior lobe 
4 
Largest in left lobe near 
spinal column; 
Sizes: 4.5mm, 2.5mm, 
1.4mm & 1.2mm 
* Note that no averages 
were used for the slices 
in these images 
YI2 7 
3 on left lobe 
& 2 on 
accessory 
lobe, 6 on 
superior lobe 
4 
Left lobe 7.6mm, 6.4mm 
& 1.08mm. 
Right lobe 1.4mm. 
YI3 2 
1 on left lobe 
& 1 on 
superior lobe 
2 
One suspect metastasis 
(slice7) 0.7mm right 
lobe near spinal column; 
possibly one in (slice 9) 
too. 
Table 4.7 The comparison of detection difference between stemi-microscope 
and MRI 
Note that lung metastases were observed using stemi-microscope in both white light 
and fluoresecence field; The detection of lung metastases were performed using 
MRI by Dr. Ross Maxwell and Mr. Ian Wilson and the analysis was carried out by 
an experienced observer (Dr. Maxwell) blinded to results from the stemi-
microscope.  
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4.2.9 Detection of lung metastases in vivo with positron emission tomography – 
computed tomography (PET- CT) 
To develop a PET-CT protocol to detect lung metastases of implanted LLC 
C57BL/6 mouse on an X-ray NanoCT scanner (Bioscan) and PET imaging system 
(Philips). Mice at late stage of primary tumour progression (day19) were 
anaesthetised by isofluorane, and fludeoxygluose (FDG) (fluorine-18 labelled, total 
activity approx. 10 MBq, volume 100-200 microlitres) was injected via tail vein 
and mouse was imaged 1 hour post injection. A homogeneous primary tumour was 
detected on the right flank of mouse (Figure 4.15), but high FDG uptake of the 
heart challenges visualisation of any lung metastases. From the preliminary data, 
PET imaging of the primary Lewis lung tumour was clear. The use of isofluorane 
inhalation affected the intensity of heart signal which was higher with isofluorane 
compared with i.p. injected anaesthetic Hypnorm/Hypnovel (personal 
communication, Dr. Ross Maxwell). In order to reduce the effect of higher heart 
signal intensity on the detection of lung metastases, 4 mice were anaesthetised by 
i.p. injection of fentanyl citrate (0.32 mg/kg), fluanisone (10 mg/kg, both from 
Hypnorm, Janssen Animal Health, High Wycombe, United Kingdom) and 
midazolam (5 mg/kg, Hypnovel, Roche, United Kingdom). Although PET scanning 
might suggest that one mouse possibly had a metastasis in the left lobe, it is also 
possible this reflected a leftward portion of the heart. As there were lung metastases 
in all 4 mice detected post mortem, this suggests PET is probably not sufficiently 
sensitive for lung metastases detection.  
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Figure 4.15 Detection of LLC primary tumour using X-ray CT and PET  
The primary LLC tumour was detected on the right flank (white arrow). High 
uptake of FDG in heart (cross) was particularly evident using isofluorane 
anaesthesia (as in this case). Mouse skeletal anatomical structure was visualized by 
X-ray CT. Acquisition time: 15 minute; Image resolution: 2-3mm; Field of view 
diameter: 128mm.  
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4.3 Discussion 
            4.3.1 Efficacy of LLC-RFP subcutaneous tumour model for investigating tumour  
            angiogenesis and metastases 
The LLC-RFP subcutaneous cancer model generated a very useful tumour model 
with which to investigate the effect of angiogenesis on tumour growth and 
metastases. In this chapter I showed that the model was reproducible and the 
vascularity of the primary tumour correlated with frequency of metastases to the 
lungs. This suggests it would be a useful model to test the anti-angiogenic effects of 
reducing endoglin expression in the next chapter. The incidence of metastases in the 
main study group was approximately 65% (15 mice had lung metastases including 
one mouse that died early (just only for roughly predicting possible incidence of 
metastases in control mice for later power and sample size analysis), whilst 8 mice 
did not). These data show that the LLC-RFP grafted primary tumour can 
disseminate to the lung, and is occuring at sufficient frequency that the model could 
be used to test the hypothesis that reducing primary tumour vascularity by targeting 
endoglin would reduce the frequency of metastases. 
            4.3.2 Results inform power and sample size calculation for main study 
The data obtained from the work described in this study was used to inform the 
experimental design for the main study to test the effect of reducing endoglin on 
tumour growth and metastases. This was done using a statistical power analysis and 
sample size calculation. These analyses will inform not only sample number, but 
also how likely the potential statistical test will detect effects of a given size in a 
particular situation. If sample size is too low, the experiment will lack the power to 
provide reliable answers to the questions it is investigating. If sample size is too 
large, time and resources will be wasted.  
 
Basically, the parameters required are:  1) inherent variability of the study material 
(coefficient of variation, CV); 2) how big a difference is expected; 3) the 
confidence required for any conclusion drawn. Therefore, based on the frequency of 
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metastases in the study described in this chapter, we can calculate how many mice 
are needed to compare the effects of endoglin loss on tumour growth and 
metastases. We plan to use single factor design with one treatment (endoglin 
depletion using the Eng-iKO
e
 mouse) and will choose P < 0.05 to be statistically 
significant and require power of 80% (0.8) for study. Consequently, we required the 
sample size to detect a difference between 68% (0.68) metastases in the control 
group and a range of metastases frequencies (0.2, 0.3, 0.4 &0.5) in the Eng-iKO
e
 
group. 
 
The analysis was performed using the power and sample size test for two 
proportions in Minitab15 statistical package (Figure 4.16 & Table 4.8), if there is a 
big difference between frequency of metastases (70%) in control group and that 
(20%) in mutant group, that means that 15 mice would be needed in each group to 
have 80% power to detect a 20% - 70% difference.  
 
1.00.80.60.40.20.0
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0.8
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Predicted Metastases Rate in Mutant Group
P
o
w
e
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A lternativ e Not =
A ssumptions
15
24
42
93
Size
Sample
Predict Power and Sample Size Needed in Main Study
 
Figure 4.16 Power and sample size needed in main study calculated based on 
frequency of metastases in C57BL/6 control mice.  
Different types and colours of bell-shaped curve represent different predictions for 
sample size, all the calculations are based on the frequency of metastases (0.7) seen 
in the mice analysed in this chapter.  
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Predicted incidence of 
metastases in Eng-iKO
e
 group 
Sample 
size 
Target 
power 
Actual 
power 
0.2 15 0.8 0.820319 
0.3 24 0.8 0.811981 
0.4 42 0.8 0.800288 
0.5 93 0.8 0.800006 
Table 4.8   Power and sample size calculation 
 
It can be seen from the results of the power analysis in Table 4.7 that if the true 
frequency of metastases is 0.2 in the Eng-iKO
e
 group, the sample size required to 
detect this change compared with a frequency of 0.68 in the control group will be 
15 mice per group. In contrast, 93 mice per group would be required to detect a 
significant difference if the true frequency of metastases in the Eng-iKO
e
 group is 
0.5.  On the basis of this analysis combined with the goal of designing a reasonably 
costed study, I decided that I would use 15 mice per group and that this study 
design would be powered to detect a change if the frequency of metastases in the 
Eng-iKO
e
 group was reduced to 0.2. If the true metastases frequency was not 
reduced to this level in the Eng-iKO
e
 group, then the effect of endoglin on 
metastases would not be detected in the study. However, it could be concluded to 
have either no effect, or a relatively small effect with limits that could be 
statistically defined.. 
            4.3.3 Tumour imaging in vivo  
Imaging has become an indispensable tool in cancer research, clinical trials and 
medical practice. In the past three decades, there has been a huge increase in the 
number of imaging technologies and their applications, particularly in the field of 
imaging of tumour angiogenesis and anti-angiogenesis.  
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In the work described in this chapter, imaging tumour angiogenesis and metastases 
was performed at the end point of the study. The investigation of tumour 
angiogenesis was performed by applying immunofluorescent staining to 
cryosections of primary tumour tissue. Lung metastases were detected by 
examining dissected lungs, also at the end of the study. However, MRI and PET-CT 
were tested in a pilot group of animals to evaluate their potential for monitoring 
metastases in vivo. The weakness of MRI is the limitation of resolution as small 
metastases (<1mm) cannot be seen and even some larger metastases (>1mm) were 
not always visible (table 4.7). The reasons for missing some metastases are unclear, 
although it probably depends on the size and location of tumours as well as how 
successful the respiratory gating method was in each individual mouse. Overall I 
found that MRI analysis did offer some potential for useful imaging of lung 
metastases that could be used in future experiments. 
  
In contrast, PET-CT scans were not very successful for detecting lung metastases 
using FDG in this model. There were three main factors that could affect the result 
of FDG-PET scan. 1) In general we have not found consistent and very high FDG 
uptake in primary tumours in mice. This is different to most cases in human 
patients. 2) The large and high uptake of FDG by heart is not helpful in trying to 
identify lung metastases. 3) The spatial resolution is limited to 1-2 mm. In 
principle, the read-outs from imaging systems should be ideally quantitative, high 
resolution, longitudinal (i.e. allow imaging over time), comprehensive, standardized 
and digital (Weissleder and Pittet, 2008). However, it is really difficult to get this 
type of ideal imaging system that has all these merits. Therefore, for the next part of 
my project I used the combination of histological analysis of the primary tumour 
and examination of dissected lungs at the end of the study for accurate evaluation of 
tumour angiogenesis and lung metastases, respectively.  
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            4.3.4 Variability of experimental mouse model 
Laboratory mice are widely and successfully used model system for studying 
human disease, but the variations of experimental mouse models cannot be 
eliminated. Basically, there are two types of variations in the experimental mouse 
model system - inherent variations (biological stochastic variations) and technical 
or human error (eg. slight differences in subdermal injection sites for tumour cells).  
 
Indeed, there were both sorts of variations (Section 4.2.5) in my experimental 
tumour model. As for the quantification of vascularity index of primary tumour, the 
repeated measurements of vascularity on a section were performed and then some 
variations (intra- or within-subject variability) were observed. This may be because 
a mouse does not respond in exactly same way and/or because of measurement 
error. However, the variation within an individual is usually less than the variation 
obtained when we take a single measurement on every individual in a group (inter- 
or between-subject variability). For example, I counted the number of lung 
metastases in every mouse in a control group (n = 22) of C57BL/6 females, and 
obtained relatively variable data. In theory, this variation in data may be caused by 
known factors (such as mouse individual differences and slight variation in 
implantation site or cancer cell number), or may be unexplainable random 
variations. Clearly, it is desirable to reduce the impact of variation as far as 
possible, and thereby increase the precision of the analysis. To address these issues 
it may be benefitial to reproduce more carefully the exact position of cancer cell 
injection on the flank of each mouse. I also decided to change the way I injected the 
cells to generate a more uniform “round” shape of implanted cell volume.  The 
vascularity of the tumour sections would be more accurately measured using 
immunostaining with anti-CD31 instead of isolectin, because isolectin also detects 
inflammatory cells in addition to vascular endothelium.  In addition, data values 
will be more precise if additional replicates are used. For this reason I planned to 
use anti-CD31 and to increase the number of fields of view (from 3 to 5) for 
calculating the vascularity index in future experiments.  
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In summary, the results described above demonstrate that the subdermal LLC 
model produces a vascularised primary tumour that can metastasize to lungs. 
Through my optimizations such as the number of LLC cells for injections, the 
position and approaches of injections, an appropriate time of LLC cells inoculation 
and colonization of lung metastases, I felt that I had been able to establish the 
subcutaneously primary LLC-RFP and spontaneously metastatic model in my host 
lab. In addition, it seemed that RFP did not affect cancer cells‟ ability to grow and 
disseminate to the lungs as previously shown for RFP and other fluorescent proteins 
(DsRed-2 and GFP) (Jiang et al., 2006; Gao et al., 2008; Zhou et al., 2009). 
Moreover, there was also a correlation between the vascularity index of the primary 
tumour and the frequency of metastases in lungs. I therefore used the 
subcutaneously implanted primary and spontaneously metastatic tumour LLC-RFP 
model to investigate the role of endoglin in tumour vascularisation and metastases 
which is described in the next chapter. 
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Chapter 5. Effect of Endoglin Depletion on Tumour 
Vascularisation, Tumour Growth and Metastases 
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         5.1 Introduction 
During tumour angiogenesis, malignant cells secrete the growth factor TGF-β, 
which is thought to stimulate new blood vessel formation by interacting with 
endoglin, a TGF-β family co-receptor located on the surface of ECs. A number of 
studies have reported that there was a positive correlation between the number of 
endoglin positive blood vessels and cancer growth, progression, and frequency of 
distant metastases in a wide range of human cancers, whilst there was a negative 
correlation between endoglin positive blood vessels and disease-free survival or 
overall survival (Kumar et al., 1999; Brewer et al., 2000; Fonsatti et al., 2003; 
Shariat et al., 2008; Bernabeu et al., 2009). I sought to test whether endoglin 
represents a potentially useful therapeutic target to inhibit angiogenesis, tumour 
growth and metastases in a clinical setting.  I therefore investigated whether loss of 
endoglin would inhibit angiogenesis of the LLC-RFP primary tumour in adult mice 
and whether this might also affect the frequency of lung metastases.  
 
LLC cells expressing RFP were subdermally implanted in female mice as described 
in chapter 4. Endoglin was depleted in the experimental group (Eng-iKO
e
) using i.p. 
injection of tamoxifen prior to injection of cancer cells. Primary tumour growth was 
monitored over 18 days and then analysed for vascularity by IHC and ImageJ 
software (NIH). At the end of the experiment, the number of lung metastases was 
assessed using fluorescent microscopy. The experimental design including 2 control 
groups (one with and one without tamoxifen treatment) is illustrated in figure 5.1. 
In addition, additional early-stage (day6) LLC tumour models were used to 
investigate the effects of endoglin loss on growth and neovascularization in day6 
LLC primary tumour and finally, experimental metastatic models were used to test 
the effect of endoglin reduction on extravasation.  
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Figure 5.1 Sumary of LLC-RFP tumour model and design of the first 
experimental approaches.  
Female mice (aged between 8 and10 weeks, weighed between 19.40 and 28.23 
grams and average weight: 24.46 grams) were divided into 3 groups: Eng-iKO
e 
(n 
=15), tamoxifen treated control (n =11) and no tamoxifen control (n =19). Mice 
were implanted subcutaneously into the right flank with 2.5 x 10
6
 (50µl) LLC-RFP 
cancer cells (refinements introduced: identity of number and position of cancer cell 
injection; uniform “round” shape of primary tumour implanted) and monitored over 
18 days. The tumour size was measured using calipers on every other day. Mice 
were sacrificed and primary tumour masses and lung lobes were removed for 
analysis. Tissue sections of the primary tumour were stained with anti-CD31 to 
examine vascularity (using anti-CD31 instead of isolectin to give more precise 
vascularity measurements) which was then quantified using ImageJ software 
(calculated from three to five measurements for each sample). Lungs were 
visualized using the stereomicroscope in both white light phase and fluorescent 
phase and the number of metastases were counted. Note: s.c. = subcutaneous. 
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             5.2 Results 
            5.2.1 Effect of endoglin depletion on primary tumour growth 
To examine the effect of endoglin depletion on primary tumour growth, the tumour 
sizes were measured on every other day over 18 days. This generated 10 values in a 
series of measurements (at day2, day4, day6, day8, day10, day12, day14, day16 and 
day18) for each individual mouse from both experimental and control groups.  
These data were analysed following statistical advice from Dr Peter Avery (School 
of Mathematics & Statistics, Newcastle University). Comparison of the primary 
tumour growth (slope of the growth curve of best fit) between Eng-iKO
e
 mice and 
tamoxifen treated control mice was performed using a t-test following 
normalization (by Log10 transformation) of the tumour size data. There was no 
significant difference in slopes between Eng-iKO
e
 mice and tamoxifen treated 
control mice (Figure 5.2 A). This indicates there is no effect of endoglin depletion 
on primary tumour growth. However, we found there was an initial delay in 
primary tumour progression in Eng-iKO
e
 mice compared to tamoxifen treated 
control mice which was most obvious at day6 (Figure 5.2 B). Hence, it seems to be 
reasonable to do a single t-test to compare tumour size at day6, since in principle 
the depletion of endoglin in ECs might affect primary tumour growth at an early 
stage of tumour progression. Interestingly, LLC primary tumour sizes at day6 were 
significantly smaller in Eng-iKO
e
 mice than in tamoxifen treated control mice (p = 
0.018, Figure 5.2 C&D). Afterwards, It seems that the primary tumour size in Eng-
iKO
e
 mice „caught up with‟ that of tamoxifen treated control at later stages of 
primary tumour progression. These data suggest that endoglin depletion may have 
caused an initial delay in primary tumour growth, perhaps due to a delay in 
angiogenesis, but that this role can be overcome in the later stages. Therefore, in 
order to confirm a delay in tumour size and angiogenesis in the early tumour, I 
performed an additional experiment following the exactly same approach as before 
to investigate tumour size and vascularity at day 6 of tumour growth, and tissues 
were harvested at day6. Once again, there was a significant difference in tumour 
size at day 6 between Eng-iKO
e
 mice and tamoxifen treated control groups (p = 
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0.019, Figure 5.3 A&B). This additional experiment confirms that the loss of 
endoglin delays subcutaneous LLC-RFP primary tumour growth in Eng-iKO
e
 mice, 
and this may be due to early defects in angiogenesis.   
 
 
 
Figure 5.2 There is no significant difference in primary tumour size between 
Eng-iKO
e
 mice and tamoxifen treated control mice, but there appears to be an 
initial tumour growth delay at day 6 in Eng-iKO
e
 mice.  
A. There is no significant difference in primary tumour growth rate base on a slopes  
     comparison between Eng-iKO
e
 mice (n = 15) and tamoxifen treated control mice  
     (n = 11) (Two samples t-test, T-Value = 1.66, P-Value = 0.110). 
B. The mean tumour growth curve of Eng-iKO
e
 mice appears to take a different  
     course than that of tamoxifen treated control mice, suggesting an initial delay in  
     tumour growth rate in Eng-iKO
e
 mice and a maximal difference between the two  
     groups at day6. 
C, The change in LLC primary tumour size over the first 6 days, suggested that the  
     initial tumour growth rate was slower in Eng-iKO
e
 mice.  
D, LLC primary tumour sizes at day6 were significantly smaller in Eng-iKO
e
 mice  
    (n = 15) than in tamoxifen treated control mice (n = 11) (Two samples t-test, T =  
     -2.63, P = 0.018). 
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Figure 5.3 An additional experiment confirmed the hypothesis that primary 
tumour size at day6 was significantly reduced in Eng-iKO
e
 mice compared to 
tamoxifen treated control mice.  
A, LLC primary tumour size over 6 days confirmed that the  
     tumour growth rate was slower at the early stage in Eng-iKO
e
 mice.  
B, LLC primary tumour sizes at day6 were significantly smaller in Eng-iKO
e
 mice  
     (n  = 9) than in tamoxifen treated control mice (n = 7) (Two samples t-test, T = - 
     2.93, P = 0.019). 
 
            5.2.2 Effect of tamoxifen on primary tumour growth 
It was important to use an additional control in this study because the tamoxifen 
used to activate Cre, also has the ability to induce TGF-β in vascular tissues, also 
tamoxifen influences a number of other cytokines that have been reported to affect  
angiogenesis (Grainger et al., 1993). I therefore tested whether or not tamoxifen 
affected primary tumour growth in the LLC mouse tumour model. Primary tumour 
size was measured from control mice with and without tamoxifen treatment over 18 
days. There were no significant differences in the size of primary tumours between 
the tamoxifen treated control mice and the mice without tamoxifen treatment 
(Figure 5.4). In addition, there were no significant differences in the size of day6 
primary tumours between the tamoxifen treated control mice and the mice without 
tamoxifen treatment (Figure 5.5 A&B). I therefore concluded that tamoxifen does 
not significantly affect primary tumour growth at both the early stage and the late 
stage. Therefore, the treatment of tamoxifen on mice for the induction of the Cre 
enzyme did not appear to be a confounding factor in this study. 
 
A B 
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Figure 5.4 There is no effect of tamoxifen on primary tumour growth at day 6 
or at day 18. 
A, Growth rate of primary tumour appears to be similar between tamoxifen treated  
     control and no tamoxifen control from day0 to day6;  
B, There was no significant difference in tumour size between tamoxifen treated  
     control (n = 11) and no tamoxifen control (n = 19) at day6 (Two samples t-test,  
         T = 0.30, P = 0.766); 
C, Growth rate of primary tumour is slightly different between tamoxifen treated  
     control and no tamoxifen control from day8 to day18;  
D, There was no significant difference in tumour size between tamoxifen treated  
     control (n = 11) and no tamoxifen control (n = 19) at day18 (Two samples t-test,  
     T = -1.93, P = 0.066). 
 
 
Figure 5.5 An additional independent experiment confirmed there is no effect 
of tamoxifen on primary tumour growth at day6. 
A, Growth rate of primary tumour appears to be similar between tamoxifen treated  
     control and no tamoxifen control from day0 to day6;  
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B, There was no significant difference in tumour size between tamoxifen treated  
     control (n = 7) and no tamoxifen control (n = 7) at day6 (Two samples t-test, T =  
     0.71, P = 0.490); 
 
            5.2.3 Effect of endoglin depletion on primary tumour vascularity  
To test whether the loss of endoglin reduces angiogenesis of the primary LLC 
tumour, adjacent cryosections were taken from the central part of each tumour 
block at day 18 and at day6 for H&E, CD31 and endoglin staining. To determine 
the vascularity index of the primary tumours, the percentage CD31 positive stained 
area on tissue sections was determined using ImageJ software and averaged from 3-
5 random fields of view (Figure 5.6), in a  similar way to a previously published 
method (Tammela et al., 2008). CD31 staining was used as this is more specific for 
ECs than IsolectinB4, used in the previous chapter, which can also stain some 
inflammatory cells. No significant differences were observed in the vascularity 
index of primary tumours between Eng-iKO
e
 mice and tamoxifen treated mice at 
the late stage of tumour growth (day18) (Figure 5.7 A). In the context of the LLC 
primary tumour model, it seems that there is no significant effect of endoglin loss 
on primary tumour angogenesis at the later stages of primary tumour progression 
(day18). In addition, there were no significant differences in the vascularity index 
of primary tumours between the tamoxifen treated control mice and the mice 
without tamoxifen treatment (Figure 5.7 B). I therefore concluded that tamoxifen 
does not significantly affect primary tumour angiogenesis at day 18 in this model. 
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Figure 5.6  Vascularity of LLC-RFP primary tumours at day 18 and the 
efficacy of endoglin depletion in Eng-iKO
e
 mice 
A, Cryosection of a primary tumour from an Eng-iKO
e
 mouse stained with CD31   
     (green) shows extensive microvasculature and the red fluorescence of LLC- RFP  
     primary tumour cells;  
B, Endoglin stained serial section of primary tumour in Eng-iKO
e
 mouse confirms   
     loss of endoglin in the vascular endothelium;  
C, CD31 stained primary tumour from a control mouse shows extensive  
     microvasculature;  
D, Endoglin stained serial section from a control mouse shows that the vascular  
     endothelium is also endoglin positive   
Note that these CD31 stained images also serve as example of images used to 
determine the vascularity index. Scale bar = 100µm. 
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Figure 5.7 There is no effect of endoglin and tamoxifen on tumour vascularity 
at day18. 
A, There was no significant difference in tumour vascularity index between Eng- 
     iKO
e 
mice (Median = 1.127, n = 15) and tamoxifen treated control (Median =  
    1.548, n = 11) at day18 (Mann-Whitney analysis, W = 185.0, P = 0.3776). 
B, There was no significant effect of tamoxifen on tumour vascularity index  
     between tamoxifen treated control (Median = 1.548, n = 11) and no tamoxifen  
     control (Mann-Whitney analysis, Median = 1.575, n = 19) at day18 (Mann- 
     Whitney analysis, W = 187.0, P = 0.4911).  
 
Although I did not find significant effect of endoglin loss on primary tumour 
angiogenesis at the later stages of primary tumour progression (day18), in order to 
test whether the loss of endoglin reduces angiogenesis of the primary LLC tumour 
at an early stage, cryosections from day6 tumours were taken from the three parts of 
each tumour block including the central part and both sides of the central part; 
adjacent sections were used for H&E, CD31 and endoglin staining. The tumour 
vascularity index was determined in a similar way to that used for the day18 tumour 
study. The LLC-RFP tumour is quite vascular at day 6 and the endoglin gene was 
effectively deleted in Eng-iKO
e
 mice from both peri-tumour skin tissue and intra-
tumour tissue (Figure 5.8). Furthermore, there was a significant decrease in the 
vascularity index of primary tumours in Eng-iKO
e
 mice compared with tamoxifen 
treated control tumours at day6 (Figure 5.9 A). In addition, there were no 
significant differences in the vascularity index of primary tumours between the 
tamoxifen treated control mice and the mice without tamoxifen treatment (Figure 
5.9 B). I therefore concluded that loss of endoglin can significantly reduce LLC-
RFP associated neovascularisation in combination with primary tumour growth 
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delay at day6 and also tamoxifen does not significantly affect primary tumour 
angiogenesis. 
 
 
Figure 5.8  Vascularity of LLC-RFP primary tumours at day6 in Eng-iKO
e
 
mouse and control mouse  
A, Cryosection stained with CD31(green) shows few microvessels within  
     the red fluorescence of LLC- RFP primary tumour cells at day6 from an Eng- 
     iKO
e
 mouse.;  
B, a serial section of primary tumour stained with endoglin (green) shows reduced  
     endoglin in the tumour-associated vascular endothelium in Eng-iKO
e
  
     mouse;  
C, CD31 stained primary tumour from a control mouse shows extensive  
     microvasculature;  
D, Endoglin stained serial section from a control mouse shows that the vascular  
     endothelium is also endoglin positive   
Scale bar = 100µm. 
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Figure 5.9 There is a significant effect of endoglin and no effect of tamoxifen 
on tumour vascularity at day6. 
A, There was a significant difference in tumour vascularity index between Eng- 
     iKO
e 
mice (Mean = 1.300, n =9) and tamoxifen treated control (Mean = 1.993, n  
     = 7) at day6 (Two sample t-test, T = -2.71, P = 0.019). 
B, There was no significant effect of tamoxifen on tumour vascularity index  
     between tamoxifen treated control (Mean = 1.993, n = 7) and no tamoxifen  
     control (Mean = 2.059, n = 7) at day6 (Two sample t-test, T = -0.40, P = 0.699).  
Note: Data for above analysis was transformed by square root and then compared 
by two samples t-test. 
 
            5.2.4 Effect of endoglin depletion on metastases at day 18 
To test whether the lung metastatic model is consistent between experiments, the 
incidence of lung metastases was compared between C57BL/6 mice at day 20 (data 
from Chapter 4) and no tamoxifen treated control mice at day 18 (also in C57BL/6 
(N5)) from work described in this chapter. The slightly different time frame applied 
in these two experiments as the size of primary tumour reached maximum 
limitation permited by the project licence at day18 in the main study of this chapter. 
Although there seems to be a higher incidence of lung metastases in C57BL/6 mice 
compared to no tamoxifen treated control mice, there was no significant difference 
between them (Figure 5.10). This indicates the lung metastatic model appears to be 
sufficiently stable to use for investigating differences in metastases incidence. 
  
Next, to investigate the effect of endoglin depletion on metastases, the number of 
lung metastases was counted directly after the lungs were dissected. There was a 
dramatic and significant increase in the number of lung metastases in Eng-iKO
e
 
mice compared with tamoxifen treated mice at day 18 (Figure 5.11, Figure 5.12 A, 
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P = 0.0159). Furthermore, there is also a significant difference in the incidence of 
lung metastases between Eng-iKO
e
 mice (100%) and tamoxifen treated control 
mice (45.5%) (Table 5.1, X
2
 = 10.639, P = 0.002). Therefore, in the context of LLC 
primary tumour model, this data suggests that targeting endoglin may delay primary 
tumour progression at an early stage, but this is coupled with a detrimental increase 
in the frequency of metastases. In addition, there were no significant differences in 
the number of lung metastases between the tamoxifen treated control mice and the 
mice without tamoxifen treatment (Figure 5.12 B). Accordingly, we therefore 
conclude that tamoxifen does not significantly affect the frequency of lung 
metastases, and the tamoxifen treatment (required for the induction of the Cre 
enzyme) does not confound our results. 
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Figure 5.10 The incidence and number of lung metastases in C57BL/6 mice (n 
= 22, pink bars, data from Chapter 4) and in no tamoxifen treated control mice 
(n = 19, purple bars). Each mouse is represented by a single bar and the height of 
the bar corresponds to the number of metastases present in the lungs. There is no 
significant difference between the incidence of metastases in two groups of mice 
(Mann-Whitney test, W = 500.0, P = 0.3069). 
Note: non-parametric Mann-Whitney analysis used to test the above comparisons as 
data from no tamoxifen control mice was not normally distributed. Attached data 
table shows the number of mice and the number of lung metastases in each 
individual mouse.  
Comparison of metastases incidence and number in two groups of control mice 
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Figure 5.11 The incidence and number of lung metastases in Eng-iKO
e
 mice (n 
= 15, yellow bars) compared to tamoxifen treated control (n = 11, red bars) 
and no tamoxifen treated control mice (n = 19, blue bars). Each mouse is 
represented by a single bar and the height of the bar corresponds to the number of 
metastases present in the lungs. The table shows the number of lung metastases in 
each mouse. In light of statistical analysis, the detailed comparison was shown in 
Figure 5.14. 
 
 
Figure 5.12  Box and whisker plots to compare the frequency of lung 
metastases in Eng-iKO
e
 mice, tamoxifen treated control mice and control mice 
without tamoxifen treatment (analysed at day 18). 
A, There was a significant difference in lung metastases between Eng-iKO
e
 mice  
     (Median = 4, n = 15) and tamoxifen treated control (Median = 0, n = 11) at  
     day18 (Mann-Whitney analysis, W = 249.0, P = 0.0159); 
B, There was no significant effect of tamoxifen on the number of lung metastases  
     between tamoxifen treated control (Median  = 0,  n = 11)  and no tamoxifen  
     control (Median = 1, n =   19) at day18 (Mann-Whitney analysis, W = 176.0, P =  
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     0.8177). 
 
                                      No. of mice                  No. of mice 
Group                        with lung mets            without lung mets                Total      
Eng-iKO
e
                      15 (11.538)                       0 (3.462)                             15 
Control+Tamoxifen        5 (8.462)                         6 (2.538)                             11 
Total                              20                                      6                                         26 
X
2
 = 10.639            P = 0.0020 
Table 5.1 X
2
 test to compare the incidence of lung metastases between Eng-
iKO
e
 mice (100%) and tamoxifen treated control mice (45.45%)  
 
            5.2.5 Investigation of potential causes for increased lung metastases in Eng-iKO
e
   
            mice 
There must be some mechanism(s) responsible for increased number of lung 
metastases in Eng-iKO
e
 mice compared with tamoxifen treated control mice, 
although this result was not expected. Possible reasons for increased lung 
metastases in Eng-iKO
e
 mice include (i) increased angiogenesis of the tumour (see 
section 5.2.3); (ii) increased invasiveness of cancer cells (Blouw et al., 2007; Du et 
al., 2008; Paez-Ribes et al., 2009); (iii) decreased muscularisation of tumour blood 
vessels (Carvalho et al., 2004); (iv) reduced integrity of vascular basement 
membrane (this study); (v) increased lymphangiogenesis of the tumour (Achen and 
Stacker, 2008); (vi) altered expression of other growth factors (Bergers and 
Hanahan, 2008; Abdollahi and Folkman, 2010); (vii) altered inflammatory response 
(Bergers and Hanahan, 2008); (viii) differences in the level of hypoxia and 
responses to hypoxia (Carmeliet and Jain, 2011a); (ix) differences in interstitial 
flow pressure and degree of necrosis (Carmeliet and Jain, 2011b); (x) differences in 
haemorrhage (this study); (xi) altered lung endothelium provided easier growth of 
metastatic cancer cells (Wels et al., 2008; Psaila and Lyden, 2009; Ebos and Kerbel, 
2011); (xii) epithelial to mesenchymal transition (EMT) and or endothelial to 
mesenchymal transition (EndMT) (unpublished data, Dr. Kristian Pietras). The 
tumour tissues at day 6 and day 18 were available for analysis, but there was 
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insufficient time to investigate all of these possibilities. Therefore, the preliminary 
examination of the primary tumour properties of invasiveness, vascularity, vessel 
muscularisation, lymphangiogenesis, the level of hypoxia and EndMT were 
performed. In addition, extravasation of circulating tumour cells was investigated 
using a different experimental metastatic model. 
 
To investigate whether the primary tumours in Eng-iKO
e
 mice were histologically 
more invasive than in tamoxifen treated control mice, H&E stained sections (from 
the central part of primary tumour mass) were quantitively given invasiveness 
scores based on the criteria described in chapter 4 (Table 4.3). Although the cancer 
invasiveness score of Eng-iKO
e
 mice (mean ± SE, 4.00 ± 0.38) appeared higher 
than that of tamoxifen treated control mice (mean ± SE, 3.09 ± 0.56), and by 
approximately 1 level according to the scoring system described in Table 4.3, there 
was in fact no significant difference (Figure 5.13 A). To pursue this further the 
incidence of highest invasiveness score in Eng-iKO
e
 mice (66.67%) was compared 
with that in tamoxifen treated control mice (45.45%) but was also found to be not 
statistically significant (Table 5.2). Similarly there was no significant difference 
between the incidence of lowest invasiveness score in Eng-iKO
e
 mice (0) compared 
with tamoxifen treated control mice (27.27%) (Table 5.3). In addition, there were 
no significant differences in the cancer invasiveness between the tamoxifen treated 
control mice and the mice without tamoxifen treatment (Figure 5.13 B). This 
suggests that tamoxifen does not significantly affect the invasive ability of LLC 
cells. Overall, the trend of increased cancer invasiveness in Eng-iKO
e
 mice 
suggests that an experiment with larger group sizes may reveal a statistically 
significant difference and that this possible explanation for increased metastases in 
Eng-iKO
e
 mice should not be ruled out at this stage. 
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Figure 5.13 There is no dramatic effect of endoglin and tamoxifen on the 
invasiveness of LLC-RFP cancer cells. 
A. There is no significant difference in the invasiveness of LLCs in Eng-iKO
e
 mice  
     compared with tamoxifen treated control mice (Two samples t-test, T = 1.34, P  
     = 0.197); 
B. There is no significant difference in the invasiveness of LLCs in tamoxifen  
     Treated control mice compared with no tamoxifen treated control mice(Two  
     samples t-test, T = -0.85, P = 0.405). 
 
Group                 with highest invasiveness   without highest invasiveness            Total      
Eng-iKO
e
                         10 (8.654)                              5 (6.346)                                  15 
Control+Tamoxifen           5 (6.346)                              6 (4.654)                                  11 
Total                                 15                                          11                                             26 
X
2
 = 1.170            P = 0.7603 
Table 5.2 X
2
 test for the incidence of highest invasiveness (scored “5”) between 
Eng-iKO
e
 mice (66.67%) and tamoxifen treated control mice (45.45%)  
 
 
Group                 with lower invasiveness   without lower invasiveness              Total      
Eng-iKO
e
                           0 (1.731)                              15 (13.269)                            15 
Control+Tamoxifen           3 (1.269)                                8 (9.731)                              11 
Total                                   3                                           23                                          26 
X
2
 = 4.626            P = 0.2013 
Table 5.3 X
2
 test for the incidence of lowest invasiveness (scored “1”) between 
Eng-iKO
e
 mice (0) and tamoxifen treated control mice (27.27%)  
 
To investigate the effect of endoglin depletion on the muscularisation of tumour- 
associated blood vessels, the integrity of vascular basement membrane and 
lymphangiogenesis of late stage of primary tumour, α-SMA, Collagen IV and 
lymphatic vessel endothelial hyaluronan receptor (LYVE)-1 stainings were 
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performed on day18 primary tumour sections from 3 mice in Eng-iKO
e
 mice and 
control mice with or without tamoxifen treatment. Representative images from this 
preliminary analysis shows staining with these three markers are shown in Figure 
5.14. In most sections, α-SMA, collagen IV and LYVE-1 staining seemed to be 
rather patchy and some collagen IV and LYVE-1 staining appears to be non-
specific. Therefore, it was difficult to randomly choose fields of view for the 
analysis. In addition, it would be helpful to perform co-staining for vascular 
endothelial cells (with anti-CD31) at the same time as α-SMA, collagen IV or 
LYVE-1. To do this I tried to optimise 4 colour “staining” to include the 
endogenous m-cherry of LLC-RFP cells, DAPI (nuclei), α-SMA conjugated to 
Alexa 488 or FITC and anti-CD31 detected by a secondary antibody conjugated to 
Alexa 647 (Figure 5.15). There remained some technical difficulties to be addressed 
to optimise this staining. For example, the signal of Alexa 647 was not strong 
enough to clearly identify the blood vessels and there was bleed-through of the 
signal from the Texas Red channel (used to visualize m-cherry) into the far red 
channel used to visualise CD31 staining with Alexa 647. Because of these technical 
issues together with the large variation of staining both between and within tumour 
sections, it was not possible within the timeframe of this project to accurately 
determine whether there were any differences in the muscularisation of tumour-
associated blood vessels, the integrity of vascular basement membrane or in the 
degree of lymphangiogenesis of late stage (day18) primary tumours between Eng-
iKO
e
 mice and tamoxifen treated control mice.      
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Figure 5.14 Collagen IV, LYVE-1, and α-SMA staining on adjacent primary 
LLC-RFP tumour sections (day 18). 
A, E, H show the endogenous m-cherry of LLC (red) visualized by TexasRed  
              Channel (some red dots seem to be stains on the coverslip);  
B, F, I represent nuclei stained with DAPI (blue);   
C, Most of Collagen IV staining seems to be localised on the circumference of  
     Blood vessels (white arrows); 
G, LYVE-1 staining identifies lymphatic vessels in this field of view, although it is   
     not very specific.  
J, shows α-SMA staining which varies in intensity in different blood vessels.  
 staining of only part of the perimeter of one blood vessel is indicated by a red  
 arrow. 
D, H, K represent the merged images. 
Scale bar = 100µm. 
 
RFP DAPI Collagen IV merged 
LYVE-1 
α-SMA 
H 
B 
E 
I 
D 
F G H 
J K 
RFP 
RFP DAPI 
DAPI 
merged 
merged 
A C 
 134 
 
Figure 5.15 Colocalisation of CD31-positive endothelial cells and α-SMA-
positive pericytes/SMCs in a day 18 primary tumour. 
A, shows the endogenous m-cherry RFP of LLC (red) visualized in the TexasRed  
     channel;  
B, represents nuclei stained with DAPI (blue); 
C, shows CD31-positive blood vessels (far-red) (arrows); there is some bleed  
     through from the m-cherry RFP (see figure A); 
D, shows α-SMA-FITC (green) staining of blood vessel walls (arrows); note that  
     The staining of the wall of some vessels is incomplete; 
E, merged image shows colocalization of CD31-positive blood vessels and α-SMA- 
     positive pericytes/SMCs (arrows). 
Scale bar = 100µm. 
 
To investigate whether the level of hypoxia in the primary tumour of Eng-iKO
e
 
mice was significantly higher than that of tamoxifen treated control mice at day 6, 
the HIF-1α stained sections (from the central part of primary tumour mass) were 
quantitively given hypoxic scores (1, 2 and 3; Figure 5.16 C) based on the level of 
HIF-1α expression (Scoring from 1 to 3 was based on the intensity and area of 
tumor cell and stromal cells staining for HIF-1α. Tumour sections with more than 
30-40% of tumor cells staining intensely were scored as 3. Figure 5.16 A&B). 
Accordingly, each individual tumour tissue was given a hypoxic score that 
relatively reflected the status of hypoxia (Figure 5.16 C). In comparison, there were 
significant differences in hypoxic scores between Eng-iKO
e
 mice and tamoxifen 
treated control mice (P = 0.026, Figure 5.16 D). This indicates the depletion of 
endoglin can cause significant hypoxic status in primary tumours of Eng-iKO
e
 mice 
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CD31 α-SMA-FITC 
merged 
A B 
C D 
E 
RFP 
 135 
at day 6. More hypoxic cells might be due to reduced neovascularisation (Figure 5.9 
A). In addition, there was a possibility that hypoxia occurred at the early stage of 
primary tumour progression was more likely to regulate hypoxic responses such as 
stimulating cancer cells to release more growth factors or selection of more 
aggressive cancer cells. Subsequently, the growth of primary tumour in Eng-iKO
e
 
mice caught up with that in control mice and this was associated with increased 
lung metastases in Eng-iKO
e
 mice. Therefore, additional experiments are required 
to investigate this dynamic hypoxic process using hypoxic probes perfusion study. 
In addition to that hypoxic score comparison, to identify whether there was a 
significant difference in the level of necrosis between Eng-iKO
e
 mice and 
tamoxifen treated control mice. The degree of necrosis from the central part of 
primary tumour mass was evaluated based on the histological criteria of necrotic 
cells (characterized by H&E staining as fat, pink cells without nuclei, personal 
communication Dr. Brian Angus, Department of Pathology, Newcastle University). 
There appeared to be slightly more necrotic cells in day6 primary tumour of Eng-
iKO
e
 mice compared with that of tamoxifen treated control mice (Figure 5.17), but 
the difference was small, and difficult to accurately quantify.  
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Figure 5.16 Representative images showing the hypoxic cells in an Eng-iKO
e
 
tumour and a significant difference in hypoxic score was identified between 
Eng-iKO
e
 mice and tamoxifen treated control mice. 
A - H, Cells nuclei stained with DAPI (A&E, blue), HIF-1α positive hypoxic cells  
            (B&F, green), endogeneous RFP positive LLC cells (C&G, red) and merged  
            images (D&H) shown in cryosections of an Eng-iKO
e
 tumour; 
I&J, Red dots indicate the hypoxic score of each individual tumour tissue (I).  
         There is a significant difference in the hypoxic score between Eng-iKO
e 
mice  
         and tamoxifen treated control mice (Mann-Whitney test, W = 88.0, P = 0.026)  
         (J). Scale bar = 200µm. 
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Figure 5.17 Necrotic cells in day6 primary tumours. 
A&B, Representative images from day6 primary tumour of Eng-iKO
e
 mice shows 
presence of necrotic cells recognised by loss of nuclear stain (black arrows); 
C&D, Representative images from day6 primary tumour of tamoxifen treated 
control mice showing necrotic cells (black arrows). 
Scale bar = 200µm. 
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Another possible reason for increased spread of the primary tumour could be 
changes in the tumour stroma. Cancer-associated fibroblasts (CAFs) are a major 
component of the tumour stroma so to investigate the level of CAFs, adjacent 
cryosections were taken from the central part of each tumour block for fibroblast 
specific protein-1 (FSP-1) and α-SMA staining. Interestingly, FSP-1 and α-SMA 
seem to be expressed in different parts of the primary tumour. In a control tumour at 
day6 FSP-1 was more likely to be expressed on myofibroblasts of the intra-tumoural 
region. However, α-SMA positive myofibroblasts were mostly located in the peri-
tumoural area (Figure 5.18). Further experiments are still required to confirm these 
findings and to compare mutant with control mice.  
 
 
Figure 5.18 Expression patterns of FSP-1 and α-SMA on adjacent cryosections 
of primary tumour at day 6 in control mice. 
A, Most of α-SMA positive mesenchymal cells (green arrows) are located in the  
     peri-tumoural area; 
B, shows detailed α-SMA positive mesenchymal cells in higher magnification (x63); 
C, A vast majority of FSP-1 positive mesenchymal cells (black arrows) is localised  
     in the intra-tumoural region;  
D, shows detailed FSP-1 positive mesenchymal cells in higher magnification (x63). 
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Note: the dotted line indicate the outer border of the primary tumour. Green arrows 
indicate α-SMA positive cells in the peri-tumoral area and black arrows indicate 
FSP-1 positive cells within the intra-tumoral region. Scale bar = 200µm. 
 
To investigate whether the extravasation of LLC-RFP cancer cells was increased in 
Eng-iKO
e
 mice compared with tamoxifen treated control mice, mice were 
anesthetised by isofluorane and then injected with 2.5 x 10
5
 LLC-RFP cells in 
100ul PBS through the tail vein. Lungs were harvested on day15 and lung lobes 
were separately examined and lung metastases were identified using fluorescent 
stemi-microscopy (Figure 5.19 A-D). The number of lung metastases for each 
mouse was shown in Figure 5.21 E. There were significant differences in the 
number of lung metastases between Eng-iKO
e
 mice compared with tamoxifen 
treated control mice (Figure 5.19 F). This suggests that significantly increased 
extravasations of LLC-RFP cancer cells into the lung might be one of the critical 
reasons for the previously observed  an increased frequency of lung metastases in 
Eng-iKO
e
 mice. 
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Figure 5.19 The number of lung metastases is increased in Eng-iKO
e
 mice 
compared to tamoxifen treated control mice following tail vein injection of 
LLC-RFP cells 
A&B, LLC-RFP metastatic lesions visualised using white light (left) and  
           Fluorescent light (right) in lung lobes of an Eng-iKO
e
 mouse; 
C&D, LLC-RFP metastatic lesions visualised using white light (left) and  
           Fluorescent light (right) in lung lobes of a tamoxifen treated control mouse.  
           Metastases are clearly seen in both views; 
E, Each mouse is represented by a single bar and the height of the bar corresponds  
     to the number of metastases present in the lungs. The table shows the number of  
     lung metastases in each mouse. 
F, There was a significant difference in lung metastases between Eng-iKO
e
 mice  
     (Median =7, n = 8) and tamoxifen treated control (Median = 0, n = 9), (Mann- 
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     Whitney analysis, W = 100.5, P = 0.0071). 
Note: non-parametric Mann-Whitney analysis used to test the above comparisons as 
data distribution patterns following statistical advice from Dr. Peter Avery (School 
of Mathematics and Statistics, Newcastle University).  
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             5.3 Discussion 
            5.3.1 Effect of tamoxifen on tumour progression 
An important control for the LLC implanted primary tumour model used in the 
work described in this chapter was to test whether there were any effects of 
tamoxifen alone. The results showed no significant effect of tamoxifen on primary 
tumour size, vascularity or lung metastases. However, tamoxifen has been reported 
to exert anti-angiogenic effects, since tamoxifen influences a number of cytokines 
involved in the regulation of angiogenesis, including insulin-like growth factor 
(IGF) (Huynh and Pollak, 1993; Huynh et al., 1993), TGF- β (Butta et al., 1992), 
bFGF (Fujimoto et al., 1997) and VEGF (McNamara et al., 2001). One possible 
reason for not finding an effect of tamoxifen in angiogenesis is that the dose used in 
this study might be low compared with that used by others where a significant 
inhibitory effect on tumour growth and/or tissue vascularity was obtained. 
However, the total dose used to activate Cre-ER
T2 
in the mice described in this 
chapter (0.4g/kg) is very similar to that used in the rat study described by 
(McNamara et al., 2001) (0.356g/kg). Furthermore, the data from the matrigel plug 
angiogenesis experiment (Section 3.2.7, Chapter 3) also showed there was no 
significant difference in angiogenesis between tamoxifen treated and no tamoxifen 
control groups, consistent with the findings from the tumour angiogenesis study in 
this chapter. It is possible that different species or different models have different 
responses to tamoxifen.  
            5.3.2 Growth and vascularity of primary tumour in Eng-iKO
e
 mice. 
A substantial number of reports have shown that endoglin is overexpressed in 
vascular ECs of tissues undergoing angiogenesis especially in the tumour-
associated angiogenic process (Burrows et al., 1995; Kumar et al., 1999; Miller et 
al., 1999; Brewer et al., 2000; Fonsatti et al., 2000; Fonsatti et al., 2003; Shariat et 
al., 2008; Bernabeu et al., 2009; Fonsatti et al., 2010). Furthermore, the potential 
efficacy of anti-endoglin antibodies
 
for clinical purposes in cancer is supported
 
by a 
number of available pre-clinical in vitro and in vivo
 
data (Fonsatti et al., 2010; Seon 
 143 
et al., 2011). Bernabeu and colleagues have investigated the role of endoglin in 
tumour
 
angiogenesis and growth using endoglin haploinsufficient (Eng
+/–
)
 
and 
control mice (Eng
+/+ 
littermates) that were subcutaneously
 
inoculated with 10
6 
LLC 
cells and tumours harvested after 9 days. The results of these
 
studies indicated that 
endoglin deficiency decreased tumour
 
vascularization and growth (reduction of 
tumour weight) in the short time frame used in this study (Duwel et al., 2007). I 
also observed a significant decrease in the size of primary tumour in Eng-iKO
e
 
mice inoculated with 2.5 x 10
6
 LLC cells at the early stage of primary tumour 
progression (at day 6) compared with control mice. This was confirmed by an 
additional day6 tumour experiment. However, at day8 and day10 of LLC primary 
tumour progression, the growth of primary tumour in Eng-iKO
e
 mice seems to 
catch up with that in tamoxifen treated control mice. Eventually, at later stages of 
LLC tumour progression, I observed no significant effect of endoglin loss on 
primary tumour angiogenesis or tumour size. The data therefore indicates that 
endoglin appears to promote primary tumour growth only in the initial stages. 
  
Other studies have shown that the tumour response to anti-angiogenic therapy is a 
highly dynamic one. For example, using a mouse model of pancreatic islet cancer 
where angiogenesis is inhibited via VEGF receptor inhibition, the initial tumour 
response is one of „vascular regression‟ and tumour growth delay. At a later stage 
the tumours then adapt and begin regrowing via a process referred to as “evasive 
resistance”.  This adaptive response is associated with upregulation of alternative 
pro-angiogenic signals that include fibroblast growth factor (FGF) ligands 
(Casanovas et al., 2005). It is therefore possible in our study that endoglin loss 
inhibits tumour growth at an early stage of primary tumour progression, but that 
secondary events give rise to revascularization and increased invasiveness. This 
might be tested by taking advantage of histological analysis on biopsy or dissected 
samples from discrete stages of tumour growth. In addition, it could be combined 
with fluorescent reflectance imaging and bioluminescence imaging which can give 
dynamic data of vascularisation and tumour size over time. Therefore, distinct 
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phenotypes mediated by endoglin in the different stages of LLC primary tumour 
progression is possibly due to an emergent resistance to endoglin depletion that 
might be similar to the resistance that is frequently seen following anti-angiogenic 
therapy in other preclinical models (Ebos et al., 2009; Paez-Ribes et al., 2009; Ellis 
and Reardon, 2010; Ebos and Kerbel, 2011). 
 
            5.3.3 Increased frequency of lung metastases in Eng-iKO
e
 mice 
In addition to the anticipated effect of anti-angiogenic therapy on primary tumour 
growth, there is still a promising expectation that this type of therapy will also 
reduce distant metastases. However, we found a detrimental increase in the 
frequency of metastases in Eng-iKO
e
 mice. At first sight, this finding is not only 
difficult to reconcile with our expectations that endoglin deficiency reduces primary 
tumour angiogenesis (as metastatic lesions require vessel supply for growth), but is 
also inconsistent with previous observations that anti-anti-angiogenic therapies 
reduce metastases (Verheul et al., 2007; Sini et al., 2008). How can we explain 
these divergent effects of “endoglin-targeted therapy”? There are a number of 
possibilities, as follows. 
 
First of all, anti-angiogenic treated tumours appear to be more invasive. A number 
of studies have also associated increased invasiveness with impaired angiogenesis 
in the context of genetic ablation of the hypoxia reponse and/or the VEGF/VEGFR 
pathways (Pennacchietti et al., 2003; Blouw et al., 2007; Du et al., 2008). In my 
study, the invasiveness of day18 primary tumours was compared between Eng-
iKO
e
 mice and tamoxifen treated control mice. It seems that there was a trend of 
increased cancer invasiveness in Eng-iKO
e
 mice and this could be one of the 
explanations for increased metastases in Eng-iKO
e
 mice. In response to the 
angiogenesis inhibitors, tumour cells may elevate the activity of a pre-existing cell 
signalling program that might contribute to intravasation and/or extravasation of 
invasive cancer cells. This suggests that the invasive growth program induced in 
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response to therapy may be different from the program occurring in natural tumour 
progression (Paez-Ribes et al., 2009). 
 
Secondly, tumour hypoxia appears to be a possible mechanism. In theory, the more 
proficient an anti-angiogenic agent is, the more efficiently it will prune tumour 
vessels and hence cause hypoxia. In my study, the comparison of HIF-1α staining 
between Eng-iKO
e
 mice and tamoxifen treated control mice indicates the loss of 
endoglin leads to significant hypoxic status in primary tumours of Eng-iKO
e
 mice 
at day 6. In the hypoxic conditions, it is more likely to regulate hypoxic responses 
such as stimulating cancer cells to release more growth factors or selection of more 
aggressive hypoxia-tolerant cancer cells, while cancer stem cells in hypoxic niches 
escape anti-angiogenic treatment (Brahimi-Horn et al., 2007). Subsequently, more 
malignant aggressive cancer cells appear to be more capable of invading into blood 
vessels (Yu et al., 2002) and eventually increased lung metastases were found in 
Eng-iKO
e
 mice. 
 
Thirdly, other up-regulated growth factors might be playing a critical role in 
promoting angiogenesis and metastases after initial anti-angiogenic therapy. In 
healthy mice, for instance, the VEGF inhibitors can elevate levels of some other 
cytokines such as PIGF and IL-6 etc. that promote angiogenesis in a VEGF-
independent manner (Ebos et al., 2007). In addition, these elevated cytokines can 
recruit bone marrow-derived endothelial progenitor cells that contribute to form 
premetastatic niches (Kaplan et al., 2006). In the tumour of Eng-iKO
e
 mice, some 
other growth factors might be up-regulated due to the depletion of endoglin and 
these elevated growth factors may contribute to the detrimental consequence that 
the growth of primary tumour in Eng-iKO
e
 mice caught up with that in control mice 
and this was associated with increased lung metastases in Eng-iKO
e
 mice. 
Therefore, additional experiments are required to investigate this dynamic growth 
factors up-regulating process in all stages of tumour progression in different cancer 
types in the future.  
 146 
In addition, the formation of pre-metastatic niches within the lung may exert 
extravasation of circulating tumour cells (CTCs). It would be possible that CTCs 
take advantage of a pre-formed suitably microenmironment within target metastatic 
sites that might be conducive to extravasation. More likely, the changes of blood 
vessel integrity occur before the arrival of CTCs at the sites of potential metastases 
and this could facilitate extravasation (Psaila and Lyden, 2009). In principle, a 
significant increase in lung metastases in Eng-iKO
e
 may be due to the formation of 
pre-metastatic niches with leakier vasculature within the lung following vascular 
specific endoglin depletion. In addition, my further experiments showed the lung 
vasculature was „predisposed‟ to develop metastases in the Eng-iKOe mice using an 
experimental metastatic model of LLC-RFP cell tail vein injection. However, 
metastasis seems to be an early event (Psaila and Lyden, 2009; Talmadge and 
Fidler, 2010; Hanahan and Weinberg, 2011). It will therefore be important to look 
at the occurrence of micrometastasis in the LLC-RFP model, as well as the 
macrometastases already examined. Further studies such as analysis of numbers of  
CTCs in different stages of primary tumour progression are also needed to find out 
the underlying mechanisms. 
 
Last but not least, more leaky and immature tumour vessels may facilitate 
intravasation of aggressive cancer cells. These newly developed blood vessels are 
often characterised by the absence of a smooth muscle wall and the presence of a 
leaky basement membrane. In theory, these properties allow malignant cells to seep 
into the circulation and to promote metastatic disease. In fact, some of these agents 
(especially the more broad-spectrum VEGFR-TKIs, which also inhibit PDGFRβ) or 
the cytokine response they induce (in the case of osteopontin) may inhibit coverage 
of tumour vessels by pericytes, which destabilizes vessels, makes them more leaky 
and immature, and hence facilitates intravasation of tumour cells and metastases 
(Bergers and Hanahan, 2008). In addition, angiogenesis involves differential 
growth and sprouting of endothelial tubes and recruitment and differentiation of 
mesenchymal cells into vascular smooth muscle cells (VSMCs) and pericytes. It 
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may therefore be important in this context that Carvalho et al. found smooth muscle 
cell differentiation was impaired in Eng
-/-
 mutant mouse yolk sacs compared with 
wild-type embryos and this was associated  with decreased levels of TGF-β1 
protein (Carvalho et al., 2004). In my study, I did not find any significant 
differences in the muscularisation of neovessels (based on α-SMA immunostaining) 
between Eng-iKO
e
 mice and control mice either at day6 or at day18. In fact, tumour 
cryosections staining with α-SMA can not reflect the comprehensive leakiness of 
tumour vasculature and also the vascular muscularisation could be a dynamic 
process. It will therefore be important to perform further studies such as testing the 
leakiness of tumour-associated blood vessels using a Dextran-FITC perfusion study 
in Eng-iKO
e
 mice and control mice. 
Taking all these factors into consideration, we can hypothesize that quantitative and 
qualitative effects of anti-angiogenic therapy may depend on a number of factors. In 
principle, these will include tumour-intrinsic parameters such as levels of pro-
angiogenic factors, vessel number and function, sprouting angiogenesis versus 
vessel co-option, pericyte coverage, recruitment of bone marrow cells, oxygen 
tension and lymphangiogenesis. In pre-clinical models, differences in experimental 
conditions such as type of tumour and metastases model, duration of treatment, 
class and dose of angiogenesis inhibitor, monotherapy versus combination 
treatment with cytotoxic or other agents, will all affect the tumour growth and 
metastatic responses. Pàez-Ribes et al. (2009) speculate that high VEGF levels 
render tumour vessels immature and facilitate intravasation and metastases while 
inhibiting VEGF may produce a similar overall effect on metastases, though via 
qualitatively distinct mechanisms, as explained above. Another unresolved issue is 
whether metastatic tumours rely as much on angiogenesis as primary tumours, 
given that metastatic tumour cells often acquire hypoxia-tolerant properties 
(Brahimi-Horn et al., 2007). 
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            5.3.4 Endoglin might be a major pro-angiogenic agent in tumour angiogenesis    
             and may be a synergistic agent in anti-angiogenic therapy 
Judah Folkman proposed that all solid tumour growth is dependent on blood vessel 
growth and that suppression of tumour angiogenesis would be a valid approach for 
cancer therapy (Folkman, 1971). In 2004, the first anti-angiogenic cancer drug, 
bevacizumab (avastin), was approved by the US FDA. There are some small 
clinical benefits using anti-angiogenic agents for treating only certain types of solid 
tumours. It seems that anti-angiogenic therapy can potentially overcome several 
major problems associated with other anti-cancer therapies, for example, the 
problems of drug resistance, poor drug delivery and tumour heterogeneity. 
However, current anti-angiogenic drugs for cancer therapy are far from optimal and 
produce only minor beneficial effects by prolonging the overall survival time of a 
few months which is effective only in combination with conventional 
chemotherapy (Kerbel, 2008). This benefit may be because of transient vascular 
normalisation and consequent improved drug delivery (Jain, 2005b). However, in a 
certain type of cancer such as pancreatic cancer anti-angiogenic monotherapy or 
combinations with chemotherapy has not shown significant clinical benefits 
(Kindler et al., 2005; Kulke et al., 2008). It is unknown why a diversity of tumour 
types responds differently to anti-angiogenic therapy. Both clinical and 
experimental results indicate that unconventional drug resistance develops in 
response to anti-angiogenic therapy (Bergers and Hanahan, 2008). Therefore, the 
novel and effective anti-angiogenic agents and methods for increasing the efficacy 
of anti-tumour agents by synergistic combination with monospecific or 
multitargeted anti-angiogenic agents are required. 
 
Endoglin is one of the most reliable markers of proliferating ECs, and it is 
overexpressed on tumour neovasculature. The potential of endoglin as vascular 
target for diagnostic and therapeutic anti-angiogenic strategies in cancer has been 
investigated at pre-clinical level both in vitro and in vivo. Recently, Ben K. Seon 
et.al found that primary tumour growth and metastases were effectively suppressed 
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by anti-endoglin monoclonal antibodies (mAb) targeting tumour vasculature in a 
range of pre-clinical cancer models, including orthotopic injection of 4T1 murine 
mammary carcinoma cells and splenic injection of two types of colon26 murine 
colorectal carcinoma cells (Uneda et al., 2009; Seon et al., 2011). More recently, a 
first phase I study in human, with the humanized-murine chimeric anti-endoglin 
mAb TRC105 in patients with refractory advanced or metastatic solid cancer is 
ongoing in order to evaluate safety and tolerability of escalating doses
 
of the 
therapeutic mAb (Fonsatti et al., 2010). Anti-endoglin mAb recognises and binds 
the target antigen (endoglin) which is upregulated in tumour-associated ECs and 
subsequently cause failure of binding between TGF-β/BMP9 ligands and endoglin, 
their endothelial receptor, as well as triggering an immune response to the targeted 
ECs. In the work described in this chapter, vascular-specific endoglin depletion 
would be expected to reduce TGF-β/BMP9 binding to the ECs, but would not be 
expected to trigger the immune system to target ECs. Also, another major 
difference between these two types of pre-clinical models is the scheduling of the 
treatments. In the work described in this chapter, endoglin gene depletion occurred 
prior to primary and secondary tumour establishment. It is possible that endoglin 
loss pre-conditions the lung micro-environment to make it more favourable for 
transendothelial migration of tumour cells and/or tumour growth. Therefore, in the 
context of the subdermal LLC tumour model, our results demonstrate targeting 
endoglin may delay primary tumour progression at an early stage, but this is 
coupled with a detrimental increase in the frequency of metastases. Also, these 
findings possibly indicate evasive resistance to “anti-endoglin therapy”.  
A combination of chemotherapy and anti-endoglin therapies might be an effective 
and beneficial treatment for cancer patients. In an established tumour of MCF-7 in 
human skin grafted onto SCID mice, Ben K. Seon et.al found improved anti-tumour 
efficacy by the combination of an anti-endoglin mAb with a chemotherapeutic drug 
(cyclophosphamide (CPA) or doxorubicin (DPX)) using an anti-angiogenic 
schedule of drug dosing (Takahashi et al., 2001a; Shiozaki et al., 2006). 
 150 
Accordingly, another clinically relevant question raised is whether concomitant 
chemotherapy in some tumour types could alter or even abrogate the increased 
malignant phenotype caused by certain anti-angiogenic therapies in different 
models. More recent metronomic chemotherapy could negate or reduce pro-
invasive and pro-metastatic responses to anti-angiogenic therapies. On the other 
hand, abnormal cancer associated neovasculature normalized by anti-angiogenic 
therapy could contribute to the delivery of chemotherapeutic regiments. To test 
whether the combination of anti-angiogenic biotherapy and metrotomic 
chemotherapy is a practical and rational strategy for cancer therapy, Seon et al 
explored the efficacy of a strategy combining low-dose cisplatin and a recombinant 
xenogeneic endoglin as a protein vaccine, which was previously demonstrated to 
have effective anti-angiogenic effects in several mouse models. The results 
demonstrate the combination therapy resulted not only in significant anti-
angiogenic effects but also additional promotion of tumour cell apoptosis and 
inhibition of tumour cell proliferation. In addition, the combination demonstrated a 
synergistic relationship, which was shown in all of the synergistic indexes, i.e., 
tumour volume, angiogenesis, apoptosis and proliferation. These observations may 
provide the basis for an effective alternative strategy for cancer therapy in the near 
future (Tan et al., 2004). 
Multitargeted antiangiogenic therapies may be another method of increasing the 
efficacy of anti-angiogenic agents by anti-endoglin antibody. Possibly, the 
consequence of anti-angiogenic therapy is to upregulate some other cytokines that 
promote reneovascularization. Therefore, a current priority is to determine whether 
there are pro-angiogenic agents upregulated due to anti-endoglin therapy. 
Taken together, the current pre-clinical data demonstrate endoglin potentially can 
be developed as a novel antibody-based diagnostic and therapeutic strategy. It 
seems to be premature timing to apply anti-endoglin therapies to the clinical setting 
of cancer. Instead the priority must be to investigate mechanisms of response to 
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anti-endoglin therapy and thereby identify the most appropriate therapeutic 
applications of endoglin targeting. Moreover, the efficacy of anti-endoglin therapies 
should be tested at all stages of tumour progression in a variety of clinically 
relevant animal models. The potential side effects of targeting endoglin are 
considered in the next chapter.  
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Chapter 6. Potential Side Effects of Using Endoglin as an Anti-
angiogenic Therapeutic Target 
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          6.1 Introduction 
Anti-angiogenic therapy is thought to be free of the most severe side effects such as 
anemia, fatigue, hair loss, appetite changes, swelling, bleeding problems and 
infection that are usually seen with conventional chemotherapy. But anti-
angiogenic drugs are not risk-free and do have their own side effects, which seems 
to be distinctly caused by anti-angiogenic therapy rather than conventional 
chemotherapy, when both in combination are used to treat patients with cancer. For 
example, humanized monoclonal antibody bevacizumab (Avastin) recognises and 
blocks VEGFA, thereby reducing stimulation of the new blood vessels that are 
required for tumour growth. There are already clinical trial results supporting its 
efficacy for the first- and second-line treatment of colorectal cancer in combination 
with chemotherapy (Hurwitz et al., 2004; Giantonio, 2005; Hochster et al., 2006). 
The main side effects associated with anti-VEGF treatment in colorectal cancer 
include hypertension, proteinuria, thrombosis, bleeding, impaired wound healing 
and gastrointestinal perforation (David Cunningham, 2007). These changes, 
however, are generally manageable and pose less risk than the tumours being 
treated. These adverse effects of VEGF inhibitors may be caused by suppressing 
VEGF signalling in ECs of normal organs, among these, the more likely 
mechanisms are endothelial cell dysfunction and regression of fenestrated 
capillaries (Kamba and McDonald, 2007). 
Endoglin has also been proposed as an anti-angiogenic target for clinical treatment, 
and is currently being tested in two phase І clinical trials 
(http://clinicaltrials.gov/archive/NCT00582985/2008). However, there are also 
concerns about the potential side effects of such therapy. These might be similar to 
those of Avastin or other anti-angiogenic agents that are currently used in clinical 
trials. On the other hand, anti-endoglin therapy could potentially cause vascular 
defects similar to those present in Hereditary Haemorrhagic Telangiectasia (HHT) 
patients. HHT type I is caused by an inherited haploinsufficiency of endoglin due to 
heterozygosity for mutation of endoglin (McAllister et al., 1994). This vascular 
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disorder is characterized by bleeding from small vascular malformations 
(telangiectases) in the nose and gastrointestinal tract, and by larger arteriovenous 
malformations (AVMs) that have most frequently been reported in the lung, brain 
or liver, but may also occur in the retina (Guttmacher et al., 1995). 
To investigate what side effects anti-endoglin therapy may potentially cause, an 
additional experiment was performed to examine the phenotypes of the Eng-iKO
e
 
mice that had been given subdermal matrigel plugs. This model was initially 
described in Chapter 3 and preliminary data indicated there was some abnormal 
vascular remodelling in the perimatrigel area. However, the experiment described 
in Chapter3 was not designed to examine the perimatrigel area in full, nor was 
control tissue taken for comparison. Therefore, a matrigel plug, supplemented with 
VEGF (300ng/ml) and bFGF (600ng/ml), as before, was injected subcutaneously 
into the right flank and examined after 15 days. For the work described in this 
chapter a full depth sample of dermal tissues (including the skin and subdermal 
muscle layer surrounding the matrigel plug) was taken at the end of the study to 
permit investigation of vascular remodelling in the tissue neighbouring the matrigel. 
Also, in this experiment, a full depth skin tissue sample was taken from the 
opposite side of the animal to the site of the matrigel plug (in the contra-lateral 
flank) to analyse unstimulated vessels as an internal control. Tissues were analysed 
using serial sections as before (Chapter 3).  
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6.2 Results  
6.2.1 The expression of endoglin in different blood vessels in normal skin 
In order to formally identify which dermal vessels express endoglin in normal skin, 
the expression of endoglin in the different blood vessels from control mice without 
matrigel or tamoxifen stimulation was assessed. From this, I could select which 
types of blood vessels were most likely to be affected by endoglin depletion. CD31 
and endoglin immunohistochemistry was carried out on cryosections of frozen skin 
tissue that obtained from control mice without matrigel and tamoxifen stimulation. 
Immunostained adjacent sections using CD31 and endoglin antibodies showed that 
endoglin similarly was strongly expressed on venules, arterioles and capillaries 
(Table 6.1). Therefore, I would conclude from this that any of these vessel types 
might be altered in the absence of endoglin. 
Table 6.1 Endoglin and CD31 expression in normal dermal blood vessels 
The extent and intensity of vessel staining was scored from 0 (no staining) to +++ 
(strong staining). The identity of venules and arterioles were determined based the 
structure of vessels. 
6.2.2 Angiogenic stimulation leads to venous enlargement in Eng-iKO
e
 mice 
Analysis of paraffin sections of skin samples containing the matrigel plugs showed 
major remodelling of blood vessels including postcapillary venules close to the 
matrigel in the Eng-iKO
e
 mice (n=5) that was not seen in the control mice (n=4) 
and resembled the dilated blood vessels seen in HHT patients (Figure 6.1). This was 
mirrored by a more modest dilation of the arteries in the Eng-iKO
e 
mice. Blood 
Samples 
(n = 9) 
CD31 Endoglin 
Capillaries Venules Arteries Capillaries Venules Arteries 
1 + + + + + (+) + + + + + + + (+) + + 
2 + + + + + (+) + + + + + (+) + + (+) + + (+) 
3 + + + (+) + +  + + + + 
4 + + + (+) + + + (+) + (+) + (+) 
5 + + + + + + + + + + + + + 
6 + + + + + + + + + + + + + + (+) + + + 
7 + + + + + + + + + + + + + + + + + + 
8 + + + + + + + + + + + + 
9 + + + + + + + + + + + + + + (+) + + + 
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vessels distant from the matrigel plug in the contra-lateral flank of the Eng-iKO
e
 
mice showed no obvious vascular phenotype (Figure 6.2). Statistical analysis 
showed there was a significant increase in venous size in distant skin in Eng-iKO
e
 
mice compared with control mice (Figure 6.3 A). On the other hand, there was no 
significant difference in venous size between contra-lateral skin and matrigel-
stimulated skin in control mice (Figure 6.3 B). These results indicate endoglin loss 
alone can cause modest dilated vessels, but angiogenic stimulation alone does not 
result in dilated vessels. However, there was a significant increase in average 
venous cross sectional area in veins from the matrigel stimulated region compared 
with distant skin in the Eng-iKO
e
 mice (Figure 6.4 A). There was also a 
significantly increased venous size in matrigel skin in Eng-iKO
e
 mice compared 
with control mice (Figure 6.4 B). Both of these changes suggest there is an 
abnormal venous enlargement response in the presence of angiogenic stimulation 
and in the absence of endothelial endoglin. This result may certainly be of clinical 
relevance. However enlarged venules did not appear to cause any detectable effects 
on the health or viability of Eng-iKO
e
 mice, and HHT1 patients may harbour 
enlarged veins without serious morbidity.  
 
Figure 6.1 Dilated blood vessels in the subdermal tissue adjacent to the 
matrigel plug in Eng-iKO
e
 mice 
A, Three obviously dilated vessels immunostained with CD31 located on the area  
     adjacent to matrigel in Eng-iKO
e
 mice; 
B, Apparently normal vessels in a similar region in control mice.  
     The dashed line indicates the margin of matrigel plug.  
Scale bar = 100µm. Abreviation: pm, panniculus carnosus muscle layer. 
Matrigel Matrigel 
pm pm 
A B  Eng-iKOe Control 
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Figure 6.2 Vascular remodelling in response to a matrigel stimulus in Eng-
iKO
e 
mice.  
A, H&E staining shows two obviously dilated veins (blue arrows) located on the  
     area adjacent to matrigel plug in the dermis of an Eng-iKO
e
 mouse;  
B, A normal sized venule (blue arrow) and artery (red arrow) sitting aside the  
     panniculus carnosus muscle layer in Eng-iKO
e
 mouse in the unstimulated  
     contralateral skin;  
C, Modest dilation of a vein (blue arrow) located on the area adjacent to  
     matrigel plug in a control mouse; 
D, Normal microvasculature in the contralateral skin in control  
     mouse (blue arrows indicate veins, red arrows indicate arteries).  
Scale bar 100µm. Abbreviation: pm, panniculus carnosus muscle layer.  
 
 
A  Eng-iKOe 
Matrigel 
pm 
Control Control 
 Eng-iKOe B 
pm 
Matrigel 
pm 
pm 
D C 
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Figure 6.3 Endoglin loss alone causes dilated vessels. 
A, There is a significant increase in venous size in contralateral skin between   
     Eng-iKO
e
 mice (n = 5) and control mice (n = 4) (t-test, T = -4.06, P = 0.010). 
B, There is no significant difference of venous size between contra-lateral skin and  
     matrigel skin in control mice (n = 4) (Paired t-test, T = -2.76, P = 0.070). 
 
Figure 6.4 The combination of endoglin loss and angiogenic stimulation results 
in enlarged veins. 
A, There is a significant increase in venous size in matrigel-stimulated skin  
     compared with contra-lateral skin in Eng-iKO
e
 mice (n = 5). (Paired t-test, T = - 
     4.83, P = 0.008). 
B, There is a significant increase in venous size in matrigel-stimulated skin in Eng- 
     iKO
e
 mice (n = 5) compared with matrigel-stimulated skin of control mice (n =  
     4). (t-test, T = -4.00, P = 0.010). 
 
6.2.3 Veins are the major responsive vessels 
To investigate this vessel enlargement in more detail and to better define the 
physical extent of the response, we undertook a systematic analysis of serial 
sections of dermal blood vessels in tamoxifen treated control and Eng-iKO
e
 mice, 
from near the matrigel plugs in skin and in the skin that was distant from the 
matrigel, taken from the contra-lateral flank. The analysis was focussed on the 
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postcapillary venules and neighbouring arterioles located close to the panniculus 
carnosus muscle layer in each case.  
 
The average venous cross sectional area of maximally enlarged vessels showed the 
postcapillary venules enlarged dramatically as shown above (Figure 6.2, 6.3 & 6.4), 
whereas the arteries only slightly increased (Figure 6.5). 
  
In order to examine this finding in more detail, multiple serial sections that 
contained at least one pair of veins and arteries close to the panniculus carnosus 
were examined and photographed for 3-D reconstruction. This further illustrates the 
obvious venous enlargement in the Eng-iKO
e
 mouse compared with the control 
(Figure 6.6). There were six 3D reconstructions (three from Eng-iKO
e
 mice and 
three from control mice) that were performed similarly in this study and were 
consistent with the results from the analysis of venous and arterial cross sectional 
area shown above. This provided additional support to the conclusion that veins are 
the major responsive vessels compared to arteries. 
 
 
Figure 6.5 No significant increase of arterial size in matrigel skin in Eng-iKO
e
 
mice.  
A, There is no significant difference of arterial size between matrigel skin and  
     contra-lateral skin in Eng-iKO
e
 mice (n = 5) (Paired t-test, T = -1.29, P = 0.267). 
      B, There is no significant difference  of arterial size in matrigel skin between Eng-    
           iKO
e
 mice (n = 5) and  control mice (n = 3) (t-test, T = -0.54, P = 0.615).  
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Figure 6.6  3D reconstructions of veins (blue) and arteries (red) from serial 
sections of adult mouse skin.  
Images show how the reconstructions are based on individual sections and the 
lowest section has been kept for illustration purposes. The position of the epidermis 
(e) is marked for orientation.  
A, A parallel vein and artery close to the Panniculus Carnosus (pc) in normal  
     skin from a control mouse.  
B, An enlarged vein running parallel to an artery from an equivalent region of  
     skin but close to matrigel (m) in an Eng-iKO
e 
mouse. Slight imperfections in the  
     serial sectioning lead to the small „gap‟seen here in the artery.  
Approximately 60 serial 5μm sections were reconstructed in each case using Amira 
4.0 software. 
6.2.4 Vascular remodeling occurs close to the source of the angiogenic stimulus  
The significant feature of vascular remodeling in the matrigel plug implanted Eng-
iKO
e
 mice is primarily the change in venous luminal dimensions. As the increase in 
venous size was far greater than could be explained simply from vasodilation, I 
examined the numbers of cells lining the vessels (assumed ECs, Figure 6.7) and 
found a significant increase of venous EC number in matrigel skin of Eng-iKO
e
 
mice compared to control mice (Figure 6.8). These results indicate this vascular 
remodelling was not due to venous dilation alone, but that EC proliferation also 
made a contribution to the venous enlargement.  
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Figure 6.7 The number of cells lining the vessels counted based on serial  skin 
sections stained with H&E from control mice and Eng-iKO
e
 mice 
A, Skin section stained with H&E from a control mouse show normal appearance  
     of post capillary venule (boxed area, and in digital zoom) adjacent to a small  
     artery (a) running next to the Panniculus Carnosus (pc).  
B, A similar section from an Eng-iKO
e
 mouse shows major venous enlargement  
(boxed area, and in digital zoom) adjacent to matrigel plug.  
Note: Nuclei of cells lining the vessles (identified as nuclei protruding into the 
vessel lumen) were counted on 3 adjacent sections for each vein. Dilated blood 
vessels were discriminated from longitudinal sections through blood vessels fusion 
by performing serial sectioning and 3-D reconstructions with Amira software. 
 
a 
Control 
pc 
matrigel 
a 
 Eng-iKOe 
pc 
A B 
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Figure 6.8 Significant increase in the number of venous endothelial cells in 
matrigel skin of Eng-iKO
e
 mice 
There is a significant increase in venous endothelial cell number comprising the 
enlarged vessels in matrigel skin of Eng-iKO
e
 mice (Median = 36, n = 5) compared 
with that of control mice (Median = 20.33, n = 4) (Mann-Whitney test, W = 10.0, P 
= 0.020).  
Note: there is not normal distribution in the number of venous endothelial cells in 
matrigel skin of Eng-iKO
e 
mice, therefore the non-parametric Mann-Whitney test 
was used in this analysis. Circle dots indicate the median, external bar and internal 
bar represents Inter-Quartile Range (IQR) and 95% confidence interval for median, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 e 
 
e 
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6.3 Discussion 
6.3.1 The potential development of HHT in patients treated with anti-endoglin 
therapy 
HHT is characterized by a highly variable expressivity and age-dependent 
penetrance. Diagnosis is based on a combination of some or all of the following 
symptoms: spontaneous epistaxis, cutaneous telangiectases and arteriovenous 
malformations in some internal organs including the lung, brain or liver (Lebrin and 
Mummery, 2008). Mutations in the endoglin gene are associated with HHT type I. 
In Chapters 3 and 5, the data showed evidence for reduced new blood vessel 
formation due to the absence of endoglin, potentially supporting the idea that anti-
endoglin therapy will be effective against new blood vessel formation in tumours. 
However, a major concern is that patients may develop HHT1 during long-term 
anti-endoglin therapy. 
6.3.2 Endothelial specific endoglin depletion does not appear to cause major 
health problems 
To investigate whether anti-endoglin therapy can cause HHT1, the experimental 
data from the matrigel plug implanted mice indicates that mutation of endoglin 
alone causes minor changes in venous size that may be due to venous dilations 
rather than major vascular remodeling. However, an angiogenic stimulus in 
combination with loss of endoglin can cause significant dilation of veins and 
increased proliferation of venous ECs. Therefore, this finding indicated that any 
angiogenic stimulus within a growing tumour might lead to abnormal venous 
enlargement during anti-endoglin therapy. However, in my tumour study, I did not 
find abnormally enlarged veins in peritumoural regions of day6 or day18 tumours 
in Eng-iKO
e
 mice. There is a possibility that the different experimental procedures 
between the matrigel plugs implantation study and the subdermal LLC-RFP tumour 
study may explain this difference in venous response. The matrigel mixed with 
growth factors was injected on the same day as the tamoxifen i.p. injections began. 
In contrast, in prior to subdermal LLC-RFP injection, 5 consecutive i.p. tamoxifen 
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injection were applied and endoglin gene were deleted. In addition, the growth of 
tumour was more aggressive and these aggressive cancer cells were more likely to 
„destroy‟ the peritumoural tissues, unlike the compact matrigel plugs. Moreover, the 
matrigel plugs containing high levels of FGF and VEGF growth factors can 
immediately affect surrounding vasculature after matrigel plug implantation, 
whereas injected cancer cells might experience a „dormancy‟ period before 
releasing growth factors.  
 
The expression of endoglin is not tumour specific, it is expressed in tumour-
associated blood vessels but is also variably expressed in the vasculature of normal 
tissues (Takahashi et al., 2001a). This finding is in line with our results from 
immunostaining. We found endoglin was highly expressed in the vasculature of 
solid tumours such as lewis lung carcinoma and neuroblastoma, but was also 
expressed in varying degrees in the vasculature of skin (Table 6.1). It is also 
expressed in adult lung vasculature (Mahmoud et al., 2009), and adult heart valves 
and capillaries (Arthur et al., 2000). Therefore, it is possible that anti-endoglin 
therapy could affect the function of major organs and tissues. From my 
experimental metastatic model study (introduced in Chapter 5), I found that 
metastases in lung were significantly increased in Eng-iKO
e
 mice compared with 
control mice. This indicates the vasculature in lung might be affected due to the loss 
of endoglin. Therefore, it would be very advantageous if different specificities of 
anti-endoglin mAbs allowed specificity for tumour vasculature compared with 
normal tissue vasculature. For example, SN6j and SN6k show higher selective 
reactivity with human tumour vasculature compared with normal human tissue 
vasculature (Matsuno et al., 1999). In principle, if an anti-endoglin mAb reacts only 
with tumour-associated vascular endothelium, this would minimize any side effects 
caused by cross interaction with vascular endothelium in normal tissues (Matsuno 
et al., 1999; Fonsatti et al., 2000). 
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However, endoglin is also an endothelial cell-associated proliferating antigen and 
its expression is upregulated in tumour-associated vascular endothelium (Seon et al., 
1997; Takahashi et al., 2001a). Therefore, the endoglin upregulation in ECs of 
tumour vasculature are likely to be more susceptible to targeting by anti-endoglin 
mAbs than any normal tissues showing low endoglin expression. 
  
An open label phase-I dose finding study of TR105 (a human/murine chimeric 
IgG1 anti-endoglin antibody) in patients with advanced solid tumour is now in 
progress (http://www.cancer.gov/search/ViewClinicalTrials.aspx). This phase-I 
study is aiming to evaluate safety, tolerability and dose limiting toxicities during an  
evaluation period (a month to years). Although the evaluation is only based on a 
small number of patients (up to date n = 50) with advanced solid tumours, it is the 
first clinical trial of anti-endoglin therapy and the preliminary data indicates the 
majority patients can tolerate doses of TRC105 that generate anti-angiogenic and 
anti-cancer activity (Goldman et al., 2011).  
6.3.3 Limitations of the matrigel skin model to investigate abnormal vascular 
remodelling in Eng-iKO
e
 mice 
The matrigel implanted skin model described in this chapter had a number of 
limitations. The most important problem was that of a rather variable response, 
despite the fact that the experimental design aimed to minimise variations, by using 
age matched and similar weight mice. However, there were some unavoidable 
sources of variation that might have altered the effect of endoglin or angiogenic 
stimulation on vascular remodelling. First of all, the responsive arteries and veins of 
interest, close to the panniculus carnosus muscle layer in mouse skin, are not visible 
at the time of injection of the matrigel. It was therefore not possible to inject the 
matrigel plug in exactly the same place close to the responsive vessels.  Therefore, 
minor variation in the location of the matrigel plug is an important factor potentially 
affecting vascular remodelling within the study group. Secondly, the mouse models 
 166 
used in this study were of a mixed genetic background due to the intercrossing of 
several transgenic lines to generate the required genotype (in contrast to the work 
described in chapter 5 that used a backcrossed line). In addition, there were some 
difficulties of examining vessels in 3-D, for example, it was difficult to obtain 
consistent serial sections including an artery and vein that ran in parallel through 
the skin tissue and also it was difficult to align the images from any damaged or 
folded sections for 3-D reconstruction. Although the Amira software can 
automatically fill the gap generated by missing sections, this did affect the accuracy 
of the study. 
To avoid the shortcomings of matrigel skin and minimize variations generated by 
models, an alternative retinal angiogenesis model was recommended by Dr. Marcus 
Fruttiger. This
 
is a good model system for study of the development of blood
 
vessels, because arteries and veins develop during the first week of neonatal life in 
a regular alternating pattern with an intervening capillary network. This vasculature 
forms a highly organised vascular plexus in
 
two dimensions, which simplifies the 
study of a vascular plexus
 
in its entirety (Fruttiger, 2002; Fruttiger, 2007). 
Colleagues in my host laboratory have shown similar responses of vessel 
enlargement  in the absence of endoglin in this more readily visualised 
physiological model (Mahmoud et al., 2010). The enlarged vessel phenotype 
appears to be caused by a deregulated EC proliferation response, the response that 
was initially indicated in the dermal model described in this chapter. 
 
In order to investigate the abnormal cell proliferation responses and any TGF-β 
family signalling defects in endoglin deficient ECs in more detail, the final part of 
this study was to isolate primary cell lines from the inducible endoglin knockout 
mice and is described in the next chapter. 
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Chapter 7. Effect of Endoglin Depletion on Endothelial Cell 
Phenotypes In Vitro 
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       7.1 Introduction 
During
 
angiogenesis, ECs organize to form three-dimensional
 
(3D) capillary 
networks, which encompasses a range of cellular
 
processes including migration,
 
proliferation and differentiation of ECs (Whelan and Senger, 2003). Endoglin, an 
auxillary receptor for TGF-β, is predominantly expressed on proliferating ECs and 
is required for efficient angiogenesis in vivo (as described in Chapter 3) (Lopez-
Novoa and Bernabeu, 2010; Mahmoud et al., 2010). To investigate the effects of 
endoglin depletion on individual aspects of ECs migration, proliferation and 
differentiation, a more readily manipulated system was required that could mimic 
some aspects of EC phenotype in vitro. I therefore aimed to derive inducible 
endoglin deficient endothelial cell lines for functional in vitro analyses that would 
complement the in vivo mouse model. 
 
ECs were purified from mouse lungs using antibody-dynabead conjugates (Figure 
4.1, & Chapter2). Primary mouse lung endothelial cells (MLECs) were isolated and 
survived well in culture for at least 4-5 passages. Cells were prepared from Eng
fl/fl
 
Cdh5(PAC)Cre-ER
T2
 mice and the endoglin gene was deleted by treatment with 4-
hydroxytamoxifen (4-OHT). (Activation of Cre-ER
T2
 by tamoxifen itself is not 
effective in vitro as it requires the active metabolite, 4-OHT; conversion of 
tamoxifen to 4-OHT normally occurs in the liver in vivo). I confirmed that endoglin 
protein was lost in Eng
fl/fl
 Cdh5(PAC)Cre-ER
T2 
MLECs within 48 hours of 1µM 4-
OHT treatment. However, isolation of primary MLECs is very challenging, due to a 
slow growth rate and early senescence, so these cells are unsuitable for more than 6 
passages. I therefore decided to generate conditionally immortalised Eng-iKO lines 
using the immortomouse (transgenic line H-2K
b
-tsA58) (Jat et al., 1991). The 
immortomouse transgene allowed the derivation of longer lasting endothelial cell 
lines from primary cells. I also used a different transgene to drive Cre expression. 
RosaCre-ER
T2
 expresses a tamoxifen activated Cre protein in most cells, including 
ECs, driven by the ubiquitous Rosa26 promoter. All mice used in this part of the 
study were in C57BL/6 background (approximately N5). 
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A temperature sensitive Simian Virus 40 Large T Antigen (SV40 TAg) expressed 
by the immorto allele, allows cell proliferation at 33°C to bypass G1 checkpoint 
control, increasing the growth rate (Lidington et al., 2002). Returning to 37°C 
allows orthodox growth at the physiological temperature. Subsequently, to 
investigate the effect of endoglin-loss on the ability of ECs to undergo the cellular 
activities required for angiogenesis, 4-OHT was used to deplete endoglin at a time 
of choice. The resultant conditionally immortalised Eng-iKO ECs were tested in the 
following assays: MTT assay to measure cell viability, cell counts to monitor 
proliferation, and a “wound healing” (scratch assay) to measure migration.  
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        7.2 Results 
7.2.1 Effect of 4-Hydroxytamoxifen on viability of ECs 
Transient exposure to 4-OHT was required to bring about endoglin deletion. 
However, to identify any confounding effects of 4-OHT on viability and 
proliferation of ECs, an MTT assay on a mouse skin dermal vascular endothelial 
cell line (sEND-1) was performed. The MTT assay gives an indication of the 
metabolic activity of cells which reflects their viability and proliferation rate. Cells 
reduce the tetrazolium component of MTT into a water insoluble formazan product, 
resulting in purple crystals being deposited. The reaction occurs only in the 
mitochondria of healthy cells (van de Loosdrecht et al., 1993). Therefore, cells 
undergoing apoptosis or in senescence convert less MTT compared to healthy or 
actively dividing cells. 
 
The MTT assay revealed that there was no apparent effect of 4-OHT treatment on 
cell viability at doses ranging from 0.1µM to 2.0 µM and that there was no 
difference between treated and untreated sEND-1 cells (Figure 7.1). This was 
confirmed statistically, using an unpaired student‟s t-test (Figure 7.1). These data 
indicate that these doses of 4-OHT may be safely used for activating Cre 
recombinase in MLECS derived from Eng
fl/fl 
Cdh5(PAC)Cre-ER
T2
 and Eng
fl/fl 
RosaCre-ER
T2 
mice.  
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Figure 7.1 The effect of 4-OHT on sEND-1 viability using MTT assay.  
Cells were seeded at 5,000 per 96-well plate and incubated for 48 hours with or 
without 4-OHT (ranging from 0.1µM to 2.0 µM). There are no significant changes 
in cell viability/proliferation of untreated versus 4-OHT treated sEND-1 (P > 0.05, 
two sample t-test, error bars:  ±1 standard error (SE); the figure was generated using 
SPSS Statistics 17 analysis package) 
 
7.2.2 Optimising methods for cell staining  
In order to examine the purity of mouse lung ECs and evaluate endoglin depletion 
in Eng-iKO
e
 MLECs, the methods of immunocytochemistry were optimised (Figure 
7.2; Table 2.6).  
 
Figure 7.2 Immunocytochemistry staining of sEND-1 and NIH 3T3 (fibroblast 
cell line) with anti-CD31  
A, sEND-1 cell line stained with anti-CD31 and an anti-rat secondary antibody  
     conjugated to Alexa-594 (red); 
A B sEND-1 NIH 3T3 
CD31 
DAPI 
CD31 
DAPI 
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B, NIH 3T3 cell line stained with anti-CD31 and an anti-rat secondary antibody  
     conjugated to Alexa-594 (red) shown as a negative cell control.  
Scale bar = 100µm. 
7.2.3 Yield and purity of Mouse Lung Endothelial Cells 
To examine the purity of primary MLECs, immunocytochemisty using anti-CD31 
was used and the CD31-positive ECs and CD31-negative non-ECs were counted 
(based on random fields of view in several wells of a multichamber slide to give a 
total of 6 images per cell line). The percentage of CD31 positive MLECs for each 
cell type were calculated and summarized in Table 7.1. The purity of MLECs was 
good enough for subsequent experiments, however the yield was not sufficient for 
the subsequent functional assays due to the slow growth rate and limited passage 
number. 
 
Cell 
type 
FOV Antibody No. of 
ECs 
No. of 
NCs  
Total ECs %  Average 
Control 1 CD31 49 3 52 94.2% 92.9% 
2 CD31 40 5 45 88.9%  
3 CD31 51 5 56 91.1%  
4 CD31 50 5 55 90.9%  
5 CD31 65 4 69 94.2%  
6 CD31 50 1 51 98.0%  
Mutant 1 CD31 58 5 63 92.1% 94.0% 
2 CD31 35 3 38 92.1%  
3 CD31 30 3 33 90.9%  
4 CD31 62 2 64 96.9%  
5 CD31 43 1 44 97.7%  
6 CD31 34 2 36 94.4%  
Table 7.1 Summary of MLECs purity based on CD31 staining. 
Note: genotype of control and mutant cells was Eng
fl/fl 
and Eng
fl/fl
 Cdh5(PAC)Cre-
ER
T2 
respectively. Abbreviation: FOV = field of view, ECs = CD31 positive cells, 
NCs = CD31 negative cells. 
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7.2.4 The lowest effective dose and timing of 4-OHT treatment for endoglin 
deletion on MLECs 
To determine the lowest effective dose and optimal time of 4-OHT treatment to 
efficiently bring about endoglin gene deletion in Eng
fl/fl
Cdh5(PAC)Cre-ER
T2 
MLECs, a series of titration experiments with different time points were performed 
(Table 7.2). These results indicate that increasing dose and timing of 4-OHT 
treatment do lead to an increasing percentage of cells with endoglin gene deletion. 
However, 0.1µM was too low to generate efficient endoglin deletion even after 9 
days. Therefore, based on this preliminary data and the published data (Loonstra et 
al., 2001), I used 1µM 4-OHT to treat primary MLECs (Eng
fl/fl 
and Eng
fl/fl 
Cdh5(PAC)Cre-ER
T2
) over 48 hours. This was sufficient to activate lacZ 
expression from the Rosa26R reporter transgene (Figure 3.2), which was shown by 
X-gal staining (Figure 7.3). This experiment was used not only to test the induction 
efficiency of Cre recombinase, but also to indirectly check the purity of MLECs. 
The majority of cells are blue cells, which are Cre induced ECs. Figure 7.4 shows 
almost 100% of Eng gene depletion in MLECs. Therefore, these results show that 
the dose of 1µM 4-OHT for 48 hours leads to efficient Cre activation, and Endoglin 
gene deletion (according to the principle shown in Figure 1.6). This protocol for 
1µM 4-OHT treatment for 48 hours was used for all subsequent experiments. 
 
Immunostain Dose of 4-
OHT 
Time course of 
treatment 
Approx. efficiency 
of endoglin gene 
deletion 
Anti-endoglin + 
Alexas-594 IgG 
0.05 µM 5 days 30% 
9 days 50% 
0.1 µM 5 days 40% 
9 days 60% 
Anti-endoglin + 
Alexas-594 IgG 
1.0 µM 2 days ~100% 
Table 7.2 Titration of 4-OHT to optimise endoglin gene deletion in Eng
fl/fl
 
Cdh5(PAC)Cre-ER
T2  MLECs. 
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Figure 7.3  X-gal staining on primary mouse lung endothelial cells carrying the 
Rosa26R Cre reporter  
A, X-gal staining on Eng 
fl/fl 
MLECs with 1µM 4-OHT treatment for 48hrs, there  
     are no blue cells detected without Cre activation. 
B, X-gal staining on Eng 
fl/fl
 Cdh5(PAC)Cre-ER
T2 
ROSA26R MLECs with 1µM 4- 
     OHT treatment for 48 hours, there are blue cells present following Cre  
     activation. Scale bar = 100µm. 
 
 
Figure 7.4 The efficiency of Eng deletion in primary MLECs is detected using 
immunocytochemistry. 
A, The expression of endoglin on primary Eng 
fl/fl
 MLECs treated with 1µM 4-OHT  
     is detected by anti-endoglin and an anti-rat secondary antibody conjugated to  
     Alexa-594 (positive cells in red, nuclei stained with DAPI in blue). 
B, The absence of endoglin on primary Eng 
fl/fl
 Cdh5(PAC)Cre-ER
T2 
MLECs  
     Treated with 1µM 4-OHT is detected by anti-endoglin and an anti-rat secondary  
     antibody conjugated to Alexa-594 (nearly 100% cells show endoglin depletion,  
     nuclei stained with DAPI in blue). Scale bar = 100µm.   
 
A  B  Eng fl/fl  
Endoglin 
DAPI 
Endoglin 
DAPI 
A B Eng fl/fl   Eng fl/fl Cdh5(PAC)Cre-ERT2; ROSA26R 
 Eng fl/fl Cdh5(PAC)Cre-ERT2  
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7.2.5 Derivation of novel conditionally immortalised cell lines using 
Immortomouse 
In order to overcome the shortcomings of primary ECs such as early senesence and 
slow growth rate, we took advantage of the immortomouse transgene to generate 
conditionally immortalized MLEC cell lines. The cell isolation protocol was exactly 
same as that used for the isolation and purifying of primary MLECs (Chapter 2, 
Figure 2.1). As explained above, the Immorto allele, allows cell proliferation at 
33°C to bypass G1 checkpoint control, increasing the growth rate. In addition, 
interferon-gamma (IFN-γ, 20U/ml) was used to stimulate Immorto gene expression 
and was removed before returning to 37°C to allow orthodox growth at the 
physiological temperature, where cells regained checkpoint control and assumed a 
growth phenotype similar to primary ECs.  
 
To identify the purity of these conditionally immortalized MLECs, 
immunocytochemistry staining was performed and also morphology of MLECs was 
shown in Figure 7.5. As similar results were obtained using both anti-endoglin and 
anti-CD31 antibodies, anti-CD31 antibody staining was subsequently used for 
determining the degree of EC purity (Figure 7.6). Purity of higher than 95% ECs 
was considered sufficient for the subsequent functional assays.  
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Figure 7.5 Immunocytochemistry staining and morphology of  the purified 
endothelial cell population. 
A & C show EC morphology and phenotype through phase contrast images; the  
            nuclei are elliptical or round  and located in the centre of cell body  
            some cells are spindle shaped in the relatively sparse cultures.  
B & D confirm EC phenotype and purity through immunofluorescence staining of  
            EC markers CD31(B) and endoglin(D), both present on the EC surface and    
            stained green (Alexa-488). The nuclei of all cells can be seen with DAPI in  
            blue.  
E, MLECs show typical cobblestone morphology of ECs at higher density. 
Scale bar = 100 µm. 
 
A B 
C D 
CD31 + DAPI 
Endoglin + DAPI 
E E 
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Figure 7.6 Purity of immortalized MLECs using immunocytochemistry 
staining with anti-CD31. 
A&B confirm the purity of immortalized MLECs through fluorescence staining  
          with anti-CD31. To analyse cell purity, three fields of view at magnification  
          of x10 were analysed using Image J software and 4 replicates were            
          performed. The nuclei of all cells can be seen with DAPI in blue.  
Scale bar = 100µm. 
 
7.2.6 Accelerated growth rate of immortalized Mouse LungEndothelial Cells 
Having generated pure MLEC populations, it was important to test whether the 
Immorto allele helps the cells incubated at the lower temperature in the presence of 
IFN-γ to proliferate more quickly. A simple cell count over 7 days showed that 
from a similar seeding density, the number of cells at 37°C increased by 
approximately 20%, whereas at 33
o
C the number of cells increased by around 80% 
(Figure 7.7). In this way, the continuous expression of immorto gene at the lower 
temperature permitted the yield of the conditionally immortalised MLECs to be 
increased for subsequent in vitro analyses.  
 
 
 
 
 
 
 
 
A B 
CD31 DAPI CD31  DAPI 
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Figure 7.7  Cell count of immortalised MLECs shows different growth rate at 
different temperatures.  
Cell counts show the proliferation rates of immortalised MLECs at different 
temperatures. Over 7 days cell counts were taken from phase contrast pictures of 
the same area of 3 different wells from both 37°C, and 33°C + IFN-γ incubation. 
This figure was generated by Dave Burn during his BSc project (which I 
supervised).  
 
7.2.7 Optimising methods for cell PCR  
In order to examine the DNA level of Eng gene depletion, PCR conditions were 
optimized first using the primary MLEC and wild type sEND-1 cell line (Figure 
7.8). The minimal cell number required to detect PCR products corresponding to 
the Eng gene was found to be approximately 50 cells. In addition, following this 
protocol, exons 5 and 6 of the Eng gene were deleted in 4-OHT treated Eng
fl/fl 
Rosa-CreER
T2
 MLECs (Figure 7.9). 
 
 
Figure 7.8 Determining the minimal cell number required for genotyping cells 
by PCR  
This PCR on genomic DNA isolated from ECs used primers F6 and R7 (Table 2.1) 
and shows a clear product for endoglin corresponding to the wild type allele (arrow) 
in both MLEC (M) and sEND-1(S) cells. The cell number used to prepare template 
     M1    M2    M3    M4    S1     S2     S3    S4      +      -    
500bp 
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Different Temperature
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o
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DNA was critical. Genotyping was possible from 50 MLEC cells and 50 sEND-1 
cells. M1 and S1 samples contain DNA from 50 cells, M2 and S2 samples contain 
DNA from 5 cells, M3 and S3 samples contain DNA from 0.5 cell, M4 and S4 
samples contain DNA from 0.05 cell. PCR products are 430bp for WT and 500bp 
for Eng
fl
 allele. Positive control (+) is a PCR from a standard preparation of DNA 
from a mouse ear clip (genotype is Eng
fl/+
) and negative PCR control (-) used  water 
as a template in place of DNA.  
 
 
Figure 7.9 Endoglin gene depletion at the DNA level identified by cell PCR 
A, a cartoon shows the position of the primers over the floxed endoglin allele and  
     the principle of endoglin gene depletion.  
B, Three PCR reactions using primers F6 & R7, F4 & R7, and F12& R13 shows  
     PCR products for three different regions of the endoglin gene (the primers and   
     PCR product sizes are also shown in Table 2.1). Lanes 1 & 2 show PCR  
     products from MLEC DNA isolated from untreated Eng
fl/fl 
Rosa-CreER
T2
 cells  
     (lane 1) and DNA isolated from similar cells following 4-OHT treatment (lane  
     2). Lane 3 is a negative control (no DNA template) whereas lane 4 contains  
         positive control (from an earclip of Eng +/Δ mouse) DNA for a deleted endoglin  
         allele. Note that the size of DNA sequence flanked by LoxP sites is approx.  
         2kbs. Therefore, primer pair F4/R7 does not generate a product with the  
         conditions used. PCR using primers F6 and R7 detects the floxed allele, which is  
         present in the untreated cells (lane 1) but at reduced levels in the 4-OHT treated  
         MLECs (Eng-iKO MLECs). In contrast, PCR using primers F4 and R7 detects  
         the Eng delete allele, which is present in MLECs only after 4-OHT treatment  
         (lane 2). There are clear PCR products in Eng-iKO and control MLECs using  
Cre-ERT2 
A 
B 
Active 
F4B R7B 
MLECs      MLECs + 4-OHT      Water         Eng +/Δ 
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         primers F12 and R13 that detect DNA in both endoglin floxed and delete alleles.  
         Template DNA used in this PCR was prepared from 50 cells, as optimized in  
         figure 7.8. This MLECs PCR figure is courtesy of Rachael Redgrave. 
 
7.2.8 Efficiency of endoglin depletion on immortalized MLECs 
Immorto-MLEC cells were tested for the loss of endoglin protein following 4-OHT 
treatment by immunocytochemistry. Endoglin protein was not detected in the 
Eng
fl/fl
 RosaCre-ER
T2
 cell lines following 4-OHT treatment (Figure 7.10). This 
shows that 4-OHT effectively generated Eng null cell lines, which can be used in 
subsequent experiments. 
 
Figure 7.10  Endoglin protein was efficiently depleted in Eng
fl/fl
 RosaCre-ER
T2
 
immortalized MLECs with 1 µM 4-OHT treatment for 48 hours.  
A, Nearly 100% cells expressed endoglin (anti-endoglin and an anti-rat secondary  
 antibody conjugated to Alexa-594 in red) in Eng
fl/fl
 RosaCre-ER
T2
 MLECs  
 without 4-OHT treatment;  
B, There was almost 100% deletion of endoglin (nuclei with DAPI staining in blue)  
 in Eng 
fl/fl
 RosaCre-ER
T2
 MLECs following 1µM 4-OHT treatment for 48 hours.  
Scale bar = 100µm. 
 
7.2.9 Effect of endoglin depletion on viability of Eng-iKO MLECs (MTT Assay) 
To investigate the effect of endoglin depletion on viability of MLECs, an MTT 
assay was performed (as described in Figure 2.2). There was no significantly 
reduced viability and or proliferation found in mutant MLECs compared with 
control MLECs (Figure 7.11, P = 0.341). As the MTT assay measures a 
combination of cell viability and cell proliferation properties, a cell counting 
method to investigate cell proliferation was performed as a separate analysis 
(Section 7.2.10).  
Endoglin + DAPI 
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Figure 7.11 A representative MTT assay demonstrates no influence of endoglin 
on the viability of MLECs 
There is no significant difference in viability/proliferation between Eng-iKO 
MLECs and control MLECs (Two samples t-test, T-Value = 0.98, P-Value = 0.341, 
n = 10). 
Qualitatively similar results were found in three independent MTT assays.  
 
7.2.10 Effect of endoglin depletion on proliferation of Eng-iKO MLECs using 
cell number counting 
 To test the effect of endoglin depletion on proliferation of Eng-iKO MLECs, an 
approach of simple cell number counting was used (as described in Figure 2.4). 
Overall, there were similar growth rates in both Eng-iKO MLECs and control 
MLECs (Figure 7.12 A). I observed increasing cell growth rate in the first 24 hr, 
decreasing growth rate in the next 24 hr, and then replication of these cycles during 
alternate days (Figure 7.12 B). It appears that cells stop growing after 64 hours and 
some cells also migrate out of the field of view. In addition, there is a slightly 
decreased proliferation rate in Eng-iKO MLECs compared with control MLECs 
during the 80 hr period, but this was not statistically significant (Figure 7.13). This 
result indicates that endoglin is not important for EC proliferation in MLECs 
cultured in microvascular endothelial cell growth medium MV2 (Promocell) 
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including a variety of growth factors.  
Figure 7.12 The growth rate of Eng-iKO MLECs and Control MLECs in the 
period of 80 hours. 
A, There are similar growth rate and trends between Eng-iKO MLECs and Control  
     MLECs, the graph shows increasing cell growth rate in the first 24 hours, a   
     reduced growth rate in the next 24 hours, and then it increases again. 
B, shows the difference of MLECs growth every 8 hours within 80 hours. In the     
     periods of 24-32 hours, 64-72 hours and 72-80 hours, there are negative growth   
     rates. Cell confluence was not reached within this 80-hour observation period. 
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Figure 7.13 No significant difference in cell proliferation rate between control 
MLECs compared and Eng-iKO MLECs  
There is no significant difference between control MLECs (18.5 ± 7.8) compared 
with Eng-iKO MLECs (10.9 ± 5.8) (T-Value = -0.78, P-Value = 0.446, n = 10). 
Bars are one standard error from mean.  
 
7.2.11 Effect of endoglin depletion on migration of Eng-iKO MLECs (Scratch 
Healing Assay) 
The migration of MLECs in response to endoglin depletion during a period of 28 
hours was investigated in an in vitro monolayer wound-healing model (as described 
in Figure 2.3). The initial wound in the MLECs monolayer culture was scratched 
using a trimmed cell scraper (approx. 1.5-2 mm width). The effect of endoglin on 
the EC migration of the wound-healing process obtained in one representative 
experiment is shown in Figure 7.14. The quantification of the wound-healing 
process was judged by the following formula: Healed area= (area of original wound 
– area of wound during healing)/area of original wound. There appeared to be a 
slightly faster migration rate in control MLECs compared with Eng-iKO MLECs 
during the period of 28-hour wound healing (Figure 7.15). However statistical 
analysis showed there was no significant difference in the average percentage of 
healed wound area between control MLECs and Eng-iKO MLECs (Figure 7.16, P = 
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0.320). Qualitatively similar results were found in 3 replicates of wound-healing 
assays. This result indicates endoglin is not important for endothelial cell migration 
in MLECs cultured in microvascular endothelial cell growth medium MV2 
(Promocell) including a variety of growth factors. 
 
Figure 7.14 Influence of Eng loss on MLECs migration using a scratch assay  
The original images were taken every 2 hours and representative images selected at 
4- hour time intervals are shown in the figure. The migrating process of Eng-iKO 
MLECs and control MLECs over 28 hours is indicated by the area outlined with red 
lines which marks the migrating cell front. The wound region was measured using 
Axiovision software, and the rate of closure of the wound was calculated from the 
difference between measurements from two time points. These images indicate that 
there is no significant difference in healing rate between control MLECs and Eng-
iKO MLECs. See also Figure 7.16. 
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Figure 7.15 Cell migration rate of control MLECs and Eng- iKO MLECs 
during the period of 28 hours wound healing  
It appears that there is a higher migration rate in control MLECs compared with 
that in Eng-iKO MLECs. Each dot represents average migration rate from three 
measurements and calculations of three fields of view within wound area. 
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Figure7.16 Cell migration rate in Eng-iKO MLECs is not significantly 
different from control MLECs 
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There is no significant difference in percentage of healed wound area between Eng- 
iKO MLECs and control MLECs during the healing period of wound (Two samples 
t-test, T-Value = 1.01, P-Value = 0.320, n = 14).   
 
7.2.12 Effect of endoglin depletion on viability of MLECs following titration of 
growth factors  
To investigate whether a variety of growth factors in microvascular endothelial cell 
growth medium MV2 (Table 2.5) could mask any effect of endoglin depletion on 
viability of control and Eng-iKO MLECs, additional MTT assays were performed.  
Eng-iKO and control MLECs were cultured with growth medium, with serially 
diluted growth factors for 24 and 48 hours. In this experiment, there were 
significant differences in viability between Eng-iKO MLECs and control MLECs 
even in full medium (Figure 7.17 A and Figure 7.18 A). This difference increased at 
1/4 and 1/8 dilutions. However, the viability of both Eng-iKO MLECs and control 
MLECs decreased as the growth factors were titrated and this was particularly 
evident at 1/16 and 1/32 dilutions (Figure 7.17 B and Figure 7.18 B). A significant 
drop in viability of control cells was firstly seen at 1/4 dilution compared with full 
medium. These results suggest the depletion of endoglin does influence the viability 
of MLECs, and that this may be partially rescued by growth factors present in the 
medium.  
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Figure 7.17 A loss of endoglin reduces viability of MLECs grown in normal 
and growth factor-reduced medium for 24 hours. 
A, MTT assay readings for Eng-iKO MLECs and control MLECs grown in normal  
     and growth factor-reduced medium for 24 hours. Growth factor supplement was  
     titrated in 2-fold dilution steps from 1/2 to 1/32 of that used to prepare normal  
     microvascular growth medium MV2 (Table 2.5).  There are significant  
     differences in viability between the viability of Eng-iKO and Control cells at all  
     dilutions (Two samples t-test, n = 8,       indicates P < 0.001,           presents P <  
A 
B 
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      0.000). 
B, Same MTT assay data as in A represented in graph format. Red squares and  
     black dots represent Eng-iKO MLECs and control MLECs respectively. 
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Figure 7.18 A loss of endoglin reduces viability of MLECs grown in normal 
and growth factor-reduced medium for 48 hours. 
A, MTT assay readings for Eng-iKO MLECs and control MLECs grown in normal   
and growth factor-reduced medium for 48 hours. Growth factor supplement was  
A 
B 
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 titrated as in Figure 7.17 (Two samples t-test, n = 8,       indicates P < 0.001,            
 presents P < 0.000). 
B, The same data as in A represented in graph format. Red squares and black dots  
     represent Eng-iKO MLECs and control MLECs respectively. 
 
7.2.13 Effect of endoglin depletion on cytoskeleton of MLECs 
The cytoskeleton generates contractile and stretching forces existing at equilibrium 
in normal endothelium. However, cytoskeletal rearrangements and actinomyosin 
contractility (formation of paracellular gaps between ECs) are coupled to vascular 
endothelium dysfunction (Garbi et al., 1990; Miettinen et al., 1994; Lum and Malik, 
1996; Dudek and Garcia, 2001; Birukova et al., 2004). In addition TGF- β 
signalling is known to regulate re-arrangements of the cytoskeleton. Therefore, to 
investigate the effect of endoglin depletion on the actin cytoskeleton of MLECs, 
fluorescent-phalloidin staining was performed. There seems to be no difference 
between overall cell shape between Eng-iKO MLECs and control MLECs. In 
addition, actin filaments stained with a phalloidin-FITC conjugate indicates there 
are similar cytoskeletal structures in Eng-iKO MLECs and control MLECs. 
However, I found the formation of dense peripheral bands in between Eng-iKO 
MLECs (Figure 7.19). These findings suggest that loss of endoglin does not affect 
the distribution of actin cytoskeleton network on MLECs, but contributes to the 
formation of dense paracellular bundles. It would be interesting to replicate this 
experiment and investigate this phenotype in more detail. The recent purchase of a 
super resolution microscope by Newcastle University may also help to gain further 
information.  
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Figure 7.19  Comparison of actin cytoskeleton of Eng-iKO and control 
MLECs. 
MLECs are stained with phalloidin-FITC (green) conjugate and nuclei stained with 
DAPI (blue). The distribution of actin filaments seems to be similar between 
control MLECs (A) and Eng-iKO MLECs (B), but the dense paracellular bands 
(arrows) are formed in between Eng-iKO MLECs. Scale bar = 200µm. 
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7.3 Discussion 
7.3.1 Challenges of purifying and passaging primary endothelial cells 
Endothelial cells play a major role in tissue homeostasis, as well as diverse 
pathologies, such as cancer, arthritis and atherosclerosis (Folkman, 1995; Griffioen 
and Molema, 2000), therefore, to understand the biology of ECs, characterization of 
this cell population is highly desirable. Cultured ECs are indispensable tools for 
functional assays and some signalling pathway studies, even though these may not 
completely mimic the phenotype of tissue ECs because the proper 
microenvironment is lacking. In 1973, ECs derived from human umbilical veins 
were first successfully cultured in vitro, since then, a substantial number of vascular 
cells have been cultured. However, it is fairly challenging to obtain sufficient 
purified primary ECs for subsequent functional studies.  
 
First of all, the protocol used to isolate mouse lung ECs in this study required 
multiple steps and considerable optimisation. Therefore, the critical criteria have 
been emphasized in the final protocol (described in Chapter2). For example, 
trimming off obvious bronchi and connective tissue is critical to avoid non-EC 
contamination; mouse lung lobes are rapidly minced as small as possible and 
subsequently digested enzymatically once with collagenase at 37 
o
C for exactly 1 
hour; MLECs in the single-cell suspension are labelled with CD31 antibody 
combined with magnetic beads using approximate 5 beads per target ECs; in order 
to obtain “pure” ECs, a second (or even a third) cell sorting is required using anti-
CD102 conjugated beads. This proved to be a really challenging technique.  
 
Secondly, ECs make up a minor population of cells in a tissue, ECs comprise only 
1-2 % of the total amount of cells in the tissue, and they are embedded in matrix 
components and tightly surrounded by various other cell types (Griffioen and 
Molema, 2000). The yield of ECs will also depend on the vascular density of the 
tissue, the expression of CD31, as well as the tissue composition which will affect 
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the efficiency of digestion (van Beijnum et al., 2008). For this reason the highly 
vascular mouse lung was used as the source of ECs in this study. On the other hand, 
the size of mouse tissue is rather small so the yield of ECs was not sufficient for 
downstream applications directly. Our solution was to culture those “pure” primary 
MLECs to build up the number of cells. However, these cells can only be passaged 
for 5-6 generations, since the majority of primary cells rapidly become senescent 
during cell culture. One report suggested single-cell suspensions might be expanded 
in vitro for 3-5 days and subsequently sorted for ECs (Dirkx et al., 2003). However, 
this culture step may induce unwanted phenotypic changes in the ECs, as 
contaminating cell types may grow more rapidly and take over the ECs population. 
On the other hand, the growth rate of primary MLECs is rather slow, it will take a 
long time to expand the cell number. Hence, these two limitations make passaging 
primary MLECs particularly challenging. Despite this problem, I successfully used 
a vascular specific inducible Cre enzyme, activated by 4-OHT, to obtain endoglin 
null ECs demonstrating that the inducible endoglin knockout system was workable 
in vitro. However, maintenance of a pure population of primary ECs was fairly 
difficult and restricted the use of these cells in angiogenesis assay systems. The 
progressive loss of cell viability and expression of endothelial markers in the course 
of in vitro propagation may have been due to increased numbers of senescent cells, 
de-differentiated cells, as well as the presence of contaminated non-ECs (Unger et 
al., 2002). Therefore, an alternative approach was required to generate larger 
numbers of ECs that could be maintained in culture for longer periods than 5-6 
passages. 
7.3.2 Conditionally immortalized endothelial cell lines 
To overcome these limitations, I took advantage of the „immortomouse‟ to isolate 
and purify conditionally immortalized MLECs.  The cell numbers were expanded at 
33°C to bypass G1 checkpoint control, to generate sufficient cells for subsequent 
experiments, which were performed at 37°C where cells regained checkpoint 
control and assumed a phenotype similar to primary ECs. Subsequently, using a 
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ubiquitous Rosa-Cre-ER
T2
 enzyme activated by 4-OHT, I also obtained sufficient 
numbers of Eng null ECs for analysis.  
7.3.3 Effect of endoglin depletion on endothelial cell phenotypes 
It is not clear whether endoglin mediates an enhanced migration and proliferative 
rate of ECs or how endoglin functions through the TGF-β/BMP signalling 
pathways in ECs. A better understanding of these functions will contribute to 
understanding the mechanisms of its role in angiogenesis. It was reported that 
endoglin is essential for angiogenesis in the mouse embryonic development and its 
expression is up-regulated on proliferating ECs during angiogenesis (Arthur et al., 
2000; Lebrin et al., 2004). Using the conditionally immortalised Eng-iKO MLECs, 
I investigated the role of endoglin in regulating cell viability, cell proliferation and 
migration. In previously published work, Eng
+/-
 ECs displayed significantly 
reduced proliferation and migration and impaired tube formation in vitro and 
endoglin positively mediated proliferation of ECs (Jerkic et al., 2006). In contrast, 
the initial work described in this chapter revealed that MLECs showed  slightly 
reduced cell viability, proliferation and migration in the absence of endoglin, but 
this difference was not statistically significant. There might be two possible 
explanations, first of all, the media used to culture these cells was rich in growth 
factor supplements (including VEGF (0.5ng/ml), bFGF (10ng/ml), IGF (20ng/ml), 
EGF (5ng/ml) and it is possible that one or more of these growth factors can rescue 
any effects of endoglin depletion in these assays. In addition, Eng-iKO MLECs 
were cultures at 37
o
C for 72 hours before the MTT assay. This relatively long 
period of time may make MLECs in orthodox growth conditions more susceptible 
to become senescent. Therefore, I determined to reduce the culture time under 
growth restrictive conditions during preparation of MLECs prior to the MTT assay. 
I also titrated the growth factor supplement used to prepare MV2 growth medium. 
Under these conditions, there were significant differences in viability/proliferation 
between Eng-iKO MLECs and control MLECs for 24 and 48 hours. This result 
suggests endoglin is important for maintaining viability of MLECs. Unfortunately, 
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there was insufficient time to use these cells to study the role of endoglin in TGF-β 
receptor superfamily signalling pathway as well. It is known that endoglin 
associates with TGF-β receptors and TGF-β is a multifunctional cytokine that 
controls proliferation, migration, adhesion, and apoptosis of a diversity of cell types 
(Lebrin et al., 2005; ten Dijke and Arthur, 2007; Holderfield and Hughes, 2008; 
Massague, 2008; Bernabeu et al., 2009; Pardali et al., 2010). 
 
In principle, VEGF is a crucial pro-angiogenic factor that promotes migration and 
proliferation of ECs and is essential for initiation of angiogenic sprouting. In 
addition, TGF-β has also been implicated in the regulation of EC migration and 
proliferation, as well as matrix synthesis (Holderfield and Hughes, 2008). It is still 
elusive how crosstalk between these two pathways can control proper patterning of 
the vasculature and how these pathways might interact to generate new ECs during 
pathological angiogenesis. It was thought that VEGF signal predominantly drives 
migration but does not stimulate proliferation, TGF-β signalling synergizes with 
VEGF to drive migration, while also blocking proliferation. Therefore, the switch 
between migration and proliferation in response to VEGF may involve synergistic 
and/or antagonistic interactions with TGF-β/BMP signalling (Holderfield and 
Hughes, 2008).  
 
In fact, there are surprisingly different conclusions regarding the specific role of 
endoglin in ECs based on published reports. For example, Michelle Letarte et al. 
demonstrated that Endoglin null ECs proliferate faster and are more responsive to 
TGF-β1 using mouse embryonic endothelial cells (MEECs) (Pece-Barbara et al., 
2005). Jerkic et al, in contrast, reported that Eng
+/-
 ECs from mouse aortic ECs 
showed significantly reduced proliferation and migration (Jerkic et al., 2006). This 
phenotype is consistent with what is seen when human umbilical vein endothelial 
cells (HUVEC) are treated with antisense endoglin (Goumans et al., 2002; Ota et 
al., 2002). The discrepancies among these similar studies are now awaiting 
resolution but probably relate to the origins of the cells used, such as human/murine 
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primary micro/macro endothelial cell and cell lines. There are some significant 
differences in phenotype between primary cells and cell lines. For example, the 
distinctive endothelial phenotypes such as constitutive expression of EC markers 
and angiogenic responses were typically observed in primary ECs. However, most 
endothelial cell lines only exhibit a few of these endothelial characteristics (van 
Beijnum et al., 2008). Furthermore, gene expression profiles might be changed over 
time possibly because of different types of medium and growth factor supplements 
used in culture. In addition, the different cells may respond distinctively to TGF-β 
signalling due to crosstalk between different TGF-β receptors and/or the other 
signalling pathways involved in phenotypic regulation of ECs. 
  
In conclusion, I have successfully derived several new EC lines that will be 
extremely useful in future studies to investigate the role of endoglin in experiments 
using defined culture media to try to resolve the disparate results obtained in 
different laboratories that have lead to current uncertainty of the role of endoglin in 
angiogenesis. 
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Chapter 8. General Discussion and Future Directions 
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8.1 Evasive resistance to anti-angiogenic therapy  
The overall aim of my project was to investigate the role of endoglin in 
angiogenesis and its potential as an anti-angiogenic therapeutic target. 
Angiogenesis was tested in vivo using the matrigel subdermal plug assay and was 
significantly reduced in endoglin-deficient adult mice compared with controls. 
Subsequently, angiogenesis and lung metastases were investigated using a 
subdermal LLC model. My findings indicate that targeting endoglin may delay 
tumour progression at an early stage (day6), but that loss of endoglin was 
associated with a significant increase in the frequency of lung metastases by day 18. 
This is a similar finding to two recent investigations of anti-VEGF treatments in 
pre-clinical mouse tumour models published in Cancer Cell. Hanahan et al. (2009) 
reported that anti-angiogenic therapy elicits malignant propression of tumours to 
increased local invasion and distant metastases (Paez-Ribes et al., 2009). Likewise, 
Kerbel and colleagues reported accelerated metastases after anti-angiogenic therapy 
(Ebos et al., 2009). Possible causes for increased metastases following this anti-
angiogenic treatment might be because the resultant hypoxia promotes tumour cell 
invasion into the surrounding tissue. Also, tumours may develop a number of 
mechanisms to evade anti-angiogenic therapy. First, evolutionary selection 
following anti-angiogenic therapy to neutralize the effect of a single angiogenic 
factor (e.g., VEGF) selects for tumour cells that express alternative pro-angiogenic 
factors (e.g., bFGF or PDGF). Second, a compensatory switch (a physiologically 
coordinated compensatory program) is activated in response to perturbations of 
homoeostatic systems after single pathway inhibition. Third, a genetic switch 
(comprising a dynamic change in expression of angiogenic factors via genetic or 
epigenetic alterations of, for example, oncogenes in tumour cells) would provide 
alternate angiogenic stimulation. Finally, a stromal switch would involve paracrine 
stimulation of angiogenesis via tumour recruitment and activation of diverse cell 
types, such as bone marrow-derived cells, immune cells and tumour associated 
fibroblasts. Any or all of these mechanisms might help the tumour to evade anti-
angiogenic therapy with a single target. Therefore, it is important to know which 
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evading mechanisms the tumour cells and microenvironment can develop over the 
time of therapy. In this regard, knowing the changes that occur following loss of 
endoglin or during anti-endoglin therapy would be very useful to determine which 
combination therapy can be used to supplement anti-endoglin therapy. 
 
8.2 Potential side effects of anti-endoglin therapy 
It is thought that anti-angiogenic therapy is generally safe and well tolerated, 
although it can be accompanied by a variety of adverse effects. In fact, Eng-iKO
e
 
mice did not lose weight and appeared healthy until the end point of the study 
(approximately 3 weeks after endoglin depletion). Also, there were no 
haemorrhagic symptoms found during this time, but these mutant mice did exhibit 
abnormal venous enlargement close to sites of local angiogenic stimulation. 
However, enlarged venules did not appear to cause any adverse effects in Eng-iKO
e
 
mice. It is important to note that no similar abnormal venous enlargement was 
found in the peripheral tumour tissue of Eng-iKO
e
 mice. 
 
8.3 Endoglin may be important for maintaining EC viability 
In parallel to the in vivo studies, ECs were isolated from the floxed endoglin mice 
for in vitro studies. Surprisingly, and in contrast to previously published works 
(Goumans et al., 2002; Ota et al., 2002; Jerkic et al., 2006), MLECs initially 
showed „normal‟ cell proliferation and migration in the absence of endoglin. In 
addition, these in vitro findings seemed to be inconsistent with the results achieved 
using the in vivo matrigel plug angiogenesis assay, where endoglin depletion caused 
an angiogenesis defect. A possible explanation for this difference is that the media 
used to culture these cells was rich in growth factor supplements (including VEGF, 
bFGF, IGF & EGF) and that one or more of these growth factors rescued the effects 
of endoglin depletion in these assays. Two further MTT assays were performed 
using Eng-iKO and control MLECs cultured with MV2 growth medium in which 
the growth factor supplements had been serially titrated. In these experiments there 
was a significant reduction in viability in Eng-iKO MLECs compared with control 
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MLECs. Although this was only preliminary data, this result suggests endoglin 
might be important for maintaining viability of MLECs. Future experiments to 
investigate the role of endoglin should use defined culture medium and take 
advantage of successfully derived endothelial cell lines from this project to resolve 
the disparate results obtained in different laboratories that have lead to current 
uncertainty of the role of endoglin in angiogenesis. An important consideration in 
relating this to the EC responses in vivo will be to compare levels of these growth 
factors in endogenous tissues (with and without endoglin) to those used in tissue 
culture. 
 
8.4 The selection of mouse tumour model 
The LLC-RFP subcutaneous cancer model generated a very useful tumour model 
with which to investigate the effect of endoglin depletion on tumour angiogenesis, 
growth and metastases. The LLC primary tumour (originally derived from mouse 
lung carcinoma) is characterised by rapid growth, high vascularity and frequent 
metastases to the lungs. However, this model also has some limitations when 
compared to the complexity of cancer development in patients. First of all, the 
subdermal LLC tumour model is a very simple one, comprising one rapidly 
proliferating cell type, that is not able to mimic the more complex tumour 
microenvironment found in patients. This complexity leads to more varied 
interactions between transplanted cancer cells and surrounding constituents, such as 
normal cells, stromal cells and immune cells (Hanahan and Weinberg, 2000; 
Hanahan and Weinberg, 2011). In addition, the LLC cancer is not a human cancer. 
However, an alternative pre-clinical mouse model which is often used in these types 
of studies is the human xenograft model. This involves injecting human cancer cells 
into immunocompromised mice. It aims to permit therapeutic assessment using 
cancer tissue from human, rather than from another species. Unfortunately, the 
results obtained from a number of xenograft studies (Boehm et al., 1997; Sarraf et 
al., 1998) have not translated well into the clinic (Kulke et al., 2002; Twombly, 
2002). It has been estimated that cancer drugs that enter clinical testing have a 95% 
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rate of failing to make it to market. The xenograft data from 39 cancer drugs that 
had already successfully completed Phase II trails in humans shows that only one of 
the xenograft models showed a similar response to the cancer drug as the patients 
who received it (Johnson et al., 2001). It seems, on the one hand, that there are 
histological differences in tumour structure and vasculature between tumours from 
xenograft or congenic graft models and tumours found in human maliganancies. In 
addition, the immunocompromised mouse involves knocking out the immune 
system to allow human cancer xenograft transplantion, at the same time it also 
fundamentally alters the interaction between cancers and the immune system during 
cancer progression, which can change the course and outcome of the disease 
(http://www.the-scientist.com/article/display/56084/). Moreover, the scheduling of 
anti-angiogenic therapy is different in pre-clinical and clinical settings. Treatments 
can be started at a much earlier stage of primary tumour progression in laboratory 
models compared with the clinic where cancers often present at a much later stage 
and/or metastatic condition may manifest before treatment begins. These 
differences may affect the response of the tumour to an anti-angiogenic therapy and 
might explain some clinical failures of anti-angiogenic approaches. Therefore, 
genetically engineered mouse (GEM) models which not only keep the mouse‟s 
immune system intact, but also genetically predispose the mouse to develop cancer 
by inducing the same genetic mutations in the mouse that cause cancer in humans, 
may have better predictive capability as models for human cancer. To date, GEM 
models have been developed for many common tumour types including lung, 
prostate, breast, colon and pancreatic cancers (Frese and Tuveson, 2007). There are 
a growing number of anti-angiogenic pre-clinical trials that take advantage of GEM 
models (Casneuf et al., 2009; Ebos et al., 2009; Noguchi et al., 2009; Paez-Ribes et 
al., 2009). However, it is still unclear whether this type of pre-clinical model is 
going to be optimal for facilitating tumour angiogenesis studies and anti-angiogenic 
drug development.  
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In addition, the metastatic process is often difficult to accurately model in 
xenografts or congeneric graft pre-clinical models owing to the rapid growth of 
primary ectopic tumours, although orthotopic implantation followed by resection 
(Vantyghem et al., 2005; Francia et al., 2011) and direct intravascular tumour cell 
injection can generate useful models of distant spread (Cruz-Munoz and Kerbel, 
2011). Even if it seems to be probably impossible to accurately mimic tumour 
metastatic cascades of human cancers, GEM tumour models are perhaps the closest 
approximation as they are more likely to develop tumours that can metastasize in 
„natural‟ ways and may offer a more optimal model to evaluate therapeutics 
directed against this process. Taken together, all of this work is for one purpose – to 
find a better cancer mouse model that can successfully predict how a human cancer 
will progress and respond to an experimental cancer drug before the drug is ever 
tried in humans. The different types of pre-clinical tumour mouse models have 
individual strengths and weaknesses. Therefore, it is critical to determine which 
xenografts, congeneric graft or GEM models will be optimal for evaluating novel 
anti-tumour or anti-angiogenesis agents prior to clinical testing (Francia and Kerbel, 
2010; Francia et al., 2011). 
 
8.5 In vivo imaging tumour angiogenesis and the response to anti-angiogenic 
therapies 
To monitor anti-angiogenic responses, immunofluorescent and histological analyses 
of tissue sections can supply detailed information about the tumour vasculature. 
However, the information provided from tissue sections is not dynamic and just 
represents the situation at a single time point. In the past three decades, there have 
been huge advances in imaging technologies and their applications, particularly in 
the field of tumour angiogenesis and vascular targeting. A number of imaging 
systems that provide anatomical and physiological information are now used in a 
variety of pre-clinical and clinical applications and include magnetic resonance 
imaging (MRI), computed tomography (CT), positron emission tomography (PET), 
single-photon-emission (SPECT), ultrasound, fluorescence reflectance imaging, 
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fluorescence-mediated tomography (FMT) and bioluminescence imaging 
(Weissleder and Pittet, 2008). Some of these technologies are widely used in the 
elucidation of morphological, functional and molecular characteristics of tumour 
vasculature and can be used to follow tumour growth and metastases in response to 
anti-angiogenic therapies. Ideally the read-outs from imaging systems should be 
quantitative, high resolution, longitudinal (allow imaging over time), 
comprehensive and standardized (Weissleder and Pittet, 2008). But several 
challenges remain, because each technology has its own strengths and limitations. 
In my project, pilot studies to image tumour angiogenesis and metastases were 
performed by applying PET-CT and MRI to the LLC mouse model. This work 
showed that MRI scanning detected lung micrometastases down to 1mm in 
diameter (or even less). In contrast, PET-CT was unable to detect even large 
metastatic lesions in preliminary studies. MRI would therefore be a useful modality 
for a longitudinal study of tumour metastases after they had reached approximately 
1mm in size. It also has the advantage of being able to detect metastatic lesions 
without additional cell labelling. However, MRI has the disadvantage of being 
relatively time consuming and expensive. Fluorescence reflectance imaging and 
bioluminescence imaging are much less time consuming, can be used on multiple 
occasions to viualise tumour metastases over time but require labelled tumour cells 
to allow visualization. For example, cancer cells can be labelled with far-red (eg. 
TomatoRed) or bioluminescence and visualized in orthotopic locations and 
metastatic sites by the IVIS imaging system (Caliper). However, all the imaging 
systems mentioned above are also limited by their lack of detailed histological 
information. Therefore, the combination of histological analysis and in vivo 
imaging systems provide the most powerful approach for investigating tumour 
angiogenesis and assessing anti-angiogenic targets.  
 
Endoglin provides a potential anti-angiogenic target because it is predominantly 
expressed in the active and angiogenic tumour associated endothelium. Its location 
on the luminal surface of blood vessels makes it an ideal target for tumour 
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vasculature detection by an antibody. Labelled anti-endoglin antibodies can 
potentially be used to distinguish malignant neoplasm from benign tissue. This 
information may also be used to select patients who would be suitable for endoglin-
targeted anti-angiogenic therapy and further imaging could be used to evaluate the 
response to this anti-angiogenic therapy. Published work showed that 
99
Tcm-
labeled anti-endoglin mAb E9 (Costello et al., 2004), 
125
I-labeled anti-endoglin 
mAb MAEND3 (Fonsatti et al., 2000) and 
111
In-labeled rat anti-mouse endoglin 
mAb MJ7/18 (Bredow et al., 2000) have been used to detect and monitor primary 
tumour growth and metastases either in human or in mouse. In the future, there 
might be additional options for labelled anti-endoglin antibodies to be used in other 
in vivo imaging systems such as MRI or PET scanning. In terms of anti-endoglin 
mAb labels for MRI, antibodies could be labelled with ferrous iron to be visualized. 
The gadolinium-modified nanoparticles are currently applied to pre-clinical and 
clinical MRI scans. Recently, iron-oxide nanoparticles (IONPs) represent a 
significant class of inorganic nanomaterial that is characterized with unique 
physical properties including high surface area to volume ratios and 
superparamagnetism (Jun et al., 2008; Laurent et al., 2008). It might be possible to 
label anti-endoglin mAb with IONPs in order to improve its stability in biological 
fluids and its ability to concentrate at the angiogenic target area. In contrast to MRI, 
PET uses radiotracers to image, map and measure target site activities such as 
angiogenesis, metabolism, apoptosis and proliferation. For visualization with PET, 
anti-endoglin antibody could be labelled using chemistries which are frequently 
used in the preparation of radiotracers including covalent (
18
F, 
123
I, 
131
I, 
75
Br, 
68
Ga 
and 
11
C) and ionic binding (a chelator is required to trap metal isotopes in complex 
chemistry) (Yang et al., 2006). A new method using N-succinimidyl 4-[18F] 
fluorobenzoate ([18F]SFB) to label peptides of proteins was performed by Dr. 
Michael Carroll, and this may be suitable for labeling anti-endoglin antibodies. In 
addition, in terms of half time, 
124
I might be a good alternative to 
18
F as this has a 
much longer half-life (4 days) than that of 
18
F (110 mins) (personal communication, 
Dr. Ross Maxwell).  Therefore, tumour imaging might be hugely improved by 
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taking advantage of endoglin labelled targets, and this approach may also be 
valuable to monitor the response to anti-cancer therapies. Through the development 
of a robust tumour angiogenesis imaging platform, molecular imaging can 
dramatically facilitate and speed up many steps of anti-angiogenic drug 
development in both the pre-clinical stages and clinical settings (Cai et al., 2006). 
 
8.6 Endoglin as an anti-angiogenic therapeutic target 
In order to examine the role of a novel agent in tumour angiogenesis and potential 
as an anti-angiogenic therapeutic target, a variety of methods have been applied in 
experimental animals. Those can be broadly divided into three categories: genetic 
depletion of target gene, RNA interference (RNAi) therapeutics and injectable or 
orally administered antibodies/drugs. In my project, the Eng-iKO
e
 mouse model 
was used to genetically deplete the endoglin gene in ECs to address the question of 
whether endoglin might be a good anti-angiogenic therapeutic target. Endoglin 
siRNA techniques have not yet been applied to tumour studies in vivo, but this 
approach has been used to silence other angiogenic target genes. For example, 
atelocollagen-complexed siRNA effectively silenced VEGF to inhibit tumour 
angiogenesis and growth in mouse xenograft model (Takei et al., 2004). Finally, a 
number of anti-endoglin antibodies, such as the immunotoxin conjugated (Seon et 
al., 1997; Matsuno et al., 1999), radiolabelled (Tabata et al., 1999), or naked anti-
endoglin mAb (Takahashi et al., 2001a; Tsujie et al., 2006; Tsujie et al., 2008; 
Uneda et al., 2009) termed SN6f, SN6j, and SN6k, were tested in pre-clinical 
studies that revealed a long-lasting regression/suppression of tumour growth and 
metastases in SCID mice, that was likely mediated by the inhibition of tumour-
associated angiogenesis (Seon et al., 2011). In addition, a phase I study which is 
aiming to evaluate safety and tolerability of escalating doses of the therapeutic anti-
CD105 mAb, its pharmacokinetics and immunogenicity, as well as signs of clinical 
activity is now in progress in a multi-centre phase I clinical trial. Patients with 
advanced and/or metastatic cancer were given naked human/murine chimeric anti-
endoglin mAb (TRC105) as a tumour vascular targeting agent 
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(http://clinicaltrials.gov/archive/NCT00582985). Preliminary data from 50 patients 
with advanced refractory cancer in this clinical trial suggest clinical activity and 
good tolerability of the TRC105 antibody at a wide range of doses used (0.01-1 
mg/kg every two weeks, 0.3-15 mg/kg every two weeks or 10-15 mg/kg/ every 
week). The preliminary data indicates the majority patients can tolerate doses of 
TRC105 that generate anti-angiogenic and anti-cancer activity (Goldman et al., 
2011). Subsequently further clinical trials will focus on the evaluation of single 
TRC105 agent and combination therapy in a variety of indications (Rosen et al., 
2008; Rosen et al., 2009; Goldman et al., 2011). 
 
8.7 Current combination therapies and future directions  
In fact, current data from pre-clinical and clinical trials of anti-angiogenic therapies 
indicates these therapies benefit a variety of patients with malignant neoplasm in 
different stages. However, the data also raise a number of important questions of 
how to effectively combat cancer with anti-angiogenic medicine in the future. It 
seems that chemotherapy and anti-angiogenic combination therapies might be a 
beneficial treatment for cancer patients. This type of combination therapy exerted 
synergistic benefits simply because cytotoxic agents directly kill cancer cells and 
anti-angiogenic drugs indirectly kill cancers by blocking the blood supply and 
starving cancer cells. Also, it was proposed that anti-angiogenic therapy can 
promote drug delivery by transiently normalizing tumour vasculature (Jain, 2005b). 
Interestingly, a synergistic effect was also reported between naked anti-endoglin 
antibodies and conventional chemotherapeutic schedules in a human skin/SCID 
mouse chimera model (Takahashi et al., 2001a). Furthermore, the combination of 
anti-angiogenic biotherapy and metronomic chemotherapy seems to be a more 
hopeful strategy for cancer therapy. The metronomic chemotherapy not only can 
inhibit cancer cell proliferation and speed up cancer cell apoptosis, but it can also 
have an anti-angiogenic effect (Tan et al., 2004; Emmenegger et al., 2010). 
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Multi-targeted anti-angiogenic therapies may be another method of increasing the 
efficacy of anti-angiogenic agents by an anti-endoglin antibody. Numerous 
angiogenic factors, including VEGF, PDGF, EGF, TGF-α TGF-β, acidic and basic 
FGF have been shown to contribute to tumour angiogenesis (Ferrara and Kerbel, 
2005; Kerbel, 2008; Chung et al., 2010). Therefore, blocking a single angiogenic 
molecule was expected to have little or no impact on tumour growth. Nevertheless, 
among a large array of novel therapeutic agents with anti-angiogenic activity tested 
in the clinical setting in the past decade, anti-VEGF/VEGFR signalling agents such 
as Bevacizumab(Avastin), Sunitinib (Sutent), Sorafenib (Nexavar) and Pazopanib 
(Votvient) were approved by FDA. Among the most promising member of this 
growing „family‟ of novel therapeutic targets, it must be carefully considered and 
investigated which type of multi-targeted anti-angiogenic combination therapy is 
ideally suitable for cancer patients. However, it is truly difficult to determine which 
type of combination and model is ideal for a certain investigation before the 
expression of target gene is manipulated on biopsy or clinical samples from cancer 
patients. Therefore, researchers should be encouraged to identify the potential 
synergy of the combination therapy using a variety of anti-angiogenic agents based 
on bench to bedside and back to bench studies. On the other hand, effective multi-
targeted anti-angiogenic therapies are now required since the consequence of single 
target anti-angiogenic therapy may be to upregulate some other cytokines that 
promote reneovascularization. Therefore, a priority in the anti-endoglin therapy 
field is to identify any pro-angiogenic agents that are upregulated due to anti-
endoglin therapy, in order to impede this insidious consequence of single anti-
angiogenic therapy. It is certainly important to investigate the potential of 
mechanism-based combination therapies in the future. 
 
Anti-angiogenic agents predominantly interfere with new blood vessel formation, 
whereas vascular disrupting agents (VDAs) are designed to target established 
tumour vasculature causing rapid and sustained inhibition of tumour blood flow and 
extensive tumour necrosis (Baguley, 2003; Siemann et al., 2005). Tumour-VDAs 
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have the potential to affect the areas of the tumour that are resistant to conventional 
cytotoxic therapies used for cancer treatment. Indeed, when combined with 
conventional chemotherapy, tumour-VDAs demonstrated synergy in pre-clinical 
models and activity in Phase II/Ш clinical trials (Hinnen and Eskens, 2007; Heath 
and Bicknell, 2009). 
  
Taken together, the current pre-clinical data significantly demonstrate endoglin has 
the potential to be developed as a novel antibody-based diagnostic and therapeutic 
target. However, it seems to be a little premature to apply anti-endoglin drugs in the 
clinical setting of cancer and it is essential to investigate the mechanisms of 
response to anti-endoglin therapy and identify the most appropriate therapeutic 
applications of endoglin targeting. This will involve using an appropriate pre-
clinical model and should take advantage of the latest imaging systems. Therapeutic 
strategies relying on targeting a single biological agent may have initial benefit but 
their ultimate impact on treatment efficacy is likely to be limited. Angiogenic 
inhibitors (AIs) and/or VDAs can augment conventional anti-cancer therapies, but 
better cytotoxics are required and the application of combined biological targeting 
strategies needs to be considered. For example, multi-target anti-angiogenic 
therapies in conjuction with anti-metastatic therapies might represent the best 
combination to address the increased metastases problem caused by anti-angiogenic 
therapy.  
 
In conclusion, in the context of a subdermal LLC-RFP primary tumour and 
„spontaneous‟ lung metastatic secondary tumour model, targeting endoglin alone is 
likely to delay early stages of primary tumour progression in association with 
reduced angiogenesis. However, targeting endoglin alone is unlikely to have a 
major anti-cancer effect at later stages of primary tumour progression and also this 
is associated with a detrimental increase in lung metastases. Apart from the benefit 
of targeting endoglin at early stages of tumour progression, the finding of 
significant increase lung metastases in Eng-iKO
e
 mice must be highlighted in the 
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context of anti-endoglin therapies currently being tested in phase I and phase I and 
II clinical trials. This increase may be due to the changes in lung vasculature and 
the formation of pre-metastatic niches within the lung following vascular specific 
endoglin depletion. Despite this major problem, endoglin may still represent an 
effective agent as a component target in anti-angiogenic multi-target combination 
therapy. Additional preclinical studies of anti-endoglin therapy (alone and in 
combination with other targets such as VEGF) in a wide range of clinically relevant 
mouse models are required to establish the broader validity of these conclusions 
and to direct the way for future clinical applications   
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